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Abstract 
Existing methodologies for biomolecular detection are limited in several key areas. 
Heterogeneous assays struggle with various wash steps which can prolong assay time, while 
other assays require costly reagents, lack mobility and can be highly complex in nature. This 
project demonstrates how a bio-nano particle in the form of M13 bacteriophage (M13) can be 
used for the basis of a novel homogeneous immunoassay which incorporates the use of linear 
dichroism spectroscopy (LD). 
M13 has a high aspect ratio which allows it to align easily in shear flow, this in turn generates a 
large LD signal. This property of M13 has been manipulated for use in a new in-vitro diagnostic 
technique. 
Existing M13 production yields are much lower than those required for this assay. A new 
method was developed which increased the yield 10 fold. Chemical modifications were made 
by covalently attaching chromophores, this enabled the M13 LD signal to be visualised in the 
visible region and develops the potential for multiplexing. 
By chemically modifying M13 with chromophores and antibodies it was possible to create an 
assay capable of detecting 105 cells/mL of Escherichia coli O157. This is 100 times more 
sensitive than the M13 based assay developed by Pacheco-Gomez et al. (2012). The assay was 
reassembled to detect small molecules and was found to have a sensitivity of 0.01 mM.  
The assays presented form a sensitive, specific, fast diagnostic tool capable of detecting 
pathogens and small molecules. It offers significant improvements over existing methods, and 
could act as a platform in developing a multimodal detection system.  
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1 CHAPTER 1 - INTRODUCTION 
It is the aim of this project to investigate whether linear dichroism spectroscopy (LD) can be 
used in combination with a bio-nanoparticle based on M13 bacteriophage (M13) to produce a 
novel bio-detection system.  This introduction aims to provide an overview of the two key 
elements of this project, bio-molecular detection and linear dichroic spectroscopy. 
1.1. Bio-detection  
Bio-detection can be defined as the application of methods that allow the presence of a 
specific biological agent to be identified and quantified. As such bio-detection has an 
important place in many commercial sectors including healthcare, environmental monitoring, 
defence and agriculture. In this project a bio-detection system will be developed that has wide 
ranging applications but initially is focused on detecting targets that are important in human 
disease and health. In these applications effective bio-detection is extremely important as it 
can be used to determine the source, diagnosis, and treatment of infections. To underline the 
importance of bio-detection, a number of reports including the Pennington report 
(Pennington, 2009), and articles written by Rice (Rice, 2011) and Kuehn (Kuehn, 2013) have 
highlighted a lack of effective bio-detection methods, emphasising the need for new and 
improved methods. 
One of the major aims of this project is to explore whether LD can be used to provide such a 
new bio-detection platform that is able to detect a wide range of biomolecules. There are 
already a number of methods that can be used to detect material of a biological origin. The 
majority of these rely on detecting proteins, toxins and DNA from an organism or antibodies 
produced by the host in response to the organism. In this section a number of the methods 
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used in microbial bio-detection will be summarised. This is not an exhaustive survey but 
provides a broad view of what is currently used in commercial laboratories. The methods 
discussed range from traditional microbial cultures to antibody based methods, including both 
homogeneous and heterogeneous assays.  
1.1.1. Major methods 
1.1.1.1. Microbial culture for detection of pathogens 
Microbial culturing is a common diagnostic technique used within pathology laboratories. 
Microbial cultures rely on the development of either a visually observable colony with a 
characteristic morphology on a plate or a turbid liquid culture. Cultures can be obtained from a 
range of sources including  urine, sputum, stool, skin and soft tissue, as well as blood 
(Abubakar et al., 2007).  
Blood cultures are used as the principle method for detecting bacteremia and fungemia 
(Reimer et al., 1997) with blood samples being incubated in anaerobic and aerobic bottles 
which contain media to support the growth of bacteria or fungi.  A large volume of blood is 
required from the patient for a blood culture (approximately 20 mL for an adult)(Reimer et al., 
1997). The blood culture bottles are then placed into incubators for 5-7 days with most 
pathogens usually growing within 2 days. The bottles are monitored for microbial growth by 
measuring the carbon dioxide production and resulting pH change in the bottle. If the sample 
is flagged as being positive by the system then an inoculum is taken for Gram staining and 
another inoculum is taken for growth on media plates for susceptibility testing (the media 
plates used depend on the result of Gram staining) (Reimer et al., 1997).  
A urine culture is carried out by simply inoculating plates containing specific growth media 
with the urine sample and incubating. Colony forming units are counted and calculated per mL 
(Lipsky et al., 1987).  
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Skin and soft tissue cultures can be used for wounds, abscesses and burns, and require swabs 
to be taken from the infected area. The swabs are stored in a collection tube and the 
specimens are inoculated onto growth media plates and allowed to incubate (Stevens et al., 
2005). Sputum and stool cultures are done in a similar way. 
Although these methods have been established for more than 50 years there are limitations 
with using culturing as a diagnostic technique, arguably the major one being its time 
consuming nature. This is inherent in the methods as it is a requirement that the bacteria have 
to multiply to a level that they become visible to the naked eye as a colony or turbid solution. 
For example, methicillin resistant Staphylococcus aureus (MRSA) can take more than 24 hours 
to form visible colonies (Zitterkopf, 2008). Patients who are extremely ill need treatment 
immediately, and to wait for a culture could be unacceptable.  
1.1.1.2. Antibody based methods (homogeneous and heterogeneous) 
Antibody based methods, also called immunoassays are also commonly used as a clinical 
diagnostic tool (Ekins, 1998). An immunoassay is a test which uses the ability of an antibody to 
form a specific complex with an antigen associated with the pathogen. This complex is 
detected using one of a range of methods. The key to such an assay is the specificity of the 
antibody for the target antigen. The majority of immunoassays can be classified into one of 
two classes, homogeneous and heterogeneous methods. The classification is based on 
whether or not the immunoassay method requires physical separation of bound antibody-
antigen complex from unbound material. If it does then this is defined as a heterogeneous 
assay, whereas if no separation step is required it is defined as a homogeneous assay. In 
general the lack of a separation step makes homogeneous assays easier and faster to perform, 
however homogenous methods are more difficult to develop (Thomas et al., 2003). In the 
following sections the most common immunoassay formats will be discussed.  
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1.1.1.2.1. Agglutination assays 
Agglutination is the clumping of particles to form aggregates, a phenomenon that forms the 
basis of this type of assay. These tests use carrier particles (also known as conjugated 
detection particles) e.g. latex particles, gelatin beads or colloidal particles derivatised with a 
pathogen specific antibody. When the specific target analyte is present an aggregate forms 
which can be easily visualised (figure 1.1). If the target analyte is not in the specimen then no 
agglutination occurs (Gella et al., 1991). For example a detection system for MRSA uses 
monoclonal antibodies directed towards the PBP2a antigen present on MRSA (Nakatomi and 
Sugiyama, 1998). The presence of the pathogen was signalled by the formation of an 
aggregate. 
Figure 1.1 - Agglutination assay process 
A schematic diagram illustrating the process of an agglutination assay. 1) A sample containing target analyte is 
placed onto a card followed by conjugated detection particles specific to the target analyte. 2) When agitated the 
target analyte molecules and conjugated detection particles begin to interact. 3) Aggregates form which result in 
colour changes and texture changes. If no target analyte is present in the sample then no changes are observed.  
This method is elegant in its simplicity, with the method being inexpensive and rapid (Myrick 
and Ellner, 1982). Woods and Iwen (1991) also found that latex agglutination required fewer 
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reagents in comparison to dot immunobinding assays and cytotoxin assays for the diagnosis of 
Clostridium difficile-associated diarrhoea. (Woods and Iwen, 1990) 
However, relatively high analyte concentrations (when compared to the culture method) are 
needed for latex agglutination, and the results are only qualitative/semiquantitative 
(Warsinke, 2009). The results could be improved using a spectrophotometer for readout 
purposes (Arsie et al., 2000), but this would require an additional device. The method is also 
difficult to multiplex, requiring separate tests for each target.  
1.1.1.2.2. Enzyme-linked immunosorbent assay  
Enzyme-linked immunosorbent assay (ELISA) is the most prevalently utilised immunoassay 
(Smith et al., 2008b) and combines the specificity of an antibody with the sensitivity of an 
enzyme assay. ELISAs can vary in format but always involve the formation of an antigen-
antibody complex, with one of the reactants immobilised onto the surface of a plate. The 
addition of the specific target analyte allows for the formation of the antigen-antibody 
complex, and this is visualised using enzyme conjugated reagents (usually in the form of an 
enzyme linked secondary antibody) (Paulie et al., 2005). A substrate is chosen which when 
added to the enzyme linked secondary antibody, changes colour. This change in colour is 
proportional to the amount of immobilised enzyme and hence the amount of target analyte 
present in the sample (Porstmann and Kiessig, 1992). Comparing the results with standard 
samples of known concentration can provide quantitation. ELISAs have been used to detect 
substances such as peptides, proteins, antibodies and hormones and as a result have 
commonly been used as a diagnostic tool to detect a wide array of organisms. For example this 
assay is used frequently to detect Helicobacter pylori infections (Logan and Walker, 2001), and 
human immunodeficiency virus (HIV) infections (von Sydow et al., 1988). There are a wide 
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range of ELISA based methods, of which two of the most common are sandwich assays and 
indirect assay. 
1.1.1.2.2.1. Sandwich assay 
Sandwich assays work by detecting the antigen of a particular target molecule. Sandwich 
assays involve coating the surface of the plate with a capture antibody. The sample is then 
added and any antigen present will bind to the surface of the plate. Unbound antigen is 
removed by washing the plate. This is followed by the addition of a primary antibody which 
acts as a detection antibody, binding specifically to the antigen. Any unbound primary 
antibody is removed by washing the plate again. An enzyme linked secondary antibody is then 
added and binds to the primary antibody. A substrate is added, and is converted by the 
enzyme into a colour or fluorescent or electrochemical signal which is measured to determine 
the presence and quantity of antigen (figure 1.2). So the more antigens present, the greater 
the signal (Prescott et al., 2005).  
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Figure 1.2 - Sandwich ELISA process 
A schematic diagram illustrating how a sandwich ELISA works. 1) Within the well of a microtitre plate, capture 
antibodies coat the well. 2) The antigens in the sample bind to the capture antibodies. 3) The antigens are 
consequently detected by a detection antibody, and an enzyme linked secondary antibody is then added. 4) A 
substrate molecule is used to produce a signal to indicate the presence of the antigen. 
1.1.1.2.2.2. Indirect assays 
Often assays are developed to detect antibodies produced by the host immune system in 
response to infection. Using ELISAs to detect antibodies is known as an indirect 
immunosorbent assay and is commonly used to detect HIV (Gurtler, 1996). In this case the 
plate is coated with inactivated HIV antigens. The patient’s sample is then added and any 
antibodies specific to HIV (indicative of a HIV infection) will also become immobilised on to the 
plate. The plate is washed to remove any unbound antibodies. The secondary enzyme linked 
antibody is then added and binds to the human antibodies. Any unbound secondary antibodies 
are again removed by washing. A substrate is finally added which changes colour in the 
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presence of the enzyme (figure 1.3). So the more antibodies present in the sample, the larger 
the change in colour, which is measured by a change in absorbance (Prescott et al., 2005). 
 
Figure 1.3 - Indirect ELISA process 
A schematic diagram illustrating how an indirect ELISA works. 1) The well of a microtitre plate is coated with 
antigens. 2) A sample containing detection antibodies bind to the antigens. 3) The detection antibodies are 
consequently detected by an enzyme linked secondary antibody. 4) A substrate molecule is used to produce a signal 
to indicate the presence of the detection antibody. 
 
Such tests are simple to perform, sensitive and inexpensive (Peruski and Peruski Jr, 2003). 
However one drawback of the indirect ELISA assay is that host antibodies (for example 
antibodies for HIV) only become detectable 6-8 weeks after the onset of infection (Gurtler, 
1996). So an assay intended to detect these antibodies may initially give a negative signal, 
when indeed the patient may be infected. Moreover the antibodies can remain in the 
bloodstream long after an infectious disease has been resolved. False positives can also occur 
due to cross reactions with the antibodies.  
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ELISAs tend to be quite rapid in comparison to culture methods i.e. ELISAs take hours 
compared to days (Bacarese Hamilton et al., 2004). However ELISAs also are not easily 
multiplexed, in general one assay can only detect one analyte at a time. However ELISAs can 
easily achieve high-throughput processing parallelized by using a microtitre plate to carry out 
multiple reactions but these have to be laboratory based. 
1.1.1.2.3. Lateral flow methods  
Lateral flow tests are a more recent development and represent one of the simplest diagnostic 
test formats currently on the market. These tests are generally still based on an antibody for 
primary detection but use chromatographic separation as a key part of the assay method. The 
detection conjugate (particle conjugated with detector molecules able to detect the target 
analyte) is initially static in nitrocellulose at one end of the sample pad and is solubilised with 
the addition of the sample. If the target analyte is present in the sample it binds to the 
detection conjugate molecules. This target analyte/detection conjugate complex then moves 
down the sample pad under capillary action, until it approaches the test line. At which point 
the target analytes bind the complex to the analyte capture molecules, forming a visible line 
and indicating a positive test result. A second capture line can be used to act as an assay 
control (figure 1.4). This second capture antibody will capture the detection conjugate, 
whether the detection conjugate is attached to the target analyte or not. If the control line is 
not visible then the test is invalid and needs to be repeated (Buhrer-Sekula et al., 2003).  
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Figure 1.4 - Lateral flow process 
A schematic diagram illustrating how lateral flow works. 1) A sample is added to the pad. 2) The specific antibodies 
within the sample form a complex with the detection conjugate. 3) The complex moves down to the test line where 
the complex binds to the capture molecule and causes a line to appear. 4) This complex then binds to the capture 
molecule on the control line forming a line which ensures the test is valid.  
 
These tests are very simple and quick, usually taking approximately 15 minutes. However a 
major disadvantage of this assay is that it can only detect one agent per assay strip. So if for 
example, a sample is obtained with an unknown agent in it, several strips would have to be 
used to identify it. Additionally, the assay readout is determined by a red line created by the 
sample/detector conjugate binding to the capture molecule. Whether or not this red line is 
visible to the human eye can be the limit to the sensitivity of this assay. Sensitivity 
quantification is achieved using a fairly arbitrary scale, typically by assigning a number 
between 0 and 5, (highest intensity of the line being 5). As the scale is arbitrary the 
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quantification is obviously limited by the skill of the individual processing the assays (Peruski 
and Peruski Jr, 2003). However Cho and Paek (2001) devised a lateral flow system that 
exploited the use of multiple test lines allowing the user to quantify the relative concentration 
of the target analyte in a less subjective manner (figure 1.5). There have been recent advances 
with lateral flow, including the use of a silver enhancement step in the conventional gold 
labelled lateral flow assays. This extra step has been found to increase the sensitivity by up to 
one order of magnitude and in doing so, allowing the detection of lower levels of antigen 
(Horton et al., 1991). (Cho and Paek, 2001) 
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Figure 1.5 - Human serum albumin signal using a semi-quantitative lateral flow system 
Patterns of signal generation when detecting increasing concentrations of human serum albumin using a semi-
quantitative lateral flow system. Each strip was duplicated (top panel). Optical intensities of the coloured bars were 
used to demonstrate changes in signal as albumin concentration increased (bottom panel). At the detection limit of 
30 µg/mL a single line is visible (in addition to the control line which appears throughout). Additional lines become 
visible with increasing albumin concentration and these are distributed evenly in multiples of the detection limit. 
Reproduced from Cho and Paek (2001). (Cho and Paek, 2001). 
1.1.1.2.4. Homogenous methods 
The immuno-methods discussed so far have been heterogeneous assays which all require 
some form of separation of antibody-antigen complex from the milieu. These separations can 
be difficult to optimise which has meant that significant efforts have been put into developing 
separation-free (homogenous) assay methods. There are a wide range of homogeneous 
methods, the most common being enzyme multiplied immunoassay technique (EMIT) and 
fluorescence polarisation immunoassay (FPIA).  
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1.1.1.2.4.1. Enzyme multiplied immunoassay technique 
EMIT is generally used to detect small molecular weight haptens including antibiotics and 
opiates. An EMIT assay consists of an enzyme bound to a hapten, it is bound in such a way that 
it does not affect the enzyme active site. An antibody specific to the hapten is added and this 
binds to the enzyme/hapten complex, blocking the enzyme active site.  
In the absence of any free haptens the enzyme active site remains blocked and the substrate is 
not broken down. In the presence of free haptens the bound haptens are displaced from the 
antibody allowing the enzyme to catalyse the degradation of the substrate. By measuring the 
quantity of the substrate products (which are generally chosen to be coloured) one can infer 
the hapten quantity within the sample (Oellerich, 1980) (figure 1.6). 
Figure 1.6 - EMIT process 
A schematic diagram illustrating how EMIT works. When no free haptens are present in a sample, 1) the enzyme 
with bound hapten is able to bind to the antibody. 2) This prevents the substrate from reacting with the enzyme 
bound with hapten as it cannot reach the active site. 3) This consequently results in no degradation of substrate and 
no signal change. However if there are free haptens present in a sample, 1) they bind to the antibody.  2) This allows 
for the substrate to react with the enzyme bound with hapten. 3) This consequently results in the degradation of 
the substrate and a signal change.  
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Drug testing is a popular use for EMIT due to its rapid response time, high sensitivity and the 
simplicity of the assay (Scharpe et al., 1976, Ullman, 1999). The EMIT assay is homogenous and 
as such does not require any wash steps, this is an important advantage over ELISA assays.  
The assay time for a commercial EMIT system is less than 1 minute (Schneider et al., 1973) 
which is quicker than any of the assays mentioned previously, it is also highly sensitive with a 
detection limit of <1 nM (Rosenthal et al., 1976). However EMIT is only used for small 
molecules (<1000 Da), although new advances have been made to produce an EMIT assay that 
can detect an influenza hemagglutinin A peptide (Chiu et al., 2011) in 13 minutes. This 
research shows that it may be possible to detect larger molecules. EMIT, like many of the other 
tests detailed in this review, is not multiplexed. 
1.1.1.2.4.2. Fluorescence polarisation immunoassay 
The fluorescence polarisation immunoassay (FPIA) was established by Dandiker et al. (1973), 
and was further developed by Abbot Diagnostics in the 1980s for commercial applications. This 
method utilises a fluorescent labelled antigen, which competes with an unlabelled antigen for 
a specific antibody. A fluorescent label is used and is excited with plane polarised light leading 
to the emission of a varying degree of plane polarised light. The degree of polarisation of the 
emitted light is determined by the tumbling time of the fluorophore e.g. a fast rotating 
fluorophore leads to less polarisation. In an assay, if an antibody binds to a small fluorescent 
antigen the antigen rotates slower, leading to an increase in polarisation. Antigen in an 
unknown sample competes with the known fluorophore for the antibody leading to 
fluorophore release and a measurable change in polarisation (Diamandis and Christopoulos, 
1996) (figure 1.7 and 1.8). (Dandiker et al., 1973)  
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Figure 1.7 - FPIA mechanism 
A schematic diagram illustrating how FPIA works. 1) Fluorescently labelled antigen-antibody complex causes slow 
rotation and high fluorescence polarisation. 2) Fluorescently labelled antigen enables fast rotation and low 
fluorescence polarisation. Adapted from Bonwick and Smith (2004). 
 
Figure 1.8 - FPIA process 
A schematic diagram illustrating FPIA. 1) A sample containing unlabelled antigen is added to the assay. 2) 
Fluorescently labelled antigen is added to the sample and 3) both antigens compete to bind to the antibodies. 4) A 
large concentration of unlabelled antigen means the amount of fluorescently labelled antigen bound to antibody 
decreases leading to faster rotation of fluorescently labelled antigens and consequently low fluorescence 
polarisation.  
 
FPIA has been successfully applied to the detection of drugs (Colbert and Chllderstone, 1987), 
metal ions (Johnson, 2003), mycotoxins (Maragos, 2009) and hormones (Hong and Choi, 2002). 
The obvious advantage of using a FPIA is that it is homogeneous and therefore does not 
require a separation step or washing. Another advantage is that the reaction is rapid and Hong 
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and Choi (2002) found that a FPIA could be carried out in one step when detecting 
progesterone, taking 7 minutes to carry out 10 samples. Typically FPIA only requires few 
reagents (Nasir and Jolley, 1999). The fluorescent labelled antigens usually use fluorescein 
derivatives as the label, these are stable on storage, highly fluorescent and do not affect the 
antigen/antibody interaction (Smith and Eremin, 2008). As FPIA is homogeneous and the 
reagents are stable, it serves as a simple and repeatable assay.  
However a limitation of this assay is that light scattering and endogenous fluorophores can 
cause noise in the fluorescence polarisation signal. For example human urine contains some 
natural fluorophores, and this was found to be the major factor limiting assay sensitivity in 
Colbert and Childerstone’s (1987) work on FPIA. They used a single reagent and FPIA to detect 
multiple drugs of abuse in one sample of urine, including benzoylecgonine (a cocaine 
metabolite) and amphetamine. However this assay was not multiplexed. 
FPIA is also limited to being applied to the detection of small molecules as the signal depends 
on molecular size. However Guo et al. (1998) have shown that FPIA can be used for high 
molecular weight antigens, by using a luminescent Re(I) metal ligand complex as the FPIA 
probe. This method was able to detect antigens with a molecular weight between 105-108 Da. 
However they did find that this probe had a lower emission intensity compared to probes such 
as fluorescein, reducing sensitivity and increasing noise. (Guo et al., 1998) 
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1.1.2. Summary  
The bio-detection techniques discussed above represent the major methods currently 
employed in infection detection. The methods discussed can be compared based on criteria 
which are important for bio-detection i.e. assay time, detection limit and limitations of 
technique. Sample types can also be an important factor in detection as they may interfere 
with the detection technique, for example urine contains natural fluorophores which can 
interfere with an FPIA technique. Table 1.1 details what each technique can detect and 
information based on each criterion. 
This section has summarised many of the current bio-detection methods and their limitations. 
The next section will explain how linear dichroism spectroscopy (LD) can be used in 
combination with a bio-nanoparticle based on M13 bacteriophage (M13) to produce a novel 
bio-detection system. This new system will solve many of the problems seen with existing bio-
detection methods.  
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Table 1.1 - Brief comparative table providing examples of bio-detection methods 
Detection 
Technique 
Analytes 
detected 
Assay 
Time 
Detection 
Limit * 
Limitations of Technique Samples used Example References 
Microbiological 
technique 
Microbes 
  
~7 days 1-108 
CFU/mL 
 
 
 Longer assay time  
 Labour intensive 
 Detection of only 
live cells 
 No detection of 
toxins or drugs 
 Not multiplexed 
All clinical samples can be 
used 
(Smith et al., 2008a, Villari 
et al., 1998, Arora et al., 
2006, Boer and Beumer, 
1999) 
Agglutination 
assay 
Microbes 
Toxins  
Antibodies 
>1 hour  0.5 ng/mL  
106 -107 
CFU/mL  
 Non-specific 
reactions can occur 
 Not multiplexed 
Whole blood, sputum, 
stool and urine samples  
(Fujikawa and Igarashi, 
1988, Hajra et al., 2007, 
Mazumder et al., 1988) 
ELISA Microbes 
Antibodies 
Toxins 
Drugs 
Hormones 
>1 hour 2.0 ng/mL  
103 -105 
CFU/mL 
 
 No information on 
activity of the 
pathogen/toxin 
 Not multiplexed 
Blood, stool, sputum and 
urine samples although not 
used for whole blood 
samples as serum is 
typically extracted from 
whole blood. 
 
(Boer and Beumer, 1999, 
Kerr et al., 2001, Reidy et 
al., 2011, Venkatratnam 
and Lents, 2011, 
Kongmuang et al., 1987, 
Drennon et al., 2003)  
Lateral flow Microbes 
Toxins 
15 
minutes 
2.8 ng/mL 
105 -107 
CFU/mL 
 Developed  for 
specific single tests 
and not high-
throughput 
screening 
 Not multiplexed 
 
 
Whole blood, sputum, 
stool and urine.  
(Chan et al., 2003, 
Posthuma-Trumpie et al., 
2008, Fisher et al., 2008) 
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EMIT Drugs 10 
minutes 
0.5ng/mL  Limited to molecules 
of small molecular 
size 
 Not multiplexed 
Urine samples (Rosenthal et al., 1976) 
FPIA Drugs 
Hormones 
0.7 
minutes 
2.7 ng/mL  Limited to molecules 
of small molecular 
size. 
 Not multiplexed 
Urine samples, although 
the results can be affected 
by natural fluorophores 
which appear in urine.  
 
(Hong and Choi, 2002, 
Colbert and Chllderstone, 
1987) 
*in terms of colony forming units (CFU) or antigen concentration
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1.2. Linear dichroism 
1.2.1. Theory and instrumentation and history 
1.2.1.1. Absorbance 
The phenomenon of light absorbance permeates our daily life, from traffic lights to stained 
glass windows; each is a product of light absorbance. Absorbance occurs when an electron 
within a molecule absorbs energy in the form of a photon of light to jump to a higher unstable 
energy level. After a period of time, the “excited” electron decays back to the stable ground 
energy level (ground state) (Hecht, 2002). The return of the electron to the lower energy level 
is usually accompanied by a release of thermal energy (figure 1.9). 
 
Figure 1.9 - Simple Jabloński diagram  
Diagram illustrates how a molecule absorbs a photon; this causes the outer shell electron to move from the ground 
state to a higher energy level. The electron can lose energy as it cascades through vibrational energy levels before a 
photon is emitted and the electron returns to the ground state (fluorescence).  
 
The phenomena can also be described by the Beer-Lambert Law which states that the optical 
absorbance in a transparent solvent is proportional to both the sample cell pathlength and the 
chromophore concentration. The Beer-Lambert Law follows: 
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Equation 1.1 - Beer-Lambert Law 
       
Where; 
  is the absorbance 
  is the extinction coefficient  
  is the concentration of the sample  
  is the pathlength of the cell 
 
Absorbance measurements are paramount to the study of biochemistry and have been used to 
study biological molecules, such as pigments, proteins, DNA, and many small organic 
molecules (Penzer, 1968). Absorbance is widely used to determine concentration, identify 
chromophores, examine enzyme-catalysed reactions and establish the structure of compounds 
(Penzer, 1968). Proteins for example absorb ultraviolet light with an absorbance maxima at 
280 and 200 nm (Yanari and Bovey, 1960). This phenomenon results from proteins containing 
amino acids with aromatic rings (tryptophan, tyrosine and phenylalanine) which absorb around 
280 nm while the absorbance at 200 nm is primarily caused by peptide bonds.  
An extension of absorbance spectrometry that is often used in biology is circular dichroism 
(CD). CD uses circularly polarised light to determine the secondary structure of proteins as well 
as other macromolecules including DNA and RNA. This technique measures the difference in 
absorption of left-handed circularly polarised light and right-handed circularly polarised light 
and is able to observe conformational changes in structure (Norden et al., 2010).  In this 
project another form of absorbance spectrometry will be used as the basis of a pathogen 
detection system. This method uses linearly polarised light and is called linear dichroism (LD).  
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1.2.1.2. Theory of linear dichroism 
Linear dichroism is a form of light spectroscopy that is based on the absorbance of linearly 
polarised light. LD is defined as “the difference in absorption, A, of light linearly polarised 
parallel (∥) and perpendicular (⊥) to an orientation axis” (Norden et al., 2010) : 
          
Linearly polarised light is a form of light in which the axis of the light wave oscillates in a single 
defined plane. LD uses two forms of plane polarised light, which are defined as parallel and 
perpendicular to a given orientation direction. An LD spectrum is only produced when the 
parallel polarised light is absorbed to a different degree than perpendicular polarised light. 
This effect is only observed when chromophores are aligned. The sign and magnitude of the LD 
signal indicates the extent of orientation of components within a sample with respect to the 
alignment axis. Figure 1.10 shows that for example, a positive LD signal implies that the 
orientation of the electronic transition of the sample is more parallel than perpendicular to the 
orientation axis (i.e. A  ＞ A⊥ and therefore, LD＞0). If the component of the sample is more 
perpendicularly aligned than parallel, the LD signal is negative (i.e. A∥＜ A⊥, therefore, LD ＜0) 
as seen in figure 1.11.  
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Figure 1.10 - LD schematic diagram (parallel) 
A schematic diagram illustrating the principles underpinning LD. When electrons within a molecule in an oriented 
sample are moving parallel to the orientation axis, they will absorb the light linearly polarised parallel to the 
orientation axis. This will cause the electrons within the molecule to move to a higher energy state. However the 
electrons will not absorb the light linearly polarised perpendicular to the orientation axis. This case therefore gives a 
positive LD signal. 
 
Figure 1.11 - LD schematic diagram (perpendicular) 
A schematic diagram illustrating the principles underpinning LD. When electrons within a molecule in an oriented 
sample are moving perpendicular to the orientation axis, they will absorb the light linearly polarised perpendicular 
to the orientation axis. This will cause the electrons within the molecule to move to a higher energy state. However 
the electrons will not absorb the light linearly polarised parallel to the orientation axis. This case therefore gives a 
negative LD signal. 
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A key aspect of LD is that to produce an LD signal the molecules in the sample need to be 
aligned at the molecular level (figure 1.12). For non-aligned molecules the overall LD signal is 
zero because the molecules are all randomly positioned. It is this observation that provides the 
basis of the assay developed in this project where LD is used as a probe for the alignment of an 
assay reagent. 
Figure 1.12 - The effect of molecular alignment on LD 
a) Demonstrates that when the electronic transitions within the sample are not aligned with one of the light beams 
absorption cannot occur. Whereas b) shows that when they are aligned absorption can occur. 
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1.2.1.3. Molecular alignment methods  
Alignment of molecules is essential in LD spectrometry and can be achieved using a number of 
different methods which are appropriate for different types of biomolecules (Rodger, 1993). 
These methods rely on some form of asymmetry in the molecular structure. This might include 
magnetic, electronic or structural asymmetry.  In this project, methods are used that allow the 
alignment of structurally asymmetric molecules. Such molecules have a high aspect ratio 
(shapes with one axis much larger than the other) e.g. DNA (Dafforn and Rodger, 2004), and 
are commonly aligned using hydrodynamic methods which include thin film orientation 
(Bechinger et al., 1999), squeezed gel orientation (Tapie et al., 1982), and shear flow 
orientation (Rodger et al., 2002). 
The most common method for aligning structurally asymmetric molecules for LD 
measurements is shear flow orientation; this method also has the advantage of being ideally 
suited to liquid samples. Such shear alignment experiments are usually carried out in a Couette 
cell, in which a sample is placed between two concentric cylinders one of which is rotated with 
respect to the other (figure 1.14). For optical measurements in this system the cylinders are 
formed from a transparent material for example a quartz rod in a quartz capillary (figure 1.15) 
(Marrington et al., 2004). Continuous flow is achieved by rotating this quartz capillary using a 
motor; this is typically fitted at the base of the cell (figure 1.13). The rotating capillary creates a 
viscous drag which causes a flow gradient in the solution flowing through the small gap 
between the capillary and the rod. 
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Figure 1.13 - LD instrument 
A) A Couette flow cell B) A linear dichroism instrument (photographed by Julia Kraemer). 
 
 
Figure 1.14 - Quartz Couette and sample chamber 
A) Quartz Couette and quartz rod used in a LD instrument. B) The quartz Couette viewed through the optical lens of 
the LD instrument. A sample is placed into the quartz Couette and the quartz rod is placed inside before an LD 
measurement is made (photographed by Julia Kraemer). 
 
A                                                      B 
A                                                                                B 
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Figure 1.15 - Capillary and rod used to produce shear flow in LD 
Capillary and rod used to produce shear flow in the LD instrument. Reproduced from Marrington et al. (2004). 
(Marrington et al., 2004) 
1.2.2. Applications in Biology 
The use of LD in biology has increased over the past 40 years; this can be seen in a survey of 
papers using Pubmed with Linear Dichroism in the title which shows that the number of papers 
increased steadily. Only one paper was published with LD in the title in the 1960s (Brahms et 
al., 1968). Prior to this paper the technique was known as ultra violet (UV) dichroism (Bendet 
and Mayfield, 1967, Higashi et al., 1963, Ruch, 1957). Between 1960 and 1980 there were 54 
papers published with LD in the title. Between 1980 and 2014, 236 papers have been 
published with LD in the title, demonstrating a steady growth of LD as a spectroscopic 
technique.  
1.2.2.1. LD and structural studies of DNA  
Part of the growth in publications using LD has been an increasing application of the technique 
to the study of a wide range of biomolecules that can be aligned. Perhaps the most important 
of these being DNA, which probably represents the system with the largest accumulation of LD 
data. For example LD has been used to examine the interactions between DNA and DNA-
bound ligands, where LD is able to probe the orientation of the ligand. This does not show 
where the particular ligand binds to the DNA, but determines the orientation of the ligand 
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providing insights into the binding mode (Rodger et al., 2006). LD Studies have shown that 
ligands are capable of intercalating between the DNA bases, for example in the case of the 
binding properties of potential anti-tumour agents (Dalla Via et al., 2002). LD has also been 
used to show ligands can be oriented by binding along the minor (Nguyen et al., 2004) and 
major groove (Lee et al., 2002) of DNA.  
The ability of LD to detect the alignment of a sample was first used as the basis of an assay 
when it was applied to the detection of DNA mutations (Halsall et al., 2001). Halsall et al. 
(2001) used LD to study the -glucocerebrosidase gene which is linked to Gaucher disease. 
Polymerase chain reaction (PCR) amplimers were prepared from exon 10 in the -
glucocerebrosidase gene in patients known to have compound heterozygous (h1/h2) and 
heterozygous (h1/wt and h2/wt) mutations. A control PCR amplimer was also prepared from 
patients with no mutations (wt/wt). The LD spectra of these samples are shown in figure 1.16. 
At 260 nm all samples exhibit a negative LD signal of similar magnitude, corresponding to the 
base pairs being oriented perpendicular to the DNA helix axis. At 230 nm the peak is positive 
for all samples corresponding to a greater parallel alignment. Crucially, the LD signal is related 
to the number of mismatched pairs, with the sample containing no mutations (wt/wt) 
producing the highest LD signal, whilst the compound heterozygous sample (h1/h2) produces 
the lowest LD signal. The LD signals from the different PCR amplimers can be discriminated and 
hence the change to the DNA structure caused by the mutations can be detected. This 
demonstrates that LD is capable of detecting mismatched base pairs in a PCR amplimer greater 
than a kilobase in length.  
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Figure 1.16 - Flow LD spectra of PCR amplimers 
Flow LD spectra of PCR amplimers prepared from patients confirmed to be a control without any mutation for the 
-glucocerebrosidase gene (wt/wt) (thick solid line), patients who were heterozygous for one mutation (h1/wt) 
(thin solid line), (h2/wt) (thin dashed line), and patients who were compound heterozygote (h1/h2) (thick dashed 
line). The maximum at 230 nm is related to the number of mis-matched base pairs. Reproduced from Halsall et al. 
(2001). (Halsall et al., 2001).  
1.2.2.2. Protein fibres  
LD has not only been used to study aligned DNA, but can also be applied to the study of 
aligned protein fibres. In the 1960s and 1970s LD was used to gain new insights into the 
orientation of secondary structure elements, aromatic amino acids and bound nucleotide 
within F-actin (Higashi et al., 1963);(Miki and Mihashi, 1976). These experiments were limited 
by the large amounts of samples required to make a measurement. More recently an 
improved capillary Couette cell has been developed (Dafforn et al., 2004) and was used with 
two medically important protein ﬁbres (the all-β-sheet amyloid ﬁbres of the Alzheimer’s 
derived protein Aβ and the long-chain assemblies of α1-antitrypsin polymers). This data 
provided information on the fibre structures (Dafforn et al., 2004). The development of a 
temperature controlled micro volume Couette LD cell also allowed the analysis of tubulin 
microtubules. This study probed the structural reorientations of tubulin chromophores which 
occur during polymerisation and determined the effect of ligand binding on fibre structure 
(Marrington et al., 2006). Adachi et al. (2007) also successfully utilised LD to detect and 
characterise fibril formation by amyloid peptides. In addition, LD has been used to carry out 
structural analysis of molecules within linear polymers. For example Small et al. (2007) used LD 
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to investigate a specific conformational change in guanosine-5'-triphosphate (GTP) bound to 
filamenting temperature-sensitive mutant Z (FtsZ) polymers (which are found in the 
cytoskeleton of bacterial cells) upon bundling by an accessory cell division protein. They found 
that the conformational change seen in bound GTP revealed a general mechanism of FtsZ 
bundling. To further explore the impact of protein conformation on LD spectra, Bulheller et al. 
(2009) constructed a model to calculate the electronic structure directly. They investigated 
prototypical proteins including a self-assembling ﬁbre and tropomyosin (all--helical), FtsZ (an 
 protein), an amyloid ﬁbril (-sheet), and collagen (poly(proline)-II helices). They found that 
combining experiment with calculation clarified the protein orientation and the orientation of 
the chromophores within the protein ﬁbres.(Bulheller et al., 2009, Small et al., 2007, Adachi et al., 2007) 
1.2.2.3. Bacteriophage 
In 1967 LD spectroscopy was first used in the study of filamentous bacteriophage (Bendet and 
Mayfield, 1967). Using LD, the internal structure of the fd bacteriophage (a type of filamentous 
bacteriophage known to infect E. coli) was studied providing insights into the orientation of 
structural elements within the bacteriophage (Bendet and Mayfield, 1967) (figure 1.17). These 
results showed that the DNA within the fd bacteriophage produced a negative LD signal, whilst 
the proteins within the fd bacteriophage gave a positive LD signal. From this they could 
conclude that molecules within the same bacteriophage have a different orientation. The 
study was further extended to show that the base pairs of tobacco mosaic virus genome are 
orientated more or less parallel to the longitudinal axis of the virus (Schachter et al., 1966). 
(Clack and Gray, 1992). 
Clack and Gray (1992) built on these studies, measuring LD of other filamentous 
bacteriophages, Pf1, Pf3 and Ike as well as fd filamentous bacteriophages. They found that 
these filamentous bacteriophages produced similar protein and DNA LD spectra.  
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Figure 1.17 - Difference in absorbance of perpendicular and parallel light by bacteriophage 
The first measurements of the difference in absorbance of perpendicular and parallel light by bacteriophage. The LD 
spectra indicates that the DNA and protein are aligned differently. Reproduced from Bendet and Mayfield (1967).  
(Bendet and Mayfield, 1967).  
It is interesting to compare the instrumentation used in these studies. Bendet and Mayfield 
(1967) used a flow cell which required 10 mL of 1.5 mg/mL of bacteriophage solution per 
experiment, which was constantly flowed through a 1 mm2 cross-section quartz capillary to 
achieve alignment. In contrast, Clack and Gray (1992) required 30 mL of 3.4 mg/mL 
bacteriophage solution for each LD experiment. This highlights large sample requirement as a 
limitation for LD in the early days. To address this, Marrington et al. (2004) developed a 
Couette cell format in which the sample requirement is reduced to 25 µL and 200 µM 
concentrations. The micro-volume LD cell uses a quartz capillary which rotates around a 
mounted rod (figure 1.15). In this project a capillary cell that requires as little as 80 µL is used, 
which is a significant decrease compared to other laboratories. 
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Figure 1.18 - Structure of M13 bacteriophage 
The structure of M13 bacteriophage is displayed in image A. Reproduced from Sidhu (2001). Image B is a model of 
the M13 coat reconstructed from fiber X-ray data of M13. This image reveals how the p8 coat proteins form an 
organised structure. The C termini are buried inwards, while the N termini are facing outwards on the surface of the 
particle. Reproduced from Sidhu (2001). Image C is a transmission electron microscope (TEM) image of wild type 
(wt) M13 bacteriophage. Reproduced from Murugesan et al. (2013). (Murugesan et al., 2013). (Sidhu, 2001) 
These early studies also show that the bacteriophage particle has a high enough aspect ratio to 
align in shear flow. Electron microscopy studies confirmed this, showing that M13 
bacteriophage has a diameter of approximately 6.5 nm and a length of 900 nm (Murugesan et 
al., 2013) (figure 1.18).  
In this project M13 bacteriophage will be used extensively as a scaffold for development of a 
novel assay. It is therefore important that the M13 structure is described in greater detail than 
the other fibres in this section. M13 consists of single stranded DNA encapsulated by a protein 
coat. The protein coat is made up of one major coat protein known as p8 and there are 
approximately 2700 copies of p8 along the coat. There are 5 copies of each of the minor coat 
proteins known as p3, p6, p7 and p9, which are situated at the ends of the bacteriophage 
A                                                                                            C 
B 
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(Sidhu, 2001). All 5 of the coat proteins provide structural properties to the M13 
bacteriophage, however only p3 is utilised for host cell infection. The major coat protein p8 is 
positioned such that its C-terminus associates with the internalised DNA. Association of the 
hydrophobic regions of adjacent p8 proteins stabilises their interaction with one another, and 
the particle itself. The N-terminus of the protein is situated externally and plays a key role in 
facilitating the bioengineering potential of the M13 bacteriophage (Sidhu, 2001).  
 
Figure 1.19 - Schematic diagram of M13 bacteriophage 
M13 bacteriophage consists of approximately 2700 copies of coat protein p8 which surrounds the internal single 
stranded DNA. There are also 5 copies of each of the minor coat proteins (p3, p6, p7 and p9), which are located at 
the ends of the bacteriophage. Reproduced from Li et al. (2010). 
M13 is a filamentous bacteriophage and infects E. coli cells which present F pili on their 
surface. Infection commences when the p3 coat protein attaches to the F pilus. This is followed 
by the insertion of the M13 single stranded DNA into the cytoplasm of the cell. In order to 
produce M13 bacteriophage proteins within the cell, the single stranded DNA is transformed 
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into double stranded DNA and is then replicated. Single stranded DNA is then produced 
through a rolling circle replication process. The coat proteins are embedded into the 
membrane of the host cell and other proteins form gated pores to allow the viral DNA to be 
extruded through the pore with its coat proteins assembling on to it (figure 1.20). The M13 
bacteriophage particles are released and this is a non-lytic process as the E. coli cells continue 
to grow and divide, but at a much slower rate (Sidhu, 2001).  
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Figure 1.20 - M13 bacteriophage lifecycle 
A diagram illustrating the lifecycle of M13 bacteriophage. (1) Infection of E. coli cell by M13 bacteriophage via the 
p3 coat protein. The single stranded viral DNA is injected into the cell and this is used as a template to produce 
double stranded DNA. (2) This results in host-mediated protein synthesis, producing the M13 bacteriophage 
proteins. (3) The viral DNA is replicated and (4) the M13 bacteriophages are assembled and released from the E. coli 
cell. Reproduced from Mullen et al. (2006). (Mullen et al., 2006). 
Examination of the LD spectrum of M13 shows positive peaks between 200-240 nm which 
arise from peptide backbone transitions. A negative band between 240 nm and 260 nm arises 
from DNA transitions indicating that the base pairs are perpendicular to the long axis of the 
bacteriophage. A positive peak between 260 nm and 300 nm is due to aromatic transitions of 
Tyrosine, Tryptophan (maximum at 280 nm) and Phenylalanine (Clack and Gray, 1992, 
Pacheco-Gomez et al., 2012). These observations of aligned bacteriophage and resulting LD 
signals have provided the basis for the LD based assay method detailed in this project.  
However it is clear that bacteriophage alone will not function as an assay reagent. To work 
with such a reagent, the bacteriophage has to be engineered in order to allow it to interact 
with the assay target. Engineering a biological molecule to function in a new system is one of 
the underlying principles of a new area of science, synthetic biology.  
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1.3. Synthetic biology 
Synthetic biology is the construction of biological systems and re-construction using 
engineering principles of existing natural biological systems, for useful purposes (Khalil and 
Collins, 2010).  
Synthetic biologists can be said to come in two classes. One uses elements from natural 
biology to form an unnatural structure or systems. Whereas the other uses unnatural elements 
to recreate naturally occurring systems (Benner and Sismour, 2005). Synthetic biology first 
appeared in the scientific literature in 1980 in an article titled “Gene surgery: on the threshold 
of synthetic biology” by Barbara Hobom (Hobom, 1980). She used the term synthetic biology 
to describe genetically engineered bacteria using recombinant DNA technology; here the term 
was synonymous with bioengineering. Synthetic biology was later mentioned in 2003 as a 
means to re-construct life which is an extension of biomimetic chemistry (Benner, 2003), 
where artificial molecules are synthesised and mimic natural molecules e.g. enzymes. 
Synthetic biology therefore attracts engineers who want to extract parts from living systems 
and test them as structural units and re-build them in a way to mimic living systems (Benner 
and Sismour, 2005). It is expected that the outputs of synthetic biology will be cheaper drugs, 
greener fuels and targeted therapies (Khalil and Collins, 2010).  
1.3.1. Synthetic biology and detection 
Synthetic biology has also provided new approaches to detection. Saeidi et al. (2011) 
engineered E. coli to detect and eradicate Pseudomonas aeruginosa (P. aeruginosa). They 
developed a synthetic genetic system which comprised of quorum sensing, killing and lysing 
devices to enable E. coli to detect and kill a strain of P. aeruginosa. The E. coli was engineered 
to firstly detect the P. aeruginosa using quorum sensing, and then to produce and release 
pyocin (an antimicrobial peptide) by lysing the E. coli chassis. They found that the engineered 
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E. coli cells were successful in detecting and killing the P. aeruginosa cells as there was a 99% 
drop in viable P. aeruginosa cells and a 90% drop in the formation of biofilms (Saeidi et al., 
2011). Similarly Ghosh et al. (2012) utilised synthetic biology in detection by using modified 
M13 bacteriophage. They were able to highlight cancer cells and tumours in mice for magnetic 
resonance imaging. Iron oxide magnetic nanoparticles were assembled along the M13 coat 
and the M13 was engineered to display the target ligand at the distal end which detects a 
glycoprotein over expressed in cancer cells (Ghosh et al., 2012). M13 bacteriophage also 
appears in another detection system where it was engineered to act as a scaffold (Lee et al., 
2012). These scientists used DNA-conjugated M13 to detect an antigen where a colour change 
occurred in the presence of the specific antigen. DNA-conjugated M13 was able to hybridise 
with DNA-conjugated gold nanoparticles in the presence of the antigen and this led to a colour 
change. The antigen was then identified using a microarray. These studies demonstrate how 
synthetic biology is advancing and that organisms can be manipulated to execute specific 
tasks, in this case detect particular target molecules.  
1.4. LD in immune detection  
Using a combination of synthetic biology and LD, a new assay has been developed in the 
laboratory of Professor Dafforn to detect specific target molecules (Pacheco-Gomez et al., 
2012).  
1.4.1. Theory 
As discussed earlier, LD requires sample alignment at the molecular level; this means that the 
amplitude of an LD signal is related to the alignment of a sample. The sensitivity of LD to the 
alignment of a biomolecular assembly in shear flow has already been used as the basis of a 
genetic assay (Halsall et al., 2001).  
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In its most basic sense any LD assay is made up of a minimum of two components, an LD 
spectrometer and a reagent. The reagent must have an LD signal which can be detected by the 
spectrometer. That signal must then be perturbed by an interaction between the reagent and 
the target, resulting in a change in the LD signal that can be measured. Crucial to a successful 
assay is the choice of reagent as the reagent has to be:  
 A long rigid rod that aligns under shear flow.  
 Biochemically flexible in order to attach chromophores and moieties which will ensure 
the specificity for the target molecule. 
 Stable. 
One such reagent is M13. 
The rigid nature of M13 allows easy alignment which produces a distinct and robust LD signal 
(Clack and Gray, 1992), making it potentially a good scaffold for an LD based assay. M13 is also 
genetically and biochemically flexible. The flexibility has been exploited for many years with 
the most common modification being the fusing of exogenous proteins to the capsid. The most 
famous example of this is the fusion of antibodies to p3 for antibody engineering (Barbas et al., 
1991). Barbas et al. (1991) demonstrated the versatility of M13 bacteriophage by producing 
M13 displaying combinatorial antibody Fab libraries.  The carboxyl-terminal domain of the p3 
coat protein was fused with Fab fragments that bound to tetanus toxin. Usefully, M13 
bacteriophage also demonstrates a high degree of stability (Branston et al., 2013) with it being 
resistant to heat (Holliger et al., 1999), various organic solvents (Olofsson et al., 2001), urea, 
acid, alkali and other stresses, (Petrenko and Vodyanoy, 2003).  
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Given all of these characteristics, recent work by Pacheco-Gomez et al. (2012) has 
demonstrated that M13 could be functionalised to detect E. coli O157 in conjunction with LD 
(as described below). 
1.4.2. Previous work on an M13/LD based assay 
Pacheco-Gomez et al. (2012) developed an assay capable of detecting E. coli O157 using M13 
and LD. They achieved this by fusing an FB domain (derived from protein A) on to the p3 coat 
protein of M13 (FB-M13). The FB domain was able to bind specifically to the secondary 
antibody forming a complex which aligned in a flow cell producing a characteristic M13 signal. 
The secondary antibody was able to interact with the constant region of the pathogen specific 
antibody (primary antibody). The primary antibody that was used in this study was raised to 
bind specifically to an antigen on the surface of E. coli O157 and was therefore used to detect 
E. coli O157.  When the anti-E. coli O157 and E. coli O157 were added to the conjugated FB-
M13 the LD signal dropped significantly (figure 1.21 and 1.22). The concentration of primary 
and secondary antibody was also reduced 10-fold and increased 2-fold to observe the 
sensitivity of the assay to antibody concentration. The results demonstrated that reducing the 
antibody concentration 10-fold limited the sensitivity of the assay, but increasing it 2-fold did 
not significantly improve the LD signal (figure 1.22B). Pacheco-Gomez et al. (2012) therefore 
confirmed that M13 coupled with LD could provide a promising new method of detection for 
bacteria based on immune techniques.  
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Figure 1.21 - Principle behind an existing M13/LD based assay 
A schematic diagram illustrating the principle behind the pathogen detection assay used by Pacheco Gomez et al. 
(2012) which utilised LD and M13 bacteriophage. M13 bacteriophage labelled with anti-E. coli O157 antibody (via 
the p3 coat protein) aligns under shear flow, thus a LD signal is seen. If a sample containing E. coli O157 is added to 
the M13 reagent, alignment is disrupted due to the formation of bonds between the antibody labelled M13 and the 
E. coli O157. Therefore a reduction in the LD signal is observed.   
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Figure 1.22 - E. coli O157 detection using an existing M13/LD based assay 
A) The effect of various protein complexes with FB-M13 on the bacteriophage LD spectrum. Thick dark line is FB-
M13 + E. coli 0157 (10
7
 cells/mL final concentration). Dotted line is FB-M13 + primary antibody (1 mg/mL) + 
secondary antibody (1 mg/mL) + E. coli BL21 (10
7
 cells/mL final concentration). Thin line is FB-M13 + primary 
antibody (1 mg/mL) + secondary antibody (1 mg/mL) + E. coli 0157 (10
7
 cells/mL final concentration). The LD signal 
only drops when the target bacterium is present. B) The effect of varying concentrations of primary and secondary 
antibodies on the assay signal. Reproduced from Pacheco-Gomez et al. (2012). (Pacheco-Gomez et al., 2012) 
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1.5. Aims 
Taken together there is a clear need for new assay methods and in this project we explore the 
use of M13 bacteriophage coupled with LD in a range of different assay types. The project is 
broken down into a number of aims and these are: 
 To increase M13 bacteriophage production to meet the requirements for the assay. 
 To covalently attach various chromophores onto M13 bacteriophage in preparation for 
a multiplexed assay and multimodal assay. 
 To increase the sensitivity of pathogen detection using LD and M13 bacteriophage. 
 To develop a method to detect small molecules using LD and M13 bacteriophage. 
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2 CHAPTER 2 
- MATERIALS AND METHODS 
2.1. Materials 
A stock of wild-type (wt) M13 bacteriophage was provided by Professor John Ward (University 
College, London). Heat-killed E. coli O157:H7 was provided from KPL (Maryland, USA). The 
quartz cuvette (0.3 cm pathlength) used to obtain the absorbance spectra, was provided by 
Starna (Essex, UK).  (Sambrook and Russell, 2001, New England Biolabs, 2011) 
2.2. Methods 
2.2.1. Production of M13 bacteriophage 
There are currently two commonly used methods for the production of wt M13. One method 
is based on Sambrook and Russell (2001), while the other is based on New England Biolabs 
(2011).   
2.2.1.1. Method based on Sambrook and Russell (2001) 
Four hundred mL of autoclaved Luria Broth (LB) medium in a 2.5 L flask containing tetracycline 
to a final concentration of 5 μg/mL was inoculated with 500 μL of (glycerol stock of log phase) 
Top10F' E. coli (Invitrogen, California, USA) (F'[lacIq Tn10(tetR)] mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 deoR nupG recA1 araD139 Δ(ara-leu)7697 galU galK rpsL(StrR) endA1 λ- 
) and 5 μL of 13 mg/mL wt M13 bacteriophage. The culture was then incubated overnight at 37 
°C at 180 rpm. The culture was then decanted into 450 mL centrifuge tubes and centrifuged at 
11000 rpm for 15 minutes at 4C in a fiberlite F10B 6X500 rotor. The supernatant was mixed 
with 20% v/v of 25% w/v PEG (polyethylene glycol) 6000/2.5 M NaCl and left on ice for 15 
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minutes. The precipitated M13 particles were then recovered by centrifugation of the samples 
at 11000 rpm for 15 minutes at 4C in a fiberlite F10B 6X500 rotor. The supernatant was 
removed and the pellet was resuspended in 50 mM phosphate buffer, pH 8.0. The M13 was 
passed through a 0.22 μm membrane filter twice (Millipore, Massachusetts, USA) to remove 
any E. coli cells.  
2.2.1.2. Method from New England Biolabs (2011) 
Two hundred and fifty mL of autoclaved LB containing tetracycline (a final concentration of 5 
μg/mL) was inoculated with 500 μL of Top10F’ E. coli (Invitrogen, California, USA) and 
incubated overnight at 37 °C, 180 rpm. The culture was diluted by transferring 40 mL of the 
overnight culture to 360 mL LB, and tetracycline was added again to provide a final 
concentration of 5 μg/mL. Five µL of 13 mg/mL wt M13 stock was added and was incubated for 
4.5-5 hours at 37 °C, 180 rpm. The culture was decanted into 500 mL centrifuge tubes and 
centrifuged at 11000 rpm for 15 minutes at 4C in a fiberlite F10B 6X500 rotor. The 
supernatant was transferred into new 500 mL centrifuge tubes and centrifuged again at 11000 
rpm for 15 minutes at 4C in a fiberlite F10B 6X500 rotor. The upper 80 % of the supernatant 
was taken and mixed with 20% v/v of 25 % w/v PEG6000/2.5 M NaCl in a new tube and, left to 
precipitate overnight at 4 °C. The tubes were then centrifuged at 11000 rpm for 15 minutes at 
4 °C in a fiberlite F10B 6X500 rotor, the supernatant was discarded and the pellet was 
resuspended in 1 mL 50 mM phosphate buffer pH 8 and transferred into a 1.5 mL eppendorf 
tube. This was then centrifuged in a bench top centrifuge (Spectrafuge 16M, Labnet) at 
14000 rpm for 5 minutes at 4 °C, to pellet the remaining cells. The supernatant was transferred 
into a new tube and precipitated with 20% v/v of 25 % w/v PEG6000/2.5 M NaCl for 1 hour at 
4 °C. These were centrifuged at 14000 rpm for 10 minutes at 4 °C in a bench top centrifuge 
(Spectrafuge 16M, Labnet). The supernatant was discarded and the pellet was resuspended in 
100 µL of 50 mM phosphate buffer pH 8. 
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2.2.1.3. New method for M13 bacteriophage production 
Four hundred mL of autoclaved LB medium in a 2.5 L flask containing tetracycline to a final 
concentration of 5 μg/mL was inoculated with 500 μL of (glycerol stock of log phase) Top10F’ 
E. coli (Invitrogen, California, USA) and 5 μL of 13 mg/mL wt M13. The culture was then 
incubated overnight at 37 °C at 180 rpm. The culture was decanted into 450 mL centrifuge 
tubes and centrifuged at 11000 rpm for 15 minutes at 4C in a fiberlite F10B 6X500 rotor. The 
supernatant was then transferred into new tubes and centrifuged for 15 minutes at 11000 rpm 
at 4C in a fiberlite F10B 6X500 rotor. The upper 80 % of the supernatant was mixed with 20% 
v/v of 25 % w/v PEG6000/2.5 M NaCl in a new tube and left to precipitate for 15 minutes at 
4 °C. They were then centrifuged for 15 minutes at 11000 rpm at 4 °C in a fiberlite F10B 6X500 
rotor. The supernatant was discarded and the pellet was resuspended in 1 mL 50 mM 
phosphate buffer pH 8 and transferred into 1.5 mL eppendorf tubes. These were centrifuged at 
14000 rpm for 5 minutes at 4 °C in a bench top centrifuge (Spectrafuge 16M, Labnet) to pellet 
the remaining cells. The supernatant was transferred into a new tube and precipitated with 
20% v/v of 25 % w/v PEG6000/2.5 M NaCl for 15 minutes at 4 °C. These were then centrifuged 
at 14000 rpm for 10 minutes at 4 °C in a bench top centrifuge (Spectrafuge 16M, Labnet) and 
the supernatant discarded. The pellet was resuspended in 100 µL 50 mM phosphate buffer pH 
8.  
2.2.1.4. Optimising precipitation time for M13 bacteriophage production 
Four hundred mL of autoclaved LB medium in a 2.5 L flask containing tetracycline to a final 
concentration of 5 μg/mL was inoculated with 500 μL of Top10F’ E. coli and 5 μL of 13 mg/mL 
wt M13. The culture was then incubated overnight at 37 °C at 180 rpm. The culture was 
decanted into 450 mL centrifuge tubes and centrifuged at 11000 rpm for 15 minutes at 4 °C in 
a fiberlite F10B 6X500 rotor. The supernatant was then transferred into new tubes and 
centrifuged for 15 minutes at 11000 rpm at 4 °C in a fiberlite F10B 6X500 rotor.  The upper 
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80 % of the supernatant was mixed with 20% v/v of 25 % w/v PEG6000/2.5 M NaCl in a new 
tube and left to precipitate for 5/30/45/60/120 minutes at 4 °C. These samples were then 
centrifuged for 15 minutes at 11000 rpm at 4 °C in a fiberlite F10B 6X500 rotor. The 
supernatant was discarded and the pellet was resuspended in 1 mL 50 mM phosphate buffer 
pH 8 and transferred into 1.5 mL eppendorf tubes. These were centrifuged at 14000 rpm for 
5 minutes at 4 °C in a bench top centrifuge (Spectrafuge 16M, Labnet) to pellet the remaining 
cells. The supernatant was transferred into a new tube and precipitated with 20% v/v of 25 % 
w/v PEG6000/2.5 M NaCl for 5/30/45/60/120 minutes at 4 °C. These were then centrifuged at 
14000 rpm for 10 minutes at 4 °C in a bench top centrifuge (Spectrafuge 16M, Labnet) and the 
supernatant discarded. The pellet was resuspend in 100 µL 50 mM phosphate buffer pH 8.  
2.2.1.5. Measurement of M13 bacteriophage concentration 
A Jasco (Japan) V550 UV/Vis-Spectrophotometer was used to measure the concentration of 
the M13 bacteriophage and a 0.3 cm pathlength quartz cuvette (Starna, Essex, UK) was used. 
The parameters used can be seen in table 2.1. 
Table 2.1 - UV/Vis-Spectrophotometer (Jasco V550 UV/Vis spectrophotometer) parameters 
Parametric mode Abs 
Response Medium 
Band width 1 nm 
Scanning speed 200 nm/min 
Start 800 nm 
End 200 nm 
Data pitch 0.5 nm 
 
The extinction coefficient of M13 bacteriophage is 3.84 cm-2/mg at 269 nm (Niu et al., 2008). 
The M13 sample was diluted using 50 mM phosphate buffer (pH 8.0) and the concentration 
was determined using the Beer Lambert’s Law (see Equation 1.1) which was rearranged to 
provide the concentration of the M13 bacteriophage: 
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Equation 2.1 - Rearranged Beer-Lambert law 
   
 
  
 
2.2.1.6. Collection of LD data 
After each M13 bacteriophage culture, the LD spectra of the purified bacteriophage was 
recorded using Jasco (Japan) J715 spectropolarimeter and a Couette flow cell. This ensured 
that bacteriophage was present in the sample and that the correct LD signal was produced.  
 
C 
 
Figure 2.1 - Components of the LD instrument 
A) Is a Couette Flow Cell (photographed by Julia Kraemer). B) Capillary and rod used to produce shear flow in the LD. 
Reproduced from Marrington et al. (2004). C) The power supply is provided by ‘m’, switching mode power supply, 
model N93CX (photographed by Julia Kraemer).(Marrington et al., 2004) 
A                                                                                    B 
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 A Couette containing the sample was placed into the spectropolarimeter and a quartz rod 
placed inside (figure 2.1 A and B). A motor is attached to the Couette and rotates the Couette, 
causing a state of continuous flow. The power supply is provided by ‘m’, switching mode 
power supply, model N93CX (figure 2.1 C). For each experiment, a baseline (non-rotating 
capillary) was collected and then subtracted from the signal and the signal was zeroed at 350 
nm. All of the rotating signals were recorded at 3V. The parameters used can be seen in table 
2.2 (see figure 2.2 for LD spectra). All LD data was processed using the Spectra Analysis 
program (version 1.53.04 Build 1). 
Table 2.2 - Jasco (Japan) J-715 spectropolarimeter parameters used to gather LD spectra. 
Sensitivity Standard (0.1 ΔOD) 
Start 350 nm 
End 190 nm 
Data pitch 1 nm 
Scanning mode Continuous 
Scanning speed 200 nm/min 
Response 1 second 
Band width 2 nm 
Accumulation 1 
 
2.2.1.7. Calibration of LD instrument 
Obtaining an LD signal is an essential part of the assay and hence it was important to 
determine the dynamic range of the instrument. Similarly high concentrations can cause 
interference by background emissions resulting in a distorted spectrum. Different dilutions 
from the same M13 stock were made and their LD spectrum was measured with 5 V applied to 
the motor of the LD Couette.  
The results were compiled (figure 2.2) and analysed to find out the optimum concentration at 
which characteristic M13 peaks could be visualised in the LD signal. The parameters used were 
the same as those used in table 2.2. The LD signal produced from 0.373 mg/mL was the 
optimal concentration for obtaining LD data because all of the peaks can be seen clearly. At 
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high concentrations the second peak is lost due to the high tension being so high, and this 
happens when there is too much absorbance and scattering. Figure 2.3 also shows that there is 
a strong linear relationship between the M13 concentration and LD signal at 280 nm. 
Figure 2.2 - LD spectra of various dilutions of M13 bacteriophage 
Graph shows the LD signals of various dilutions from the same M13 bacteriophage stock. 
 
 
Figure 2.3 - LD signal at 280 nm for various dilutions of M13 bacteriophage 
Plot showing change in LD signal with change in concentration of wt M13. 
 
When the LD readings at 280 nm for different concentrations were plotted, these data showed 
a linear relationship (figure 2.3). This indicates that LD could be used to determine the 
concentration of M13 bacteriophage in a sample. 
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2.2.2. Labelling of M13 bacteriophage with extrinsic chromophores 
2.2.2.1. Labelling M13 bacteriophage with fluorescamine 
A 10 mg/mL fluorescamine (Invitrogen, California USA) solution was freshly prepared by 
dissolving 10 mg of fluorescamine in 1 mL of DMSO (Fisher Scientific, New Hampshire, USA). A 
volume of 20 µL of fluorescamine solution was mixed with 0.8 mL of 2.5 mg/mL wt M13 in a 
test tube. The mixture was then incubated for 1 hour at room temperature with continuous 
mixing. The reaction mixture was then dialysed using 3,500 molecular weight cut off (MWCO) 
dialysis tubing (Sigma-Aldrich, Missouri, USA) in the presence of 50 mM phosphate buffer (pH 
8), to remove unbound dye. Dialysis was firstly carried out for 1 hour, followed by repeating it 
overnight and replacing the 50 mM phosphate buffer pH 8 with 250 mL of fresh buffer. The 
dialysed solution was stored in the absence of light at 4°C. 
2.2.2.2. Labelling M13 bacteriophage with rhodamine B isothiocyanate  
A 10 mg/mL stock of rhodamine B isothiocyanate (rhodamine) (Invitrogen, California, USA) was 
made in DMSO (Fisher Scientific, New Hampshire, USA). A volume of 20 µL of the dye was 
added to 0.8 mL of 2.5 mg/mL wt M13. This was incubated for 1 hour at room temperature 
with continuous mixing in the absence of light. This was then dialysed for 1 hour using 3,500 
KDa MWCO dialysis tubing (Sigma-Aldrich, Missouri, USA) in 250 mL of 50 mM phosphate 
buffer pH 8 at 4C, and then repeated overnight after replacing the buffer. 
2.2.2.3. Labelling M13 bacteriophage with fluorescein isothiocyanate isomer 1 
A 10 mg/mL stock of fluorescein isothiocyanate isomer 1 (FITC) (Sigma-Aldrich, Missouri, USA) 
was made in DMSO (Fisher Scientific, New Hampshire, USA). A volume of 100 µL of the dye 
was added to 1 mL of 2 mg/mL wt M13. This was incubated for 1 hour at room temperature in 
the absence of light with continuous mixing. The solution was then dialysed for 1 hour using 3 
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500 KDa MWCO dialysis tubing (Sigma-Aldrich, Missouri, USA ) in 250 mL of 50 mM phosphate 
buffer pH 8 at 4C. The dialysis was repeated overnight after replacing the buffer.  
2.2.2.4. Labelling M13 bacteriophage with 4-chloro-7-nitrobenzofurazan 
A 10 mg/mL stock of 4-chloro-7-nitrobenzofurazan (NBD chloride) (Invitrogen, California, USA) 
was made in DMSO (Fisher Scientific, New Hampshire, USA). A volume of 20 µL of the dye was 
added to 0.8 mL of 2.5 mg/mL wt M13. This was incubated for 1 hour at room temperature in 
the absence of light with continuous mixing. Following this, the solution was dialysed for 1 
hour using 3,500 MWCO dialysis tubing (Sigma-Aldrich, Missouri, USA) in 250 mL of 50 mM 
phosphate buffer pH 8 at 4C and this was repeated overnight after replacing the buffer. 
2.2.2.5. Labelling M13 bacteriophage with black hole quencher-10 
A 10 mg/mL stock of black hole quencher-10 (BHQ-10) (Biosearch Technologies, California, 
USA) was made in DMSO (Fisher Scientific, New Hampshire, USA). A volume of 20 µL of the dye 
was added to 0.8 mL of 2.5 mg/mL wt M13. This was incubated for 1 hour at room 
temperature in the absence of light with continuous mixing. Following this, the solution was 
dialysed for 1 hour using 3,500 MWCO dialysis tubing (Sigma-Aldrich, Missouri, USA) in 250 mL 
of 50 mM phosphate buffer pH 8 at 4C and this was repeated overnight after replacing the 
buffer. 
2.2.2.6. Labelling M13 bacteriophage with eosin-5-maleimide 
A starting material of 2 mg of wt M13 was mixed with 0.1 M phosphate buffer, pH 7.5 to give a 
volume of 400 µL. A 1 mg/mL stock concentration of N-succinimidyl-S-acetyl thioacetate 
(SATA) (Fisher Scientific, New Hampshire, USA) was made using DMSO (Fisher Scientific, New 
Hampshire, USA), and a 0.3:1 molar ratio of SATA (Fisher Scientific, New Hampshire, USA) to p8 
coat protein was added to the wt M13 and incubated for 1 hour at room temperature. The 
reaction was quenched by adding 10 % v/v of 50 mM ethylene diamine tetra acetic acid 
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(EDTA)/2.5 M Hydroxylamine solution pH 7.0 and left to incubate for another 15 minutes. To 
separate the M13 bacteriophage from the SATA, 100% v/v of 25 % w/v PEG6000/2.5 M NaCl 
was added and left on ice. After 15 minutes the M13 solution was centrifuged in a bench top 
centrifuge (Spectrafuge 16M, Labnet) for 10 minutes at 14000 rpm. The pellet was 
resuspended in 200 µL conjugation buffer, (50 mM phosphate buffer, 150 mM NaCl, 5 mM 
EDTA, pH 7) and the supernatant was discarded.  
A 10 mg/mL solution of eosin-5-maleimide (Invitrogen, California, USA) was freshly prepared 
by dissolving 1 mg of eosin-5-maleimide in 100 µL of DMSO. Of this 10 mg/mL stock of eosin-5-
maleimide solution, 100 µL was taken and mixed with 200 µL of M13 bacteriophage which had 
been modified using SATA. The mixture was then incubated overnight at 4°C. A 1 mg/mL 
solution of N-ethylmaleimide (NEM) (Thermo Scientific, New Hampshire, USA) was added to 
the M13 and dye solution to provide a 0.3:1 molar ratio of NEM to p8 coat protein, and left to 
incubate at room temperature for 15 minutes. 100% v/v of 25 % w/v PEG6000/2.5 M NaCl was 
added to the M13 solution and left on ice. After 15 minutes the M13 and dye solution was 
centrifuged in a bench top centrifuge (Spectrafuge 16M, Labnet) for 10 minutes at 14000 rpm. 
The pellet was resuspended in 500 µL 50 mM phosphate buffer, pH 8 and the supernatant was 
discarded.  
2.2.2.7. Measurement of labelling efficiency 
To measure the absorbance of the chromophores as well as the concentration of the M13, a 
Jasco (Japan) V-550 spectrophotometer was used. 
UV/Vis absorption spectra were measured at room temperature in a 0.3 cm pathlength quartz 
cuvette (Starna, Essex, UK). The parameters used are shown in table 2.3. Spectra of 50 mM 
phosphate buffer, pH 8 was also collected and used as the baseline for each experiment.  
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Table 2.3 - UV/Vis-Spectrophotometer (Jasco V550 UV/Vis spectrophotometer) parameters 
Parametric mode Abs 
Response Medium 
Band width 1 nm 
Scanning speed 200 nm/min 
Start 800 nm 
End 200 nm 
Data pitch 0.5 nm 
 
To measure the labelling efficiency, firstly the concentration of M13 was calculated and this 
was done by taking the absorbance value at 269 nm and inserting it into the Beer Lambert Law 
equation(see Equation 1.1), which was rearranged to provide the concentration (see Equation 
2.1). It is assumed that the binding of the dye does not change the extinction coefficient.  
The p8 concentration and the label concentration were calculated for each sample with 
extinction coefficients for the labels given in table 4.2. The labelling efficiency was calculated 
assuming 2700 p8 coat proteins on each M13 bacteriophage are available for reacting with the 
chromophores. This could then be expressed as a percentage of available p8 coat protein. 
Equation 2.2 - Labelling efficiency of M13 
                       
       
        
   
Where; 
C label is the concentration of label 
C M13 is the-concentration of M13 
 
2.2.2.8. LD measurements of chromophore labelled M13 
The LD experiments were carried out using a Jasco (Japan) J-715 (LD) spectropolarimeter and 
processed using the Spectra Analysis program (version 1.53.04 Build 1). LD spectral data were 
recorded at room temperature with the parameters in table 2.4. For each experiment, a 
baseline (non-rotating capillary) was collected and then subtracted from the signal and the 
signal was zeroed at 800 nm. All of the rotating signals were recorded at 3V. 
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Table 2.4 - Jasco (Japan) J-715 spectropolarimeter parameters used to record LD spectra 
The parameters used when using the Jasco (Japan) J-715 (LD) spectropolarimeter to measure the M13 labelled with 
chromophores. 
Sensitivity Standard (0.1 ΔOD) 
Start 800 nm 
End 190 nm 
Data pitch 1 nm 
Scanning mode Continuous 
Scanning speed 200 nm/min 
Response 1 second 
Band width 2 nm 
Accumulation 3 
 
2.2.2.9. Fluorescence measurements 
Fluorescence was measured using a luminescence spectrometer (Perkin Elmer Instruments LS 
55). The sample was placed into a 0.3 cm pathlength cuvette and the fluorescence was 
measured. The parameters used differed depending on which chromophore was used (table 
2.5).  
Table 2.5 - Fluorescence parameters  
 Parameters 
Sample Start 
(nm) 
End (nm) Ex Slit 
(nm) 
Em Slit 
(nm) 
Excitation 
(nm) 
Scan 
speed 
(nm/min) 
wt M13 290 500 2.5 2.5 280 100 
M13+fluorescamine 385 650 5 5 381 200 
Fluorescamine 385 650 5 5 381 200 
M13+rhodamine 500 900 5 5 556 200 
Rhodamine 500 900 5 5 556 200 
M13+NBD chloride 340 650 5 5 337 200 
NBD chloride 340 650 5 5 337 200 
M13+eosin-5-
maleimide 
525 650 2.5 2.5 520 100 
Eosin-5-maleimide 525 650 2.5 2.5 520 100 
 
2.2.3. Conjugation of wt M13 with purified goat-anti-mouse 
The assay requires M13 to detect specific targets, to achieve this, the p8 coat proteins on M13 
bacteriophage need to be covalently linked to antibodies. In a realistic setting this antibody 
would be one raised to an antigen on a pathogen such as E. coli O157. But to simply show 
proof of concept goat anti-mouse (GAM) was used as the antibody. Heterobifunctional 
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crosslinkers (such as SATA and succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate 
(SMCC)) are used to introduce reactive groups to p8 and the GAM, which will result in the 
formation of a covalent bond between the two molecules.  
2.2.3.1. Thiolation of wt M13 bacteriophage (method 1) 
The method for thiolation was a modified protocol of Aslam and Dent (1998).  A starting 
sample of 2 mg of wt M13 was mixed with 0.1 M phosphate buffer, pH 7.5 to give a volume of 
400 µL. A 0.3:1 molar ratio of SATA (Fisher Scientific, New Hampshire, USA) to p8 coat protein 
was added to the wt M13 and incubated for 1 hour at room temperature. The SATA introduces 
a thiol group to the p8 coat protein on the bacteriophage. The reaction was quenched by 
adding 10 % v/v of 50 mM EDTA/ 2.5 M Hydroxylamine solution pH 7 and left to incubate for 
another 15 minutes. To separate the bacteriophage from the SATA, the sample was mixed with 
conjugation buffer (50 mM phosphate buffer, 150 mM NaCl, 5 mM EDTA, pH 7) to make a 
volume of 20 mL and then concentrated in a centrifugal tube (Vivaspin centrifugal 
concentrator from Sigma-Aldrich, Missouri, USA) in a Beckman GS-6R centrifuge, using a GH3.8 
rotor at 3750 rpm at 4C. When the M13 solution was reduced in volume to 5 mL, another 15 
mL of conjugation buffer was added and concentrated again until the volume reached 1 mL. 
The absorbance of the sample was measured to calculate the concentration of recovered M13. 
2.2.3.2. Maleimide derivatisation of affinity purified goat anti-mouse antibody 
The GAM antibody (Abcam, Cambridge, UK) is provided as a lyophilized powder. 1 mg of the 
powder was dissolved in 1 mL distilled water. The antibody was then desalted using a PD-10 
desalting column (GE Healthcare, Buckinghamshire, UK), which was first equilibrated with 25 
mL of 0.1 M phosphate buffer pH 7.5. The 1 mL GAM sample and 1.5 mL 0.1 M phosphate 
buffer pH 7.5 were applied and allowed to enter the packed bed completely. The GAM sample 
was eluted with 2.5 mL 0.1 M phosphate buffer pH 7.5.  
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The absorbance of the eluted GAM sample was measured to calculate the GAM starting 
concentration (ε280nm, GAM =1.4 mg
-1 mL cm-1 (information provided by Abcam, Cambridge, 
UK)). This was used to calculate the required amount of SMCC (Merck Millipore, Darmstadt, 
Germany) in DMSO (Fisher Scientific, New Hampshire, USA) solution to provide a 10x molar 
excess to GAM. The SMCC reacts with amine groups to introduce a maleimide group on to the 
antibody. After 1 hour incubation at room temperature the solution was quenched with 1 % 
v/v of 10 mg/mL glycine (Fisher Scientific, New Hampshire, USA) made in conjugation buffer 
and left for 15 minutes.  
A PD-10 column (GE Healthcare, Buckinghamshire, UK) was used to separate the maleimide-
derivatised GAM from the SMCC after first being equilibrated with 25 mL of conjugation 
buffer. After the sample was eluted its absorbance was measured at 280 nm to calculate the 
recovered concentration of GAM.   
2.2.3.3. Bioconjugation 
The wt M13 and GAM were mixed together and left to incubate overnight at 4 °C. A 1 mg/mL 
solution of NEM (Thermo Scientific, New Hampshire, USA) was prepared and a 0.3:1 molar 
ratio of NEM was added per mole of p8 coat protein on the M13 to the overnight mixture 
containing the M13 conjugate with GAM. The sample was then concentrated in a centrifugal 
concentrator (Vivaspin centrifugal concentrator from Sigma-Aldrich, Missouri, USA) in a 
Beckman GS-6R centrifuge, using a GH3.8 rotor at 3750 rpm at 4C until only 2 mL remained. 
The conjugated wt M13 was then precipitated by adding an autoclaved 20% v/v PEG6000/2.5 
M NaCl solution until a visible precipitate formed (approx. 320 µL). Finally, the sample was 
centrifuged for 5 minutes at 14000 rpm in a bench top centrifuge (Spectrafuge 16M, Labnet). 
The supernatant was discarded and the pellet was resuspended in phosphate buffer pH 8. The 
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obtained sample contained M13 bacteriophage with GAM antibodies covalently attached to it. 
This was stored at 4C, no preservatives were added. 
2.2.4. Electron microscopy 
Electron microscopes use a beam of highly energetic electrons to observe samples and create 
an enlarged image. The image is formed by the use of electrostatic and electromagnetic lenses 
which control the electron beam to focus it at a specific plane. One of the most prevalent 
forms of electron microscopy is transmission electron microscopy (TEM). An electron beam is 
focussed upon the sample and many of the electrons pass through the sample. These electrons 
are gathered by a series of electromagnetic lenses and focussed onto a screen. The screen can 
comprise of a fluorescent screen or photographic plate or, as is common in modern 
applications, a charge-coupled device (CCD) camera. A major advantage of using CCDs is that 
the image can be displayed in real time.  
2.2.4.1. Sample preparation 
In order to scatter imaging electrons and achieve a good contrast, the samples were stained. 
Staining the samples with aqueous or alcoholic solutions of heavy metals is a common practice 
for biological specimens since many biological samples are nearly transparent to electrons. 
2.2.4.2. Preparation of carbon-coated grids for electron microscopy 
2.2.4.2.1. Glow discharge of the carbon-coated copper grids 
The carbon-coated grids were glow discharged prior to negative staining. Glow discharge is 
formed by applying a potential difference between two electrodes that are inserted in a cell 
that is filled with an inert gas at a certain pressure. Glow discharge makes the carbon coated 
electron microscopy grids hydrophilic in preparation for the negative staining since the sample 
will be applied onto the grids. In order to glow discharge the carbon coated grids, the grids 
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were placed carbon side up onto a glass slide and inserted in the glow discharge instrument for 
20 seconds at lower settings (10 mA, pale purple glow). 
2.2.4.2.2. Staining and visualisation 
A 1% uranyl acetate stock solution (UA) was prepared and stored at 4 °C in the dark when the 
solution was not used. The stock was prepared by diluting a 4% UA solution. UA contains 
insoluble salts and consquently 1 mL of the 1% stock solution was filtered using a 0.2 μm filter 
and kept in a 1.5 mL eppendorf. There are several methods for negative staining the sample. 
The method used in this study is described below. 
Firstly a 50 μL sample of 0.3 mg/mL of M13 conjugated with GAM was prepared. A filter paper 
was then placed in a petri dish, a grid was carefully taken by the rim edge of the copper mesh 
using a pair of tweezers provided with a rubber ring which ensured that the grid was not 
moving while the sample was being applied and the sample was applied onto the carbon side 
of the grid. Five μL of the sample mixture was then placed onto the carbon side for 1 minute 
and the sample was immediately stained by washing with three drops of the 1% UA solution. 
The grid was oriented 45° with respect to the surface as the wash should be gentle. The last 
drop of the 1% UA solution was left for 45 seconds before the excess liquid was blotted from 
the sample by gently touching/dragging the grid parallel or perpendicular to the filter paper. 
The grid was then released from the tweezers and the tip of the tweezers were dried with 
filter paper. Samples were stored in a cool dry place, in the absence of light. The grids were 
then viewed in a (Joel JEM-2010, Tokyo, Japan) TEM at 15,000X, 25,000X, 30,000X and 40,000X 
objective magnification. 
2.2.5. Conjugation of wt M13 with goat anti-E. coli O157 and BHQ-10  
To detect E. coli O157 in this current assay a goat anti-E.coli O157 antibody (GAE) (Thermo 
Scientific, New Hampshire, USA) was required and was conjugated on to the M13 
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bacteriophage. For a multiplexed assay various chromophores would be enlisted to detect 
different pathogens, and in this case BHQ-10 dye was chosen as the chromophore.  
2.2.5.1. Thiolation of wt M13 bacteriophage (method 2) 
This thiolation method differs from the one described in section 2.2.3.1; it uses a much larger 
molar ratio of SATA and a PD-10 desalting column was employed. A starting material of 2 mg 
of wt M13 was prepared with 0.1 M phosphate buffer, pH 7.5 to gain a volume of 1 mL. A 
volume of 50 µL of 1% v/v tween 20 was added to give a final concentration of 0.05%. A 50 
mg/mL stock concentration of SATA (Fisher Scientific, New Hampshire, USA) was made using 
DMSO (Fisher Scientific, New Hampshire, USA) and a 50:1 molar ratio of SATA to p8 coat 
protein was added to the M13 solution and incubated for 1 hour at room temperature. The 
reaction was quenched by adding 10 % v/v of 50 mM EDTA/ 2.5 M Hydroxylamine solution pH 
7 and left to incubate for another 15 minutes.  
To separate the thiolated M13 from the SATA a PD-10 desalting column (GE Healthcare, 
Buckinghamshire, UK) was used. The PD-10 desalting column was firstly equilibrated with 25 
mL of conjugation buffer (50 mM phosphate buffer, 150 mM NaCl, 5 mM EDTA, pH 7) and 
secondly the M13 solution was added with the volume made up to 2.5 mL with conjugation 
buffer. M13 was eluted with 3.5 mL conjugation buffer. 
2.2.5.2. Maleimide derivatisation of goat anti-E. coli O157  
A 5.5 mg/mL stock of GAE antibody (Thermo Scientific, New Hampshire, USA) was diluted in 
0.1 M phosphate buffer pH 7.5 to provide a final concentration of 0.5 mg/mL.  The antibody 
was desalted using a PD-10 desalting column (GE Healthcare, Buckinghamshire, UK), which was 
first equilibrated with 25 mL of 0.1 M phosphate buffer pH 7.5. The 1 mL GAE sample was 
made up to 2.5 mL with 0.1 M phosphate buffer pH 7.5 and applied to the PD-10 desalting 
column (GE Healthcare, Buckinghamshire, UK). The GAE sample was eluted with 3.5 mL 0.1 M 
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phosphate buffer pH 7.5. A 1 mg/mL stock concentration of SMCC (Merck Millipore, 
Darmstadt, Germany) was made in DMSO (Fisher Scientific, New Hampshire, USA), and a 10:1 
molar ratio of SMCC to GAE was added to the GAE solution. This solution was left to incubate 
for 1 hour at room temperature. The SMCC reacts with amine groups to introduce a maleimide 
group on to the antibody. The solution was quenched with a 1 % v/v solution of glycine (Fisher 
Scientific, New Hampshire, USA) in conjugation buffer (10 mg/mL) and left for 15 minutes. A 
PD-10 column (GE Healthcare, Buckinghamshire, UK) was then used to separate the 
maleimide-derivatised GAE from the SMCC after first being equilibrated with 25 mL of 
conjugation buffer. The GAE solution was made up to 2.5 mL with conjugation buffer and 
added to the column and eluted in 3.5 mL conjugation buffer. 
2.2.5.3. Bioconjugation and labelling with BHQ-10 
The eluted M13 solution was mixed with the eluted GAE solution and incubated overnight at 
4C. 
A mass of 0.5 mg BHQ-10 (Biosearch Technologies, California, USA) was dissolved in 180 µL N-
(2-aminoethyl) maleimide (AEM) (Sigma-Aldrich, Missouri, USA) solution (1 mg/mL stock 
solution made in 0.1 M phosphate buffer pH 7.5). This was incubated at room temperature for 
1 hour in the absence of light. 
This BHQ-10 solution was added to the M13-GAE solution and incubated at room temperature 
for 1 hour in the absence of light with continuous mixing. Following this, 100% v/v of 25 %  w/v 
PEG6000/2.5 M NaCl was added to the M13 conjugated with GAE and BHQ-10 solution and 
kept in the absence of light at 4C for 1 hour. The solution was aliquoted into 1.5 mL 
eppendorf tubes and centrifuged in a bench top centrifuge (Spectrafuge 16M, Labnet) for 10 
minutes at 14000 rpm. The pellets were resuspended in a total volume of 1 mL of 50 mM 
phosphate buffer, pH 8 and the supernatant was discarded.  
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2.2.6. Detection of E. coli O157 using M13 bacteriophage and LD  
To detect the heat-killed E. coli O157 (KPL, Maryland, USA), M13 conjugated with GAE and 
BHQ-10 (double labelled M13) was used as the reagent and LD was used as the spectroscopic 
technique to detect the bacteria. 
2.2.6.1. E. coli O157 preparation 
The heat-killed E. coli O157 (KPL, Maryland, USA) was provided in a lyophilized form and 
contained 1.15 x 109 cells/mL. To prepare the E. coli O157 it was dissolved in 1.15 mL of water 
and aliquoted into separate eppendorfs ready for storage at -18C. When required an aliquot 
was thawed at room temperature ready for use. A 0.8 µL volume of heat-killed E. coli O157 
from the stock provided 107 cells/mL. To provide 106 and 105 cells/mL a 1 in 10 and 1 in 100 
dilution was made respectively with water.  
2.2.6.2. E. coli XL10 preparation 
For a control, E. coli XL10 cells were used in the assay. A 100 µL culture was provided from Dr 
Mohammed Jamshad at the University of Birmingham. The 100 µL culture was thawed at room 
temperature, centrifuged at 14000 rpm for 1 minute in a bench top centrifuge (Spectrafuge 
16M, Labnet). The supernatant was discarded and the pellet was resuspended in 100 µL of 50 
mM phosphate buffer pH 8. This solution was centrifuged again at 14000 rpm for 1 minute and 
the supernatant was discarded and the pellet was resuspended in 100 µL of 50 mM phosphate 
buffer pH 8. The absorbance of the E. coli XL10 cells was measured using a Jasco (Japan) V-550 
spectrophotometer at 600 nm to calculate the number of cells per mL. An absorbance of 1.0 at 
600 nm is equal to approximately 8.8 x 108 cells/mL (Brown, 2010). An absorbance of 0.13 was 
measured at 600 nm in a cuvette with a pathlength of 0.3 cm.  
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Therefore using the Beer-Lambert law; 
      
  
  
  
  
  
    
    
   
   
      
      
                                         
Where; 
   is the E. coli concentration, 
        is the measured absorbance,  
          is the measured pathlength 
           
          ,       ,           
 
A total volume of 80 µL was required for the LD measurements, therefore: 
 
      
        
                of E. coli XL10 cells was required to provide 107 cells/mL 
2.2.6.3. Sample preparation 
Each sample was made in triplicate and can be seen in table 2.6. 
Table 2.6 - Assay constituents for the detection of E. coli O157 
Samples Reagents 
 Double labelled 
M13 
(M13-GAE-BHQ-
10) (3.6 mg/mL) 
(µL) 
0.1M 
phosphate 
buffer pH 7.5 + 
tween (0.05%) 
(µL) 
E. coli O157 (µL) E. coli XL10 
107 cells/mL 
(µL) 
 
107 
cells/mL 
106 
cells/mL 
105 
cells/mL 
Control 1 20 60     
Control 2 20 57.9    2.1 
1 20 59.2 0.8    
2 20 59.2  0.8   
3 20 59.2   0.8  
 
2.2.6.4. LD measurements 
The LD experiments were carried out using a Jasco (Japan) J-715 (LD) spectropolarimeter and 
processed using the Spectra Analysis program (version 1.53.04 Build 1). LD spectral data were 
recorded at room temperature with the parameters in table 2.7. For each experiment, a 
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baseline (non-rotating capillary) was collected and then subtracted from the signal and the 
signal was zeroed at 800 nm. All of the rotating signals were recorded at 3V. 
Table 2.7 - Jasco (Japan) J-715 spectropolarimeter parameters used to gather LD spectra 
The parameters used when using the Jasco (Japan) J-715 (LD) spectropolarimeter as part of a detection system to 
detect E. coli O157. 
Sensitivity Standard (0.1 ΔOD) 
Start 800 nm 
End 190 nm 
Data pitch 0.5 nm 
Scanning mode Continuous 
Scanning speed 500 nm/min 
Response 1 second 
Band width 5 nm 
Accumulation 1 
 
2.2.7. Conjugation of wt M13 with anti-FITC antibody  
The M13 aggregation assay was utilised for the detection of small molecules. Two reagents 
were required for this assay; M13 conjugated with target molecule and M13 conjugated with 
anti-target antibody. To show proof of concept the target antigen used in this assay was 
fluorescein. This meant that one reagent required would be M13 labelled with fluorescein and 
another was M13 conjugated with anti-fluorescein. Fluorescein isothiocyanate isomer 1 (FITC) 
(Invitrogen, California, USA) was used to label M13 (see section 2.2.2.3. for method) and anti-
FITC antibody (Invitrogen, California, USA) was used to conjugate another sample of M13. 
2.2.7.1. Thiolation of wt M13 bacteriophage (method 2) 
This method is the same as described in section 2.2.5.1. A starting material of 2 mg of wt M13 
was prepared with 0.1 M phosphate buffer, pH 7.5 to gain a volume of 400 µL. A 50 mg/mL 
stock concentration of SATA (Fisher Scientific, New Hampshire, USA) was made using DMSO 
(Fisher Scientific, New Hampshire, USA) and a 50:1 molar ratio of SATA to p8 coat protein was 
added to the M13 solution and incubated for 1 hour at room temperature. The reaction was 
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quenched by adding 10 % v/v of 50 mM EDTA/ 2.5 M Hydroxylamine solution pH 7.0 and left to 
incubate for another 15 minutes at room temperature.  
To separate the thiolated M13 from the SATA a PD-10 desalting column (GE Healthcare, 
Buckinghamshire, UK) was used. The PD-10 desalting column was firstly equilibrated with 25 
mL of conjugation buffer and secondly the M13 solution was added with the volume made up 
to 2.5 mL with conjugation buffer. The M13 was eluted with 3.5 mL conjugation buffer. 
2.2.7.2. Maleimide derivatisation of anti-FITC antibody  
In an attempt to conjugate each M13 bacteriophage with 20 rabbit (polyclonal) anti-FITC 
antibodies (Invitrogen, California, USA), 351 µL of 1 mg/mL anti-FITC antibody was initially 
added to 649 µL 0.1 M phosphate buffer pH 7.5. A 1 mg/mL stock concentration of SMCC 
(Merck Millipore, Darmstadt, Germany) was made in DMSO (Fisher Scientific, New Hampshire, 
USA), and a 10:1 molar ratio of SMCC to anti-FITC antibody was added to the anti-FITC 
antibody solution. This solution was left to incubate for 1 hour at room temperature. The 
SMCC reacts with amine groups to introduce a maleimide group on to the antibody. The 
solution was quenched with a 1 % v/v solution of glycine (Fisher Scientific, New Hampshire, 
USA) in conjugation buffer (10 mg/mL) and left for 15 minutes at room temperature. A PD-10 
column (GE Healthcare, Buckinghamshire, UK) was then used to separate the maleimide-
derivatised anti-FITC antibodies from the SMCC after first being equilibrated with 25 mL of 
conjugation buffer. The anti-FITC antibody solution was made up to 2.5 mL with conjugation 
buffer and added to the column and eluted in 3.5 mL conjugation buffer. 
2.2.7.3. Bioconjugation  
The eluted M13 solution was mixed with the eluted anti-FITC antibody solution and incubated 
overnight at 4C. A 1 mg/mL solution of NEM (Thermo Scientific, New Hampshire, USA) was 
made in conjugation buffer and a 10:1 molar ratio of NEM to p8 coat protein was added to the 
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M13 and anti-FITC antibody solution and incubated at room temperature for 15 minutes. This 
solution was then concentrated in a centrifugal tube (Vivaspin centrifugal concentrator, Sigma-
Aldrich, Missouri, USA) in a Beckman GS-6R centrifuge, using a GH3.8 rotor at 3750 rpm at 4C 
until the volume was reduced to 3 mL. This volume was required in order to put the solution 
through a size exclusion chromatography (SEC) column (HiLoadTM 16/60 SuperdexTM 200 
Prep grade). This was done to remove any unreacted molecules and free antibodies from the 
solution. The detectors were set to 269 nm and 280 nm and the flow rate was ~1.0 mL/min. 
The column was equilibrated overnight in 50 mM phosphate buffer pH 8 with 150 mM NaCl to 
prevent non-specific binding. The fraction collector was set to collect the appropriate fractions 
and 3 mL of the sample was injected and ran for several column volumes (~3 hours). The 
column was then equilibrated in storage buffer before being switched off. A pure sample of 
M13 conjugated with anti-FITC was then generated as this procedure ensured all contaminants 
had been removed. 
2.2.8. Detection of fluorescein using the M13 bacteriophage aggregation assay 
The M13 aggregation assay was utilised for small molecule detection and was used to detect 
fluorescein. M13 conjugated with anti-FITC antibodies and M13 conjugated with FITC were 
used as the reagents and LD was used as the spectroscopic technique to detect fluorescein. 
Varying concentrations of fluorescein were added to the assay to establish the sensitivity of 
the assay. 
2.2.8.1. Fluorescein preparation 
A 10 mM stock of fluorescein (Invitrogen, California, USA) was prepared in water for the 
samples requiring a larger concentration of fluorescein (1 mM, 0.5 mM and 0.2 mM) and was 
diluted 10 fold to provide lower concentrations (0.1 mM, 0.04 mM, 0.02 mM and 0.01 mM). 
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2.2.8.2. Rhodamine 6G preparation 
A stock of 20 mM rhodamine 6G (Invitrogen, California, USA) was made up in ethanol (70%) 
and this was diluted 100 fold to 0.2 mM for the assay to provide a final concentration of 0.02 
mM.  
2.2.8.3. Sample Preparation 
For each of the experimental samples the specific volume of 50 mM phosphate buffer pH 8 
and 10 mM or 1mM fluorescein (Invitrogen, California, USA) was added to 30 µL of 0.07 mg/mL 
M13 conjugated with anti-FITC and left to incubate overnight at 4C in the absence of light. 
The following day 30 µL of 0.08 mg/mL M13 labelled with FITC was added to compete with the 
free fluorescein and the LD measurements were taken immediately.  
The mixture sample consisted of 30 µL of 0.07 mg/mL M13 conjugated with anti-FITC antibody 
and 30 µL of 0.08 mg/mL M13 labelled with FITC and had no fluorescein added.  
The rhodamine 6G sample had the addition of 8 µL of 0.2 mM rhodamine 6G (to provide a final 
concentration of 0.02 mM) and 12 µL of 50 mM phosphate buffer pH 8 to 30 µL of 0.07 mg/mL 
M13 conjugated with anti-FITC antibody and left to incubate overnight at 4C in the absence of 
light. The following day 30 µL of 0.08 mg/mL M13 labelled with FITC was added and the LD 
measurements were taken immediately. Each sample was made up 3 times and the LD signal 
was measured. 
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Table 2.8 - Assay constituents for the detection of fluorescein  
Sample Reagents 
 0.08 mg/mL 
M13-FITC (µL)  
0.07 mg/mL 
M13-anti-FITC 
antibody (µL) 
Fluorescein (µL) 0.2 mM 
Rhodamine 
6G (µL) 
50 mM 
Phosphate 
buffer pH 8 
(µL) 10 mM 1 mM 
Mixture 30 30    20 
0.02 mM 
Rhodami
ne 6G 
30 30   8 12 
1 mM 
Fluoresce
in 
30 30 8   12 
0.5 mM 
Fluoresce
in 
30 30 4   16 
0.2 mM 
Fluoresce
in 
30 30 1.6   18.4 
0.1 mM 
Fluoresce
in 
30 30  8  12 
0.04 mM 
Fluoresce
in 
30 30  3.2  16.8 
0.02 mM 
Fluoresce
in 
30 30  1.6  18.4 
0.01 mM 
Fluoresce
in 
30 30  0.8  19.2 
 
2.2.8.4. LD measurements 
The LD experiments were carried out using a Jasco (Japan) J-715 (LD) spectropolarimeter and 
processed using the Spectra Analysis program (version 1.53.04 Build 1).  LD spectral data were 
recorded at room temperature with the parameters in table 2.9. For each experiment, a 
baseline (non-rotating capillary) was collected and then subtracted from the signal and the 
signal was zeroed at 600 nm. All of the rotating signals were recorded at 3V. 
Table 2.9 - Jasco (Japan) J-715 spectropolarimeter parameters used to gather LD spectra 
The parameters used when using the JASCO J-715 (LD) spectropolarimeter as part of a detection system to detect 
fluorescein. 
Sensitivity Standard (0.1 ΔOD) 
Start 600 nm 
End 200 nm 
Data pitch 1 nm 
Scanning mode Continuous 
Scanning speed 200 nm/min 
Response 1 second 
Band width 2 nm 
Accumulation 6 
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3 CHAPTER 3 
- OPTIMISATION OF M13 
PRODUCTION 
3.1. Production of M13 bacteriophage  
This project involves the production of a reagent using M13 as a starting point for a number of 
chemical modification steps. Given that the yields for such reactions are significantly less than 
100%, it is clear that the production of sufficient quantities of M13 during the project will be 
important. In this chapter a number of parameters within the M13 production process are 
varied to enhance the yield of material and the specific activity. (New England Biola bs, 20 11, Sambrook and Russell, 20 01) 
There are currently two established methods for the production of M13, one method based on 
the work of Sambrook and Russell (2001) and another method from New England Biolabs 
(2011). This chapter describes how these two methods were assessed in terms of speed, ease 
of use, purity, yield of product and its specific activity. It should be noted that previous uses of 
M13 bacteriophage have been restricted to the area of Molecular Biology where it has been 
used for things such as bacteriophage display; however in these areas M13 is not required in 
large quantities (0.1-20 µg) (Kunkel et al., 1986, Liu et al., 2001, Sung and Stratton, 1996). In 
this project, M13 was required in larger quantities as sufficient functionalised M13 is required 
to produce an LD signal. To produce a reasonable LD signal approximately 0.4 mg is required; 
any less than this and not all of the peaks in the LD signal can be identified. If we assume that 
to get a suitable dose response curve we need 10 points with 3 repetitions, this means 30 
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separate reactions, which would require 12 mg of M13 bacteriophage. The quantity of M13 
bacteriophage produced therefore needed to meet the high demand required for this project.  
In this study the yields produced from the method based on Sambrook and Russell (2001) and 
from the New England Biolabs (2011) method were initially assessed. These two methods each 
have different limitations. The method based on Sambrook and Russell (2001) requires a filter 
to remove E. coli cells, whereas the New England Biolabs (2011) method uses various 
centrifugation steps to remove any E. coli cells. The method based on Sambrook and Russell 
(2001) has the benefit of only requiring 2 days in comparison to the New England Biolabs 
(2011) method, which requires 3 days. 
To assess which method was best, a number of parameters were measured. These included 
the yield and purity of M13 bacteriophage produced in each method. Conventionally M13 
concentrations were determined by measuring plaque forming units. This is a very time 
consuming method, and in this context, we are only interested in whether the M13 aligns and 
produces an LD signal, not whether it can replicate. We therefore used the inherent LD signal 
of M13 as a measure of the yield. The LD spectrum produced from M13 has 3 clear peaks, a 
positive peak between 200-240 nm which arises from peptide backbone transitions, a negative 
peak between 240-260 nm which arises from DNA transitions and another positive peak 
between 260-300 nm which is due to the aromatic transitions of Tyrosine, Tryptophan 
(maximum at 280 nm) and Phenylalanine. The presence of these peaks indicates that the M13 
is intact and the structure is not damaged and therefore reveals the quality of the M13. To 
produce an LD signal, M13 needs to be able to align, and for this to happen, M13 has to retain 
its long, thin structure. If the structure of the M13 is damaged it will no longer produce its 
distinctive LD signal. This makes LD a good technique to measure the amount of M13 in the 
samples produced during these methods. The LD signal is only produced by the aligned M13 
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and is not affected by the presence of any non-aligned impurities. However, the presence of 
such impurities (e.g. DNA, protein and cells) has the potential to disrupt the conjugation 
reactions which are essential to developing M13 as an assay reagent.  
To assess purity we measure the absorbance of the sample at 269 nm. This provides a measure 
of the amount of material that absorbs at this wavelength. This includes DNA and protein, both 
of which are likely to be common contaminants of the solution.  
The average UV absorbance at 269 nm and LD signal at 220 nm were also used to determine 
the specific activity of the M13 product from each method. Specific activity in this case can be 
defined as the LD signal produced from the M13 per milligram of protein produced from each 
method. Our aim is to create a method which produces a high M13 yield which has a high 
specific activity.  
The ease of use of each method was also taken into consideration as well the time required for 
each method because a fast and simple method was desired. 
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Figure 3.1 - Comparison of two existing M13 production methods 
A comparison of the two current methods used to produce M13 bacteriophage; one is based on Sambrook and 
Russell (2001) and the other is based on New England Biolabs (2011).  
 
3.1.1. Production of M13 bacteriophage using the method based on Sambrook and 
Russell (2001) 
This method of making bacteriophage was based on Sambrook and Russell’s (2001) method 
(figure 3.1) and produced an average yield of 3.24 mg (+/-0.2) of M13 per Litre of culture 
based on the absorbance at 269 nm (table 3.1) (extinction coefficient of M13 bacteriophage is 
3.84 cm-2/mg at 269 nm (Niu et al., 2008)). The yield based on LD at 220 nm shows that a yield 
of 0.0084 (+/-0.001) OD (The units of LD are delta optical density, abbreviated to OD) per 
Litre of culture was produced (table 3.2). The filtering step in this method proved to be very 
challenging with continuous blockages increasing the time taken to carry out the method. The 
final M13 sample was also usually still contaminated with E. coli cells and the results show that 
the final M13 solution is not concentrated. Overall this method took 2 days to produce M13 
Based on Sambrook and Russell 
(2001) 
Mix E. coli Top10F and M13 stock and 
incubate overnight 
Sediment cells 
Precipitate remaining M13 solution using 
PEG for 15 minutes, centrifuge and 
resuspend pellet 
Filter twice to remove any remaining cells 
New England Biolabs 
(2011) 
Grow E. coli Top10F overnight 
Inoculate with M13 and leave 
for 4 hours 
Sediment cells twice  
Precipitate remaining M13 
solution with PEG overnight 
Centrifuge and resuspend 
pellet and precipitate again 
for 1 hour 
Centrifuge and resuspend 
pellet 
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bacteriophage, this is mainly because the M13 bacteriophage and E. coli Top10F’ cells were 
added together and left to incubate overnight without initially allowing the E. coli Top10F’ cells 
to grow.  
Table 3.1 - M13 yield based on UV absorbance 
This table shows 3 repeats and the average yield of M13 produced based on UV absorbance from the method based 
on Sambrook and Russell (2001).  To determine the yield of the final M13 solution, the absorbance was measured at 
269 nm, the starting volume of LB was required and the volume of phosphate buffer used to resuspend the M13 
pellet was required. This method of calculation was repeated for all of the M13 production methods. 
A269(M13) 0.51 0.57 0.42 
  dilution factor 2 2 2 
  V(LB) [L] 2.4 2.4 2.4 
  V(M13) [mL] 8 9 10 
  c(M13) [mg/mL] 0.88 1.00 0.73 
  m(M13) [mg] 7.0 9.0 7.3 Average Standard deviation 
Y(m(M13)/V(LB)) 2.94 3.7 3.1 3.24 0.43 
 
Table 3.2 - M13 yield based on LD absorbance  
This table shows 3 repeats and the average yield of M13 produced based on LD spectra from the method based on 
Sambrook and Russell (2001).  To determine the yield of the final M13 solution, the LD signal was measured at 220 
nm, the starting volume of LB was required and the volume of phosphate buffer used to resuspend the M13 pellet 
was required. This method of calculation was repeated for all of the M13 production methods.  
LD220(M13) 0.0031 0.0017 0.0020 
  V(LB) [L] 2.4 2.4 2.4 
  V(M13) [mL] 8 9 10 Average Standard deviation 
Y(V(M13)*LD220)/V(LB) 0.01 0.0064 0.0084 0.0084 0.002 
 
The specific activity is used to determine how much of the M13 present in the yield calculated 
from the absorbance at 269 nm actually produces an LD signal at 220 nm. As the absorbance 
signal can be affected by impurities, the specific activity can be thought of as a pseudo purity 
measure. To calculate the specific activity, equation 3.1 was used: 
Equation 3.1 - Specific activity definition 
                                               
The specific activity for the M13 solution produced from the method based on Sambrook and 
Russell (2001) was 0.0026 OD/mg (figure 3.3C). 
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3.1.2. Production of M13 bacteriophage using the New England Biolabs method 
(2011)  
This method of making M13 was appealing because it lacked the filtration step which was very 
time consuming. Instead it used two centrifugation steps to sediment any unwanted E. coli 
cells and also used repeated precipitation steps to produce the end sample. However this 
method required 3 days compared to the 2 days required for the Sambrook and Russell 
method. The extra day was because the protocol initially involved growing E. coli Top10F’ cells 
overnight and then inoculating with M13. This is to allow the M13 bacteriophage to infect the 
E. coli Top10F’ cells during their exponential phase. The method was carried out on 3 separate 
occasions and the yield based on the absorbance at 269 nm produced a yield of 0.91 mg (+/-
0.18) of M13 per Litre of culture (figure 3.3A). This is 3.5 times smaller than the average yield 
of M13 produced from the Sambrook and Russell method. However the final M13 solution was 
more concentrated than those produced from the Sambrook and Russell method. The yield 
based on the LD signal at 220 nm produced a yield of 0.0072 (+/-0.00155) OD per Litre of 
culture (figure 3.3B). This is similar to that produced by the Sambrook and Russell method. 
The specific activity for the M13 solution produced from the New England Biolabs (2011) was 
0.0079 OD/mg (figure 3.3C). This specific activity is larger than that produced by the method 
based on Sambrook and Russell (2001). However if a greater specific activity can be achieved it 
would greatly satisfy the needs of this assay. 
3.1.3. New method of M13 bacteriophage production 
As a result of a limited amount of M13 being produced from the current methods, it was 
necessary to try to optimise the yield produced. As well as optimising the yield, a protocol that 
was quick, not labour intensive and would produce a cell free yield of M13 with a good LD 
signal was desired. For example the method based on Sambrook and Russell (2001) used a 
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filtering step which was found to be labour intensive and unreliable. As a starting point for 
optimisation of the protocol, a method was developed that combined aspects of both 
established protocols (figure 3.2). For example instead of using a filter to remove the cells, the 
centrifugation and precipitation steps from the New England Biolabs protocol were used. To 
shorten the protocol both the M13 and Top 10F E. coli cells were added together as was done 
previously with the method based on Sambrook and Russell (table 3.3). This new method was 
assessed in the same way as the two established methods, and the results were compared.  
 
Figure 3.2 - New M13 production method 
The new method proposed to optimise the production of M13 bacteriophage after combining aspects of two 
established methods; Sambrook and Russell (2001) and New England Biolabs (2011).  
  
New Method 
Mix E. coli Top10F and M13 and 
incubate overnight 
Sediment cells twice 
Precipitate remaining M13 solution 
using PEG for 15 minutes, centrifuge 
and resuspend pellet 
Precipitate final M13 solution using 
PEG for 15 minutes, centrifuge and 
resuspend pellet 
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Table 3.3 - Comparison of M13 production methods 
Table describes the steps from the current M13 production methods which have been modified to produce the new 
method and a justification for the changes. 
Steps changed in 
method 
Methods Justification  
Sambrook and 
Russell (2001) 
New England 
Biolabs (2011) 
New Method  
Growth of E. coli 
Top10F’ cells and 
M13 inoculation 
time 
E. coli Top10F’ 
and M13 added 
together and 
incubated 
overnight 
E. coli Top10F’ 
grown 
overnight, and 
then inoculated 
with M13 and 
incubated for 4 
hours. 
E. coli Top10F’ 
and M13 added 
together and 
incubated 
overnight 
Quicker 
Number of times 
the cells are 
sedimented  
Once Twice Twice Ensures removal 
of E. coli cells 
Precipitation 
time with PEG 
15 minutes Overnight 15 minutes Quicker 
Final M13 
purification step 
Filter M13 
twice 
Precipitate with 
PEG for 1 hour 
Precipitate with 
PEG for 15 
minutes 
Less labour 
intensive and 
quicker 
 
The average yield produced based on the LD signal was in line with those produced by the 
existing methods (at 220 nm the LD per Litre of culture was 0.008 OD (+/-0.003)) (figure 
3.3B). This material also had a much lower OD signal at 269 nm, suggesting a purer sample 
(0.55 mg (+/-0.14) per Litre of culture) (figure 3.3A). 
The specific activity for the M13 solution produced from the new method was 0.015 OD/mg 
(figure 3.3C).  
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Figure 3.3 - Comparison of M13 production yields and specific activities 
A) Comparison of the M13 yield produced from 2 current established methods and a new method which combines 
the two together to form an easier method. The yield was calculated from the UV absorbance at 269 nm. The error 
bars show standard deviation. B) Comparison of the M13 yield produced from the 3 methods, the yield was 
calculated from the LD signal at 220 nm. The error bars show standard deviation. C) Comparison of the specific 
activity of the final M13 solution produced from the 3 methods investigated. 
As the main aim of this project is to use M13 in an LD based assay, it is essential that the 
material produced using the new method still maintains the LD signals required for the assay. 
The M13 yield based on the LD signal at 220 nm, produced from all three methods (figure 
3.3B) were all very similar. This therefore proves that the yield produced from the UV 
absorbance was affected by other contaminants that may have been present in the M13 
solutions. The Sambrook and Russell method produced the largest UV signal, followed by the 
A B 
C 
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New England Biolabs method and finally the new method. This indicates that despite the new 
method producing a similar LD yield to the other methods, the new method produced a 
solution of M13 which was of higher quality containing fewer contaminants and more 
concentrated. In addition, the new method is also much easier, quick and less labour intensive.  
The specific activity was calculated from the UV absorbance yield and the LD signal yield 
(equation 4), and provides a measure of the amount of M13 in each solution that was actually 
providing an LD signal per milligram of total protein. Figure 3.3C clearly indicates that the new 
method produced a specific activity which was approximately 5 times larger (0.015 OD/mg) 
than the specific activity produced from the M13 solution from the Sambrook and Russell 
method (0.0026 OD/mg) and twice as large than the specific activity produced from the M13 
solution from the New England Biolabs method (0.0079 OD/mg). Thus it can be concluded 
that the new method produced better quality M13 than the other methods.  
The final check of the material produced using this method involved the collection of an LD 
spectrum of the sample. As mentioned earlier M13 has a particular LD spectrum that includes 
signals from proteins and DNA in the particle. Figure 3.4 is an LD spectrum from the M13 
produced using this new method and it shows the presence of all the characteristic peaks of 
M13, demonstrating that the M13 is viable for further work.  
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Figure 3.4 - LD spectrum of M13 bacteriophage generated from the new method 
LD spectrum of M13 bacteriophage (0.04 mg/mL) generated from the new method, with peaks labelled.  
 
Overall the new method has provided the easiest and quickest method to produce M13 and 
the final M13 solution has the highest specific activity.  
3.1.4. Optimisation of precipitation time in M13 production 
The new method is a much easier and quicker method to use and produces a more 
concentrated and higher quality stock of M13 which has a larger specific activity. However the 
yield is still not sufficient to carry out an assay.  One of the essential steps in bacteriophage 
production is the precipitation step as the PEG/NaCl solution acts to sediment the M13 
(Yamamoto et al., 1970). Work published after the development of the new method for 
producing M13 (shown in the preceding section) showed that PEG based precipitations could 
be optimised to result in bacteriophage purity and yield improvements (Branston et al., 
2011a). This observation was used as a basis to further optimise the new method by examining 
the effect of precipitation times on the M13 yield. 
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The New England Biolabs (2011) method precipitated the M13 with the PEG/NaCl solution 
overnight, whereas the M13 method based on Sambrook and Russell (2001) used only 15 
minutes to precipitate the M13 with the PEG/NaCl solution. The new method developed in the 
preceding section similarly used only 15 minutes to precipitate the M13 with the PEG/NaCl 
solution. To investigate whether, as shown by Branston et al. (2011), precipitation time affects 
the yield (according to UV absorbance at 269 nm and LD signal at 220 nm) of M13 and the 
specific activity of the final M13 solution, the precipitation times of the new method were 
varied to 5, 30, 45, 60 and 120 minutes and compared to the original 15 minute precipitation 
time.  
Table 3.4 - Comparison of M13 yields and specific activities  
Compares the yield (both based on LD and UV absorbance) and specific activity of M13 produced from two 
established methods (Sambrook and Russell (2001) and New England Biolabs (2011)) for producing M13 
bacteriophage and a newly developed method. The new method is further modified by varying precipitation times.  
Method M13 Yield 
mg/L 
M13 
Yield 
OD/L 
Specific Activity 
OD/mg 
Sambrook 
and Russell 
(2001) 
3.24 0.0084 0.0026 
New England 
Biolabs (2011) 
0.91 0.0072 0.0079 
 
New Method 
Precipitation 
Time (min) 
M13 Yield 
mg/L 
M13 
Yield 
OD/L 
Specific Activity 
OD/mg 
5 0.1 
 
0.00092 
 
0.0092 
 15 0.55 
 
0.0081 
 
0.015 
 30 5.84 
 
0.11 
 
0.018 
 45 8.02 
 
0.073 
 
0.0091 
 60 24.6 0.25 0.0095 
 120 36.65 0.44 
 
0.012 
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Figure 3.5 - The effect of precipitation time on M13 production yield and specific activity 
A) Comparison of the M13 yield produced from a newly developed method where the precipitation time has been 
varied from 5, 15, 30, 45, 60 and 120 minutes to investigate whether this affects the M13 yield. The yield was 
calculated from the UV absorbance at 269 nm. The error bars show standard deviation. B) Comparison of M13 yield 
calculated from the LD signal produced at 220 nm. This graph displays the differing precipitation times used within 
the method and the effect on the yield. The error bars show standard deviation. C) Comparison of the specific 
activity of the final M13 solution produced from the new method when the precipitation times have been varied.  
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The current two established methods produce very low M13 yields according to their UV 
absorbance at 269 and their LD signal at 220 nm. The new method, although considerably 
easier and quicker to carry out and producing a much larger specific activity, also produces a 
low yield. This led to varying the precipitation times within the new method to investigate if 
this affects the M13 yield and specific activity.  
Lengthening the precipitation time from 5 minutes to 120 minutes had a profound effect on 
the yield of M13. Figure 3.5A demonstrates that there is a linear rise in M13 yield based on UV 
absorbance at 269 nm as the precipitation time increases to 120 minutes. The yield increased 
approximately 360 times as the precipitation time increased from 5 minutes to 120 minutes. 
However UV absorbance also measures contaminants which may be present in the solution. To 
therefore measure the quality of each sample, LD was used.  
Similarly, the LD data from 220 nm revealed a linear rise in M13 yield as the precipitation time 
increased. The M13 yield increased approximately 400 times as the precipitation time 
increased from 5 minutes to 120 minutes (figure 3.5B). This data indicates that increasing the 
precipitation time not only increases the number of M13 bacteriophages present in the final 
sample, but it also improves the quality of the M13 produced. The M13 solutions produced 
large LD signals, confirming the intact and well assembled structure of the M13. 
The specific activity was measured using the yield from the UV absorbance at 269 nm and LD 
signal at 220 nm. The specific activity of the M13 bacteriophage produced from the new 
method initially doubled as the precipitation time increased from 5 minutes to 30 minutes 
(figure 35C and table 3.4). However when the precipitation time further increased to 45, 60 
and 120 minutes, the specific activity decreased by a half. This could be due to the fact that the 
yield based on the UV absorbance was increasing at a faster rate than the yield based on the 
LD signal. The yield based on the UV absorbance may be increasing at a faster rate because 
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when precipitating for a longer time, it may be precipitating contaminants as well as the M13. 
This may lead to a larger absorbance at 269 nm. So although the yield from both the UV 
absorbance and LD signal is larger when precipitated for longer, it may lead to more 
contaminants being present. It could therefore be concluded that precipitating for 30 minutes 
would be more advantageous. As precipitating for 30 minutes produces the largest specific 
activity, which indicates that there is more M13 producing an LD signal per milligram of total 
protein. In addition the contaminants could interfere with conjugation processes occurring in 
later stages; this could lead to conjugating specific molecules (e.g. antibodies) to contaminants 
rather than M13 bacteriophages. It would therefore be more beneficial to remove the 
contaminants in the first instance. Not only this but precipitating for 30 minutes rather than 2 
hours makes the method much quicker and achieves an M13 yield suitable for assay 
development.  
3.1.5. Conclusion 
Developing an assay where M13 bacteriophage is the key reagent requires an enhanced M13 
production process. We assessed the speed, ease of use, purity, specific activity and yield of 
M13 of two established methods based on Sambrook and Russell (2001) and New England 
Biolabs (2011). The results show that although both produced samples with high absorbance 
(potentially indicating the presence of M13) the amount of M13 as measured by LD was low, 
indicating a low specific activity. In addition the work identified inherent limitations to both 
methods. The Sambrook and Russell method required the use of a filter to remove the E. coli 
cells which proved extremely difficult and resulted in a less concentrated sample of M13 which 
was also still contaminated with E. coli cells. The New England Biolabs method required 3 days 
rather than 2 days to produce M13 bacteriophage because it involved incubating E. coli 
Top10F’ cells overnight before inoculating them with M13 bacteriophage and also at a later 
stage precipitating the M13 solution with PEG/NaCl overnight. These limitations collectively 
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provided the impetus to develop a new method to produce M13 bacteriophage and took 
aspects from both established methods. In particular the new method added both the M13 
and E. coli Top10F’ together to incubate overnight, as was done in the Sambrook and Russell 
method. This new method also used various centrifugation steps to remove the E. coli cells and 
various PEG/NaCl precipitation steps to concentrate the sample as was done in the New 
England Biolabs method. However the new method only required 15 minutes to precipitate 
the M13 solution as was used in the Sambrook and Russell method.  This new method had the 
benefit of being quick, easy, not labour intensive and resulted in a clean, concentrated and cell 
free solution of M13. The yield produced by the new method, as measured by LD, was on 
parity with the original methods and encouragingly, the specific activity and hence purity was 
significantly improved.  
Work done by Branston et al. (2011) highlighted the importance of the PEG precipitation step 
on final M13 purity and yield. In an effort to further optimise the new method and produce a 
larger yield of M13 which would be sufficient for use in an assay, the precipitation time with 
PEG was varied. The original precipitation time used in the new method was 15 minutes and 
this was altered to 5, 30, 45, 60 and 120 minutes. The results indicate that extending the 
precipitation time from 5 minutes to 120 minutes significantly increase the yield based on LD 
and UV spectra. Interestingly the specific activity initially increases significantly from 5 to 30 
minutes, after which it declines. This could be due to the precipitation time being too long as it 
starts precipitating more contaminants. Given that the presence of contaminants is not ideal 
for downstream conjugation experiments, the decision was taken to precipitate the M13 for 
30 minutes which provides a sufficient yield for this assay and a high specific activity. This 
precipitation time also provides a method which is less time consuming. When comparing this 
new method with a precipitation time of 30 minutes to the two established methods that were 
originally used, the yield and specific activity has significantly improved. The M13 yield based 
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on UV spectra increased by approximately 5 times when compared to the yield produced from 
the New England Biolabs method and doubled when compared to the yield of the Sambrook 
and Russell method. The yield based on the LD signal has improved approximately 10 times 
when compared to the two established methods and the specific activity has increased 7 times 
when compared back to the Sambrook and Russell method and has doubled when compared 
back to the New England Biolabs method. These significant improvements have established a 
method which is quick, easy, produces a large yield and a large specific activity.   
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4 CHAPTER 4 
- FLUORESCENT LABELLING OF 
M13 FOR USE IN ASSAYS 
The previous chapter described a method that was developed to produce an increased 
quantity of M13 for subsequent conjugation reactions. The next stage in the development of 
an assay is the production of M13 derivatised with coloured dyes (figure 4.1). These dyes allow 
different antibody conjugated M13 bacteriophages in the same test to be detected 
independently using LD (figure 4.2) as each dye will produce an individual LD signal related to 
its spectroscopic characteristics. This offers the exciting prospect of being able to: 
1. Detect more than one type of pathogen in a sample (multiplexing) 
2. Detect one pathogen using more than one method (multimodality) 
3. Embed control reactions in one assay 
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Figure 4.1 - M13 production, labelling and LD measurement process 
Demonstration of the process of making M13 bacteriophage, labelling M13 bacteriophage with dyes and measuring 
the LD signal of the label once attached to the M13 bacteriophage. 
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Figure 4.2 - Schematic illustrating the principle behind an M13/LD assay capable of multiplexing 
Schematic diagram illustrating how M13 bacteriophage conjugated with antibodies and dyes (double labelled M13) 
can be used to detect different targets simultaneously using LD. In this figure there are 3 types of M13 
bacteriophage. Green M13 is M13 bacteriophage labelled with green dye and is a control and therefore always 
produces an LD signal. Blue M13 is M13 conjugated with blue dye and antibodies specific to E. coli O157. Orange 
M13 is M13 conjugated with orange dye and antibodies specific to MRSA. In the absence of any pathogens all 3 
types of M13 bacteriophage align and produce an LD signal corresponding to the dye attached. However if E. coli 
O157 is present in a sample, the blue M13 binds to the pathogen and stops aligning, this causes a drop in LD signal 
for that particular M13 bacteriophage. However the other bacteriophages are still able to align and produce LD 
signals corresponding to their dye. When MRSA is present, the orange M13 is able to detect it and this prevents it 
from aligning, causing a drop in LD signal. However the other bacteriophages are again still able to align and hence 
produce LD signals corresponding to the dyes attached. This illustration demonstrates that this assay is capable of 
detecting more than one pathogen simultaneously. 
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Currently the pathogen detection system relies on the LD signal produced from M13, which 
occurs in the near UV region of the electromagnetic spectrum. This necessitates the use of 
large complex instrumentation limiting the use of M13 and LD as a detection assay.  
The conjugation of dyes to the M13 protein coat provides a route to shift the LD signal into the 
visible region of the electromagnetic spectrum. Thus offering the potential to develop an 
economical, hand held, portable detection device. Furthermore, the addition of dyes could be 
used to develop a multimodal and multiplexed detection assay.  
In this chapter methods are developed to introduce coloured dyes into the M13 structure. To 
achieve this, a dye with a reactive chemical group that can form a covalent bond with a residue 
on the surface of M13 was added to the virus. Once reacted, a dialysis step is used to remove 
the free, unbound dye. Dyes were chosen to label the M13 on the basis of cost, spectroscopic 
characteristics and linkage chemistry. The dyes used to label M13 in this chapter include 
fluorescamine, rhodamine B isothiocyanate (rhodamine), 4-chloro-7-nitrobenzofurazan (NBD 
chloride) and black hole quencher-10 (BHQ-10).  Fluorescamine forms an animine bond, NBD 
chloride forms an amine bond and BHQ-10 forms an amide bond with the free amine groups 
on the p8 coat protein. Rhodamine forms a thiourea bond with the free amine groups on the 
p8 coat protein. 
There are two possible reactive amine groups on the p8, one is located on the N-terminus and 
the other is located on an accessible lysine residue (Lys-8 (Niu et al., 2008)) (figure 4.3). The 
amines of the p8 protein of wild type (wt) M13 have been shown to be amenable to chemical 
modification without damaging the M13 structure and its infectivity (Muzard et al., 2012). 
Muzard et al. (2012) highlight the easy accessibility of Lys-8 on p8 of the virus and describe 
methods to modify M13 bacteriophage for use in affinity separation. Similarly Lee et al. (2012) 
chemically modified M13 without disrupting its ability to bind to a particular antigen. They 
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modified the M13 bacteriophage by incorporating thiol groups on to the accessible amine 
groups and allowed them to react with maleimide-derivatised DNA to form reagents for their 
assay.  
Figure 4.3 - Images illustrating the location of the p8 coat proteins within M13 
The image on the left displays the helical organisation of M13 major coat proteins p8. The second image is a ribbon 
diagram of a single subunit of p8 with the lysines being highlighted. Lys-8 is easily accessible and is shown in green, 
whereas the other 4 lysines are buried in the coat protein and shown in blue. Reproduced from Niu et al. (2008). 
(Niu et al., 2008). 
Table 4.1 - The dyes proposed to label M13 bacteriophage. 
Dye Conjugation 
Method 
Mr Absorbance  Extinction Coefficient of dye (M-1 cm-1) 
Fluorescamine  Animine 
linkage 
278 381 7600 (Haugland, 1996) 
Rhodamine Thiourea 
linkage 
536 556 87000 (Ma et al., 2008) 
NBD chloride Amine 
linkage 
200 337 9800 (Haugland, 1996) 
BHQ-10 Amide 
linkage 
703 516 28700 (Biosearch Technologies, 2010) 
 
Various methods were used to confirm that the dye had labelled the M13. The labelled M13 
was first tested using UV/Vis spectroscopy to determine if an absorbance peak corresponding 
to the dye was present. If a peak was observed this indicated dye was present in the sample 
with the M13 as well as providing a measure of the amount of dye attached to the M13. The 
labelling efficiency was calculated using equation 2.2. For example, a labelling efficiency of 
20% indicates that ~540 of the 2700 p8 coat proteins have been labelled. LD was then used to 
determine if the dye covalently linked to the M13 was able to align. If the dye was bound and 
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aligned then a LD peak would be expected where the dye absorbs (NB: free dye cannot align 
and hence is unable to produce an LD signal as the dye is very small and lacks sufficient aspect 
ratio). Fluorescence of the dye labelled M13 was also measured to examine whether 
conjugation had altered the fluorescent characteristics of the dyes.  
4.1. Labelling M13 bacteriophage with fluorescamine 
Unconjugated fluorescamine is not a fluorescent compound, but produces fluorescent 
products on reaction with primary amine groups (De Bernardo et al., 1974). Conveniently this 
means that a coloured solution after a reaction indicates the covalent linking of fluorescamine 
to a primary amine group (figure 4.4). Fluorescamine also has a low molecular weight (278.26 
g/mol), meaning it should not affect the alignment of the M13 in an LD experiment. For these 
reasons fluorescamine was chosen as one of the labelling dyes.  
 
Figure 4.4 - Labelling M13 with fluorescamine 
 
 
 
 
 
 
It should also be noted that fluorescamine is a light sensitive molecule, so all labelling 
reactions were carried out in the absence of light.  
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Fluorescamine was added to the M13 and after incubation, the sample was dialysed. To test if 
fluorescamine had labelled the M13, the UV/Vis absorbance, LD and fluorescence were 
measured.  
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Figure 4.5 - UV/Vis absorbance spectra, LD spectra and fluorescence spectra of fluorescamine and 
M13 labelled with fluorescamine 
(A) UV/Vis absorbance spectra of M13 labelled with fluorescamine (0.5 mg/mL) and fluorescamine alone (0.036 
mM). (B) Shows the LD spectra of M13 labelled with fluorescamine (0.5 mg/mL), fluorescamine alone (0.036 mM) 
and wt M13 (0.35 mg/mL). Inset highlights the peak caused by fluorescamine when conjugated to M13.   (C) Shows 
the fluorescence spectra of M13 labelled with fluorescamine (0.5 mg/mL) and fluorescamine alone (0.036 mM ). 
Excitation wavelength - 381 nm.  
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Fluorescamine alone absorbs at 381 nm and the UV/Vis absorbance shows that fluorescamine 
has a peak at 381 nm (figure 4.5A). M13 labelled with fluorescamine also has a peak at 381 
nm, therefore indicating that there is fluorescamine present. The presence of an LD signal 
further confirms that fluorescamine has labelled the M13 because fluorescamine alone cannot 
align and consequently cannot produce an LD signal. M13 labelled with fluorescamine 
produces a peak at approximately 381 nm (figure 4.5B), indicating that when M13 aligns, the 
dye aligns with it because it is bound to the M13. The positive peaks at 200-240 nm and 260-
300 nm and the negative band between 240-260 nm are all characteristic of M13, indicating 
the presence of M13 in the sample. The positive peak at 200-240 nm arises from the peptide 
backbone transitions, whilst the negative band between 240-260 nm arises from DNA 
transitions indicating that the base pairs are perpendicular to the long axis of the 
bacteriophage. The positive peak between 260 nm and 300 nm is due to aromatic transitions 
of Tyrosine, Tryptophan (maximum at 280 nm) and Phenylalanine.  
Fluorescence measurements also show that fluorescamine does not fluoresce alone, but when 
it forms the animine bond with the primary amine groups (on the lysine side chains and N-
terminus amine groups) on the M13 it produces a large peak between 450-500 nm (figure 
4.5C). 
4.2. Labelling M13 bacteriophage with rhodamine B isothiocyanate 
Rhodamine reacts with the primary amine group on the lysine side chains and N-terminus on 
the p8 coat proteins on the M13 to form a thiourea linkage (figure 4.6). Rhodamine has an 
absorption maximum of 556 nm (Haugland, 1996); this is in the visible region. The molecular 
weight of rhodamine is 536 g/mol, and so again it would not be expected that rhodamine 
would affect the alignment of the M13 in an LD experiment.  
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Rhodamine, like fluorescamine is a light sensitive molecule, so all reactions were carried out in 
the absence of light.  
 
 
 
Figure 4.6 - Labelling M13 with rhodamine 
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Figure 4.7 - UV/Vis absorbance spectra, LD spectra and fluorescence spectra of rhodamine and 
M13 labelled with rhodamine 
(A) UV/Vis absorbance spectra of M13 labelled with rhodamine (0.4 mg/mL) and rhodamine alone (0.012 mM). (B) 
LD spectra of M13 labelled with rhodamine (0.2 mg/mL), rhodamine alone (0.012 mM) and wt M13 (0.3 mg/mL). 
Inset highlights the peak caused by rhodamine when conjugated to M13.  (C) Fluorescence spectra of M13 labelled 
with rhodamine (0.4 mg/mL) and rhodamine alone (0.012 mM). Excitation wavelength - 556 nm.  
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The UV/Vis absorbance spectra of rhodamine and M13 labelled with rhodamine shows that 
rhodamine alone absorbs at 556 nm and the M13 labelled with rhodamine also produces a 
peak at 556 nm (figure 4.7A) therefore suggesting that rhodamine has covalently linked to 
M13. The LD spectra verify this because rhodamine alone produces no LD signal, but the M13 
labelled with rhodamine produces a modest peak at 556 nm. The positive peaks at 200-240 nm 
and 260-300 nm and the negative band between 240-260 nm are all characteristic of M13, 
indicating the presence of M13 in the sample (figure 4.7B). Figure 4.7C also shows how both 
rhodamine and M13 labelled with rhodamine both fluoresce between 550-600 nm, this 
indicates successful labelling. A small stokes shift peak can be seen in figure 4.7C at 550 nm. 
The fluorescence spectra also show that there is a red shift of approximately 4 nm when the 
rhodamine is covalently attached to the M13 bacteriophage. A possible explanation for this is 
that rhodamine is in a more polar environment because it is in contact with glutamates which 
are adjacent to the lysine and N-terminus in p8 where the dye is bound. 
4.3. Labelling M13 bacteriophage with 4-chloro-7-nitrobenzofurazan 
Unconjugated NBD chloride is not a fluorescent compound, but like fluorescamine produces 
fluorescent products on reaction with primary amine groups and also thiol groups (Fager et al., 
1973). Therefore, in this case a coloured solution after a reaction indicates the attachment of 
NBD chloride to a primary amine group. The molecular weight of NBD chloride is 200 g/mol, 
and so again should not affect the alignment of the M13 in an LD experiment.  
NBD chloride is also a light sensitive molecule, so all reactions were carried out in the absence 
of light.  
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Figure 4.8 - Labelling M13 with NBD chloride 
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Figure 4.9 - UV/Vis absorbance spectra, LD spectra and fluorescence spectra of NBD chloride and 
M13 labelled with NBD chloride 
(A) UV/Vis absorbance spectra of M13 labelled with NBD chloride (0.35 mg/mL) and NBD chloride alone (0.05 mM). 
(B) LD spectra of M13 labelled with NBD chloride (0.35 mg/mL), NBD chloride alone (0.5 mM) and wt M13 (0.3 
mg/mL). Inset highlights the peak caused by NBD chloride when conjugated to M13. (C) Fluorescence spectra of 
M13 labelled with NBD chloride (0.35 mg/mL) and NBD chloride alone (0.5 mM). Excitation wavelength - 337 nm. 
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The UV/Vis absorbance spectra of NBD chloride and M13 labelled with NBD chloride both 
show peaks at approximately 336 nm. This is characteristic of NBD chloride, indicating the 
presence of the chromophore in both samples (figure 4.9A). The LD spectrum of M13 labelled 
with NBD chloride also shows a peak at 336 nm, confirming that the dye has covalently 
attached to the M13. The LD spectrum also shows peaks characteristic of M13 (positive peaks 
at 200-240 nm and 260-300 nm and the negative band between 240-260 nm) (figure 4.9B). 
This indicates the successful labelling of M13 with NBD chloride.  
NBD chloride is similar to fluorescamine as it does not fluoresce alone, however on producing 
the amine bond with M13 it fluoresces and emits light between 500-600 nm (figure 4.9C). 
4.4. Labelling M13 bacteriophage with black hole quencher-10 
BHQ-10 is a non-fluorescent dye that is often used to quench the fluorescence of other dyes. 
The lack of fluorescence makes this sort of dye attractive for use in LD assays as it is possible 
the fluorescence could interfere with LD detection in simple assay instruments. BHQ-10 like 
the other dyes in this chapter reacts with the primary amine groups on the lysine side chains 
and N-terminus on the p8 coat proteins on the M13 (figure 4.10). The molecular weight of 
BHQ-10 is 703 g/mol, and so should not affect the alignment of the M13 in an LD experiment. 
For these reasons BHQ-10 was chosen as a labelling dye. BHQ-10 is not fluorescent and so the 
fluorescence was not measured. 
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Figure 4.10 - Labelling M13 with BHQ-10 
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Figure 4.11 - UV/Vis absorbance spectra and LD spectra of BHQ-10 and M13 labelled with BHQ-
10  
(A) UV/Vis absorbance spectra of M13 labelled with BHQ-10 (0.4 mg/mL) and BHQ-10 alone (0.014 mM). (B) LD 
spectra of M13 labelled with BHQ-10 (0.4 mg/mL), BHQ-10 alone (0.014 mM) and wt M13 (0.35 mg/mL). The inset 
highlights the peak caused by the BHQ-10 labelling the M13.  
The UV/Vis absorbance spectrum of BHQ-10 reveals that it absorbs at a broad range (400-600 
nm) with a maximum at 516 nm. The M13 labelled with BHQ-10 also produces a peak at 516 
nm (figure 4.11A) therefore suggesting that BHQ-10 is present in the sample with M13. The LD 
spectra confirm that BHQ-10 dye has covalently labelled the M13 because BHQ-10 alone 
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produces no LD signal, but M13 labelled with BHQ-10 produces a peak at 516 nm. The positive 
peaks at 200-240 nm and 260-300 nm and the negative band between 240-260 nm are all 
characteristic of M13, confirming the presence of M13 in the sample. 
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4.5. Summary 
Table 4.2 - Percentage labelling and dye LD to M13 LD ratios 
Table shows the percentage labelling of M13 with dye and dye LD to M13 LD ratio achieved when different dyes are used to label M13 bacteriophage. 
Sample Extinction Coefficient of dye 
(M-1 cm-1) 
Absorbance 
of dye (nm) 
Mr 
 
% 
Labelling 
     
             
 
Chemical structure of dye 
M13 + 
fluorescamine 
7600 (Haugland, 1996) 381 278 27.5 (SE 
+/- 2.2) 
0.120 
 
O
O
O O
 
 
M13 + NBD 
chloride 
9800 (Haugland, 1996) 337 200 261.7 (SE 
+/- 9.6) 
0.079 
 
N
+
O
O
-
Cl
N
ON  
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M13 + 
rhodamine 
87000 (Ma et al., 2008) 556 536 30.5 (SE 
+/-0.87) 
 
0.047 
 
N C SO
N
CH3
CH3
N
+
CH3
CH3
OH
OCl
-
 
M13 + 
 BHQ-10 
28700 (Biosearch 
Technologies, 2010) 
516 703 24.3 (SE 
+/-7.6) 
0.147 
 
N
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N
N
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O
N
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O
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A comparison of each labelling reaction shows that percentage labelling for each dye is 
surprisingly repeatable but varies considerably between the different dyes (table 4.2). The 
largest dye used to label M13 was BHQ-10, and this produced the lowest percentage of 
labelling (24%). This could be due to its large size (703 g/mol) which sterically hinders the 
formation of covalent bonds with the accessible amine groups on the M13 bacteriophage. 
Rhodamine is smaller than BHQ-10, with a molecular weight of 536 g/mol and when combined 
with M13 bacteriophage resulted in 30.5% labelling. This is slightly larger than the percentage 
labelling seen with BHQ-10 and this may be due to rhodamine being smaller and so is more 
accessible to the free amine groups on M13 bacteriophage. Fluorescamine is smaller than 
rhodamine with a molecular weight of 278 g/mol, and produced a very slightly lower 
percentage of labelling to rhodamine of 27.5%. This could be due to the differing chemical 
structure of fluorescamine. The rigid central ring of fluorescamine could be sterically hindering 
the p8 amine groups from reacting with it. However rhodamine has a long, flexible linker 
which allows for easier incorporation into the M13 structure. The percentage labelling 
significantly increased when NBD chloride was used to label M13.  NBD chloride has a 
molecular weight of 200 g/mol and resulted in 261.7% labelling of M13. This means there was 
roughly 2.5 NBD chloride dye molecules per p8 coat protein. There are only 2 primary amine 
groups which are accessible on the p8, one on a lysine side chain at position 8 and one at the 
N-terminus. There are 4 other lysine residues in the p8 structure but these are thought to be 
inaccessible (Niu et al., 2008). However, because NBD chloride is extremely small it may gain 
access to some of them and therefore form covalent linkages and increase labelling. Mass 
spectrometry could be used get an accurate picture of the covalent attachment sites of these 
dyes and has been used in a number of papers (Lee et al., 2012, Li et al., 2010, Muzard et al., 
2012). However a number of attempts were made during this study to obtain similar results, 
with little success. 
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All of the dyes used to label M13 bacteriophage proved to produce peaks consistent with their 
absorbance peaks within their LD signal. This confirmed that the dyes had all been conjugated 
to the M13 bacteriophage. To investigate which dyes produced larger LD signals, a ratio was 
derived which compared the intensity of the dye LD signal to that of the M13 core particle. 
This was calculated by dividing the dye absorbance peak in LD by the 280 nm absorbance peak 
in LD for M13. This value indicates the ratio of dye peak to M13 peak; consequently a larger 
value indicates a larger dye peak to M13 peak. Therefore a larger value is more desirable as a 
large dye peak is required for the assay.  
There are several factors which determine the size of an LD signal produced by a dye attached 
to M13. The first factor is how much dye is covalently attached to the M13, since if more dye 
molecules are attached then more dye molecules will align with the M13 in shear flow, leading 
to a larger LD signal. Secondly, the mobility of the dye is an important factor because if the dye 
is sterically hindered (e.g. large molecular weight) it will form a more rigid structure with the 
M13, and therefore align much better in shear flow and produce a larger LD signal. In addition 
the extinction coefficient of the dye is also a factor to be considered because if the dye has a 
larger extinction coefficient it will absorb more and hence produce a larger LD signal. Lastly the 
alignment of the transition polar moments is also a key factor because if they are aligned more 
parallel than perpendicular to the long axis of the M13, the LD signal will be more positive. In 
contrast, if the transition polar moments are aligned more perpendicular than parallel to the 
long axis of the M13, the LD signal will be more negative. Whilst if the transition polar 
moments are exactly in between (at approximately 54.7) to the long axis of M13, then the LD 
signal will be zero. All of these factors affect the size of the dye peak in the LD spectra. 
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Table 4.3 - Factors affecting the LD signal of chromophore labelled M13 
Table compares the LD ratios of dye peak to M13 peak when different dyes are used to label M13 bacteriophage, along with the factors causing these LD signals.  
Sample 
     
             
 
% Labelling Dye Mobility Extinction 
Coefficient of dye 
(M-1 cm-1) 
Alignment of transition 
polar moments 
M13 + 
fluorescamine 
0.120 27.5 (SE +/- 2.2)  Low molecular weight 
provides high dye 
mobility. 
 Sterically hindered by 
rigid central ring.  
7600 (Haugland, 
1996) 
More parallel than 
perpendicular to the 
long axis of the M13. 
M13 + rhodamine 0.047 30.5(SE +/-0.87) 
 
 Long flexible linker 
provides high dye 
mobility. 
87000 (Ma et al., 
2008) 
More parallel than 
perpendicular to the 
long axis of the M13. 
M13 + NBD chloride 0.079 261.7 (SE +/- 9.6)  Low molecular weight 
provides high dye 
mobility. 
9800 (Haugland, 
1996) 
More parallel than 
perpendicular to the 
long axis of the M13. 
M13 + BHQ-10 0.147 24.3 (SE +/-7.6)  Large molecular 
weight provides low 
dye mobility.  
28700 (Biosearch 
Technologies, 
2010) 
More parallel than 
perpendicular to the 
long axis of the M13. 
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The results indicate that M13 labelled with BHQ-10 produced the largest dye peak in 
comparison to the other dyes as it produced the largest ratio value (0.147) (table 4.3). This is 
surprising because BHQ-10 provided the lowest percentage labelling of M13. However this 
might be explained by the size of BHQ-10, because it is much larger than the other dyes and 
therefore is providing a more rigid structure which will lead to a larger dye LD signal. Also BHQ-
10 has the second largest extinction coefficient of the dyes used in this chapter. The LD signal 
produced from BHQ-10 is also positive, indicating that the transition polar moments are more 
parallel than perpendicular to the long axis of the M13. 
M13 labelled with fluorescamine produced a slightly smaller dye peak with a ratio value of 
0.120 in comparison to M13 labelled with BHQ-10. An explanation for this is that despite M13 
labelled with fluorescamine producing a larger percentage of labelling than M13 labelled with 
BHQ-10, fluorescamine has a much lower extinction coefficient, the lowest of all of the dyes 
used. Also fluorescamine is much smaller in size in comparison to BHQ-10 and this therefore 
makes it more mobile in shear flow, reducing the LD signal. However fluorescamine is also 
sterically hindered by its rigid central ring, which restricts movement of the dye, therefore 
producing a larger LD in comparison to NBD chloride and rhodamine. The positive LD signal 
produced from fluorescamine also reveals that the transition polar moments are more parallel 
than perpendicular to the long axis of the M13. 
M13 labelled with NBD chloride produced the largest percentage of labelling in comparison to 
the other dyes used, interestingly however, it produced the second smallest dye peak, with a 
ratio of 0.079. This can be explained by the high mobility of NBD chloride due to its small 
molecular weight as there is more space to move around (figure 4.12). Furthermore, the 
extinction coefficient for NBD chloride is small; the second smallest of the dyes used. The LD 
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signal of the NBD chloride also reveals that the transition polar moments are more parallel 
than perpendicular to the long axis of the M13 because the dye produces a positive signal.  
Lastly, M13 labelled with rhodamine produced the smallest ratio value (0.047) indicating a 
smaller dye peak. This is in spite of the reasonable percentage of labelling and rhodamine 
having the largest extinction coefficient and second largest molecular weight. However, this 
can be explained by the chemistry used to covalently attach rhodamine to the M13. The 
thiourea linkage between rhodamine and M13 is a longer and more flexible link, which may be 
increasing the mobility of rhodamine in shear flow and therefore preventing it from aligning 
and forming a rigid structure with M13 bacteriophage. Thus a low LD signal was produced. 
Although small, the LD signal produced was positive, indicating that the transition polar 
moments were more parallel than perpendicular to the long axis of the M13.  
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Figure 4.12 - Schematic diagram illustrating M13 labelled with NBD chloride and M13 labelled 
with BHQ-10 
Schematic diagram illustrating M13 labelled with NBD chloride and M13 labelled with BHQ-10 in shear flow within 
an LD cell. NBD chloride is a small chromophore and when it is covalently attached to M13 this allows it to be 
flexible and mobile which results in a smaller LD signal. In contrast BHQ-10 is much larger and therefore provides a 
more rigid structure with M13 which is less mobile and this could explain why it provides a larger LD signal. The 
arrow in the top left illustrates the flexibility of the NBD chloride when conjugated to the M13 bacteriophage.  
4.6. Conclusion 
To develop this assay system, which currently involves M13 bacteriophage and LD, it is 
important that it is able to detect more than one target at once and that it has embedded 
control reactions within it. In addition, to make the instrumentation more compact, 
transportable and economical, signals in the visible region need to be attained. 
One way of achieving this is to incorporate dyes into the assay which provide a signal in the 
visible region and provide an independent signal for each assay in a multiplexed test. 
Covalently linking dyes on to the p8 coat proteins of M13 bacteriophage along with specific 
antibodies will allow the M13 to detect its target whilst also producing specific peaks in the LD 
spectrum relating to the dye used. If the target is present then the peak drops and this 
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indicates the presence of the target. The dyes are therefore useful as they allow for the assay 
to be multiplexed and can allow for controls to ensure the assay is valid.  
Various dyes were chosen to label M13 bacteriophage, based on cost, spectroscopic 
characteristics and linkage chemistry. The dyes used included fluorescamine, rhodamine, NBD 
chloride and BHQ-10, and all reacted with the amine groups present on the p8 coat protein. 
The results confirmed that they had all successfully labelled M13 bacteriophage. The UV/Vis 
absorbance spectra were used initially to indicate that the dye was present with the M13 
bacteriophage. The LD spectra confirmed whether the dye had labelled the M13 because dye 
alone cannot align due to its small size. However when covalently attached to M13, the dye is 
able to produce an LD peak corresponding to where the dye absorbs.  
The UV/Vis absorbance spectra of the dye labelled M13 allowed for the percentage labelling of 
M13 to be calculated. The results highlighted that molecular weight may play a role in 
determining how well a dye labels the M13. The results showed that BHQ-10, the largest dye 
used, produced the lowest percentage labelling whilst NBD chloride, the smallest dye used, 
produced the highest percentage labelling. An explanation for this is that larger dye molecules 
are sterically precluded from interacting with amine groups on the M13 and therefore fail to 
label the M13. Whilst smaller dye molecules are able to obtain access to the free amine groups 
and therefore result in a larger percentage of labelled M13.  
The LD spectra of M13 conjugated with various dyes confirmed that all of the dyes used had 
formed covalent attachments with the M13. The results indicated that 4 specific factors 
determined the size of the dye peaks within the LD spectrum and these are: 
 percentage of labelling 
 dye mobility 
112 
 
 extinction coefficient of dye 
 alignment of transmission polar moments 
M13 labelled with BHQ-10 produced the largest ratio value which compared the dye 
absorbance peak to the M13 peak at 280 nm. This was explained by the large molecular weight 
of BHQ-10, as this would cause steric hindrance when conjugated to the M13, resulting in a 
very rigid structure which consequently produced a large LD signal for the dye. Contrastingly, 
NBD chloride which had a very small molecular weight produced a lower ratio value, indicating 
that it was more flexible and able to move around in shear flow. Fluorescamine and rhodamine 
both proved that the linkage chemistry also affects the dye mobility, which consequently can 
affect the size of the dye peak. Since long flexible linkers can increase the dye mobility, as was 
seen with rhodamine which produced the lowest LD ratio value. Whereas fluorescamine was 
covalently linked via its central ring which essentially stuck the dye to the M13, providing a 
very rigid structure which provided a reasonably large LD ratio value.  
This research has demonstrated the potential to use dyes in assay systems, however only a 
small group of dyes were investigated and more work is required to investigate a broader 
range of dyes with varying absorbance maxima. Also the linkage chemistry used to attach the 
dyes can be further examined to optimise the labelling and LD dye peak. 
Overall the results demonstrate that dyes can be incorporated into the assay and this 
demonstrates the potential of this detection system to become multiplexed, multimodal and 
miniaturised into a smaller and more affordable format.  
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5 CHAPTER 5 
- DEVELOPMENT OF A HIGH 
SENSITIVITY ASSAY USING M13 
BACTERIOPHAGE AND LINEAR 
DICHROISM 
Pacheco-Gomez et al. (2012) established that LD and M13 bacteriophage can be coupled 
together to form a detection assay which can successfully detect E. coli O157. The assay was 
developed by producing M13 bacteriophage with an FB domain fused to the p3 protein (FB-
M13) (figure 5.1). The FB domain was able to specifically bind to the secondary antibody, via its 
constant region, forming a complex which was found to be aligned in a flow cell producing a 
characteristic M13 LD signal. The primary antibody that was used in this study was raised to 
specifically bind to an antigen on the surface of E. coli O157 and was therefore used to detect 
E. coli O157.  When the anti-E. coli O157 and E. coli O157 were added to the conjugated FB-
M13, the LD signal dropped significantly (figure 1.22 and figure 5.2). This detection assay 
proved to be a promising method for the detection of bacteria. However, this assay was only 
capable of detecting 107 cells/mL which is well below that required for a clinical assay where a 
limit of 105 cells/mL is more usual. It is therefore clear that the sensitivity of this assay needed 
to be improved. In addition, the reliance of the assay on a non-covalent interaction between 
the secondary antibody and primary antibody also meant that the assay was not suitable for 
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assay multiplexing. This is because the antibodies would be able to dissociate from one set of 
M13 particles and re-associate with a second set thus scrambling the assay. 
 
Figure 5.1 - A schematic diagram of the M13 reagent used by Pacheco-Gomez et al. (2012) 
A schematic diagram of the M13 reagent used by Pacheco-Gomez et al. (2012) in their detection assay. They 
produced M13 bacteriophage with an FB domain fused to the p3 coat protein. The FB domain specifically attached 
to a secondary antibody via the constant region. The primary antibody was raised to specifically bind to an antigen.  
 
 
 
 
Figure 5.2 - A schematic diagram illustrating the principle behind the pathogen detection assay 
used by Pacheco-Gomez et al. (2012). 
A schematic diagram illustrating the principle behind the pathogen detection assay used by Pacheco Gomez et al. 
(2012) which utilised LD and M13 bacteriophage. M13 bacteriophage labelled with anti-E. coli O157 antibody (via 
the p3 coat protein) aligns under shear flow, thus a LD signal is seen. If a sample containing E. coli O157 is added to 
the M13 reagent, alignment is disrupted due to the formation of bonds between the antibody labelled M13 and the 
E. coli O157. Therefore a reduction in the LD signal is observed.  
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It was clear from the work done by Pacheco-Gomez et al. (2012) that the assay could be 
further developed by utilising a covalent linkage to conjugate the primary antibody directly 
(e.g. anti-E. coli O157) on to the M13. This removes the need for a secondary antibody and 
therefore reduces costs and time and also makes the structure more stable for detection. Also 
rather than utilising the p3 coat protein of which there is only 5 copies in each M13 particle, 
the p8 coat protein could be used to chemically conjugate the primary antibody (figure 5.3). 
The primary reason for this is because there are 2700 copies of the p8 coat protein within the 
M13 coat. This increases the number of antibodies on each particle potentially leading to an 
increase in assay avidity. The conjugation of antibodies onto the p8 coat protein which runs 
the whole length of the M13 also ensures that the M13 adheres to the target along its length 
ensuring a full disruption of M13 alignment and hence maximum signal change (figure 5.4). In 
addition to this, utilising the p8 coat protein and directly conjugating a primary antibody to it 
will help establish a multiplexed assay; the previous method used by Pacheco-Gomez et al. 
(2012) involving a primary and secondary antibody would not support a multiplexed assay.  
 
Figure 5.3 - A schematic diagram of the M13 reagent proposed for a detection assay 
A schematic diagram of the M13 reagent proposed for a detection assay based on the work done by Pacheco-
Gomez et al. (2012). The M13 bacteriophage is covalently conjugated with primary antibodies via the p8 coat 
protein which runs along the length of M13.  
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Figure 5.4 - A schematic diagram illustrating the development of the M13/LD based assay 
A schematic diagram illustrating assay development based on the work done by Pacheco-Gomez et al. (2012) where 
LD and M13 bacteriophage are utilised for pathogen detection. M13 bacteriophage labelled with anti-E. coli O157 
antibody (via the p8 coat protein) aligns under shear flow, thus a LD signal is seen. If a sample containing E. coli 
O157 is added to the M13 reagent, alignment is disrupted due to the formation of bonds between the antibody 
labelled M13 and the E. coli O157. Therefore a reduction in the LD signal is observed. 
5.1. Conjugation methods 
M13 bacteriophage has to be conjugated to an antibody in this assay; the heterobifunctional 
coupling of amines to thiols method was used to achieve this (Aslam and Dent, 1998). 
For bioconjugation to occur the p8 coat protein on M13 and the antibody need to be 
chemically activated. The p8 coat protein on M13 is activated using succinimidyl acetyl 
thioacetate (SATA); this introduces protected sulfhydryl groups onto the primary amine groups 
on the lysine residue and N-terminus of the p8 coat protein. Deprotection reagent 
(hydroxylamine/EDTA) is then added to free the sulfhydryl group by deacylating (removing the 
RCO- group) the sulfhydryl group. In parallel the antibody is activated using succinimidyl-4-(N-
maleimidomethyl) cyclohexane-1-carboxylate (SMCC), which modifies the amine groups to 
create derivatives that terminate in sulfhydryl reactive maleimide groups. The maleimide 
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activated antibody is then added to the thiol labelled M13 and as a result undergoes a 
nucleophillic reaction and a thioether bond forms (figure 5.5).  
The conjugated M13 does not affect the ability of M13 to align or its LD signal, and this 
therefore helps to provide a stable assay (Pacheco-Gomez et al., 2012). 
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A) SATA is incubated with M13 and introduces sulfhydryl groups to the amine groups on the p8 coat protein. 
Deprotection reagent (hydroxylamine/EDTA) is then added to deacylate the sulfhydryl groups to produce thiol 
labelled M13. 
 
B) SMCC is added to the antibody and it modifies its amine groups to form amide linkages, which upon modification 
then creates derivatives that terminate in reactive maleimide groups.  
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c) The maleimide-activated antibody is added to the thiol labelled M13 and a thioether bond forms. 
Figure 5.5 - Chemistry used to conjugate M13 to an antibody. 
 
SMCC and SATA allow for the formation of a thioether bond between M13 bacteriophage and 
the antibody. 
A three step strategy was used to develop this conjugation method, each stage beginning with 
M13 modified to contain thiol groups: 
1. The number of available thiol groups on the derivatised M13 was assessed by 
derivatisation with a thiol specific reagent, eosin-5-maleimide. 
2. The availability of thiol groups for conjugation to maleimide derivatised antibodies was 
assessed using a readily available antibody with the resultant complexes visualised 
using transmission electron microscopy. 
3. The final conjugate between M13 and an E. coli O157 specific antibody was produced 
and its ability to detect E. coli O157 assessed. 
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5.2. Labelling M13 bacteriophage with eosin-5-maleimide  
To conjugate an antibody to the p8 coat protein of M13 bacteriophage, both the p8 and 
antibody need to be activated using SATA and SMCC respectively. This will result in a thioether 
linkage between the two. To examine and visualise this conjugation method, a dye was initially 
used to mimic the maleimide-antibody reagent. Eosin-5-maleimide is an inexpensive dye and 
already contains a maleimide group (which therefore removes the need to use SMCC) and is 
able to react with thiol groups to form thioether bonds (figure 5.6). For M13 to react with 
eosin-5-maleimide it would therefore require the introduction of sulfhydryl groups on to the 
primary amine groups on the lysine residues and the N-terminus on the p8 coat proteins using 
SATA. Deprotection reagent was used to free the sulfhydryl groups by deacylating them 
(removing the RCO- group), thus resulting in thiol labelled M13. 
Eosin-5-maleimide has an absorption maximum of 524 nm (Haugland, 1996); this is in the 
visible region. To determine if eosin-5-maleimide was present in the final sample of M13 after 
labelling, the UV/Vis absorbance and fluorescence was measured. The LD signal of the 
conjugate was also measured to assess the formation of the covalent complex (a peak should 
appear at 524 nm where the dye absorbs) as well as the structural integrity of the M13 
particle. The molecular weight of eosin-5-maleimide is 743 g/mol, and so should not affect the 
alignment of M13 in an LD experiment. Eosin-5-maleimide was therefore selected as the 
labelling agent.  
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Figure 5.6 - Labelling M13 with eosin-5-maleimide 
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Figure 5.7 - UV/Vis absorbance spectra, LD spectra and fluorescence spectra of eosin-5-maleimide 
and M13 labelled with eosin-5-maleimide 
(A) UV/Vis absorbance spectra of M13 labelled with eosin-5-maleimide dye (0.6 mg/mL) and of eosin-5-maleimide 
dye (0.04 mM). (B) LD spectra of M13 labelled with eosin-5-maleimide dye (0.6 mg/mL), eosin-5-maleimide dye (0.1 
mM) and wt M13 (0.2 mg/mL). Inset highlights the peak caused by eosin-5-maleimide when conjugated to M13. (C) 
Fluorescence spectra of M13 labelled with eosin-5-maleimide dye (0.26 mg/mL) and of eosin-5-maleimide dye 
(concentration of 0.01 mM). Excitation wavelength - 520 nm. 
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Figure 5.8 - Image showing the change in colour during the labelling process 
Comparison of the colour of three solutions, where (A) is eosin-5-maleimide dye alone. After leaving eosin-5-
maleimide dye to react with M13, the solution was precipitated and centrifuged to spin down the M13 labelled with 
eosin-5-maleimide. The resulting supernatant (B) thus contained the free unreacted eosin-5-maleimide dye. The 
pellet of M13 labelled with eosin-5-maleimide was resuspended in phosphate buffer (C).  
 
Eosin-5-maleimide alone produces an absorbance peak at 524 nm in the UV/Vis spectrum. 
M13 labelled with eosin-5-maleimide also absorbs at this wavelength, indicating the presence 
of the dye with M13 (figure 5.7A). The fluorescence spectrum (figure 5.7C) also highlights how 
M13 labelled with eosin-5-maleimide dye emits light between 530-560 nm which is also where 
the eosin-5-maleimide dye emits light.  
The LD spectrum of M13 labelled with eosin-5-maleimide dye confirms that the dye was bound 
to the M13 because a peak is seen at 524 nm (5.7B). Eosin-5-maleimide alone does not 
produce any LD signal. The LD spectrum of M13 labelled with eosin-5-maleimide dye also 
displayed the characteristic peaks of M13. The percentage of labelled p8 coat proteins 
calculated from the UV/Vis absorbance spectra was 16.5%. To put this into context, if this level 
of labelling was replicated with antibodies then each M13 particle would have more than 400 
antibodies on its surface. These results show that the modification of amine groups on the 
surface of M13 to produce thiol groups has been achieved successfully with a sufficient 
labelling yield to proceed with antibody conjugation. It is of course possible to attempt to 
  A        B       C 
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optimise the yield of conjugate further. However in the previous chapter it was shown that 
conjugation levels for eosin-like moieties seldom increase above 30%.  
5.3. M13 bacteriophage conjugated with GAM 
The formation of a thioether bond as a means of conjugating another molecule to M13 has 
previously been proved successful with eosin-5-maleimide dye. The next stage of this process 
is to conjugate an antibody on to M13 via the p8 coat proteins. Development of the assay 
requires the covalent attachment of antibodies on to M13 so that it is able to detect particular 
targets. The model antibody being used to confirm conjugation on to M13 is a goat anti-mouse 
(GAM) antibody which offers two benefits over using the E. coli O157 specific antibody: 
1. The antibody is considerably cheaper than the E. coli O157 specific antibody 
2. The M13-GAM conjugate that results from these experiments could be a useful 
reagent in assays where a covalent coupling between the M13 and a target mouse 
antibody is not required. 
To couple the GAM to M13, the GAM must be treated with SMCC in order for it to acquire a 
maleimide group. Similarly M13 has to be treated with SATA and deprotection reagent to 
acquire thiol groups, after which the GAM and M13 will be combined to form thioether bonds 
with each other. 
UV/Vis spectroscopy was used to measure the absorbance of the GAM solution, the GAM 
solution following treatment with SMCC for one hour and the M13 solution following 
treatment with SATA for one hour. The UV/Vis and LD absorbance of the final solution of M13 
conjugated with GAM was also measured to determine if its spectrum would retain its 
characteristic features. This would in turn allow us to determine if the structure of the M13 
would be maintained after conjugation. To also determine if the GAM had conjugated the 
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M13, transmission electron microscopy (TEM) was utilised to visualise the covalent linkages 
between the two structures.  
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Figure 5.9 - The UV/Vis and LD spectra of the process of bioconjugating M13 with GAM 
Graph A shows the UV/Vis absorbance spectra of GAM (0.38 mg/mL) in distilled water, GAM following treatment 
with SMCC for one hour and undergoing a PEG precipitation step to remove the SMCC (GAM-SMCC) (0.17 mg/mL) 
and M13 following treatment with SATA for one hour and deprotection reagent and a PEG precipitation step to 
remove the SATA once reacted (M13-SATA) (0.22 mg/mL). Graphs B and C show the UV/Vis absorbance and LD 
spectrum of M13 conjugated with GAM (0.2 mg/mL) respectively. 
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Figure 5.10 - Transmission electron microscopy images of M13 conjugated with GAM 
Transmission electron microscopy images, the bar represents 100 nm; A and B both display 0.3 mg/mL M13 conjugated with GAM. The arrows point to where the GAM has covalently
attached to M13. 
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Conjugating M13 with GAM proved to be successful. Figure 5.9 demonstrates that following 
M13 conjugation with GAM, the M13 still maintains its characteristic spectrum. The TEM 
images display where the antibodies conjugated onto the M13 bacteriophages, confirming that 
the chemistry used achieved covalent attachments (figure 5.10).  
5.4. Production of double labelled M13 reagent  
Given the success with conjugating M13 to chromophores and antibodies, the next stage was 
to couple the M13 to the E. coli O157 specific antibody. The chosen target pathogen was E. coli 
O157 as detection of this pathogen is appropriate for food samples and medical samples, since 
E. coli O157 can be found in both food and human samples (Pennington, 2010). In addition to 
coupling this antibody to the M13 we also aim to couple a dye to the surface of the same M13 
to produce a double labelled M13. As discussed in an earlier chapter the addition of a dye to 
the M13 with an LD signal in the visible part of the spectrum enables the simplification of the 
instrument used to detect the LD signal. The addition of different dyes to different 
M13:antibody conjugates also provides the basis for a multiplexed test. 
Double labelled M13 was produced using goat anti-E. coli O157 antibody (GAE) as the chosen 
antibody and BHQ-10 as the chosen dye. GAE antibody was chosen because it is able to detect 
the O and H antigens present on E. coli O157 (information provided by Thermo Fisher 
Scientific). BHQ-10 was chosen because it proved to produce an LD signal with a large peak 
where it absorbed at 516 nm. The dye was inexpensive and the chemistry used to covalently 
link it to M13 via the amine groups on the p8 coat proteins was straightforward.  
M13 had to be modified with SATA in order to covalently attach GAE and BHQ-10 to its p8 coat 
proteins. SATA works by attaching sulfhydryl groups on to the free amine groups (one on the 
N-terminus and one on a lysine residue). The GAE was modified by the addition of SMCC which 
attaches a maleimide group on to the GAE (figure 5.5). The maleimide groups on the GAE react 
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with the thiol groups on the M13 and form thioether bonds. The BHQ-10 was similarly 
modified by the addition of N-(2-Aminoethyl) maleimide (AEM). The amine group of the AEM 
reacts with the carbonyl group of the N-hydroxysuccinimide ester (NHS ester) on BHQ-10, 
substituting the NHS for a maleimide group. This then allows BHQ-10 to form a thioether bond 
with M13 (figure 5.11).  
 
Figure 5.11 - Covalently linking thiol labelled M13 with maleimide labelled BHQ-10 
Chemistry used to attach maleimide groups on to BHQ-10 using AEM and chemistry used to react this with thiol 
labelled M13 to form a thioether bond. 
 
To produce the double labelled M13, the thiol labelled M13 was initially incubated with 
maleimide labelled GAE overnight. Following this the maleimide labelled BHQ-10 was added to 
the M13 and GAE solution and left to incubate for a further hour. This solution was then 
allowed to precipitate with PEG and centrifuged to spin down the double labelled M13 and 
these pellets were resuspended in phosphate buffer (see section 2.2.5.). The UV/Vis 
absorbance spectrum was then measured to determine the concentration.  
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BHQ-10 dye absorbs at 516 nm, and figure 5.12A shows that double labelled M13 produces a 
fairly large broad peak at 516 nm, confirming the presence of the dye in solution. The LD signal 
confirmed that the BHQ-10 had covalently attached to the M13 as there was a peak at 516 nm 
in the LD spectrum (figure 5.12B). 
A
B 
Figure 5.12 - UV/Vis spectrum and LD spectrum of double labelled M13 
The UV/Vis spectrum (A) and LD spectrum (B) of double labelled M13 made by covalently linking GAE and BHQ-10 
to the M13 (0.9 mg/mL). 
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5.5. Detection of E. coli O157 using double labelled M13 and LD  
LD was examined as a diagnostic method by adding E. coli O157 into a solution of double 
labelled M13 (M13 conjugated with a dye and anti-E. coli O157 antibody). Solutions containing 
105, 106 and 107 cells/mL of E. coli O157 were added to the double labelled M13 to determine 
the sensitivity of the assay. A control of double labelled M13 alone was used to determine the 
baseline LD signal. To determine the specificity of the assay, E. coli XL10 was added to the 
double labelled M13. 
Three different dilutions of E. coli O157 (105, 106 and 107 cells/mL) were introduced to double 
labelled M13 and then placed into the LD instrument to examine the sensitivity of the assay. 
The LD spectra verifies that the addition of E. coli O157 causes a significant drop in LD signal as 
the double labelled M13 is no longer able to align. This confirms that LD and double labelled 
M13 are able to detect E. coli O157. All of the samples produced LD spectra with the 
characteristic M13 signals (positive peaks at 200-240 nm and 260-300 nm and the negative 
band between 240-260 nm), and all samples likewise produced a peak at 516 nm which 
corresponded to the BHQ-10 dye used to label the M13. The peaks however decreased as the 
concentration of E. coli O157 cells present in the solution increased. A further comparison was 
made between the peaks at 280 nm and 516 nm to indicate if both peaks decreased with 
increasing concentrations of E. coli O157 cells. A t-test was used to determine the significance 
of the results in comparison to the control. 
The control sample which consisted of double labelled M13 with 0.1 M phosphate buffer pH 
7.5 and tween (0.05%) (tween was used to prevent any non-specific binding) produced a large 
LD signal (0.004 OD at 280 nm and 0.0014 OD at 516 nm) (figure 5.13). A similar signal was 
produced when 107 cells/mL of E. coli XL10 was added to the double labelled M13 and 0.1 M 
phosphate buffer pH 7.5 and tween (0.05%) (0.0039 OD at 280 nm and 0.0011 OD at 516 
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nm). The E. coli XL10 cells were used to test the specificity of the assay. An unpaired two tailed 
t-test between the control and the addition of E. coli XL10 cells at 280 nm and 516 nm showed 
no significance as both p values at 280 nm (0.31) and 516 nm (0.097) exceeded the 0.05 
significance level. The results therefore show that the assay is specific. 
A considerable drop in LD signal was seen when 107 cells/mL of E. coli O157 was added to the 
double labelled M13 and 0.1 M phosphate buffer pH 7.5 and tween (0.05%). The LD signal at 
both 280 nm and 516 nm was approximately 3 times smaller than that of the control. A t-test 
comparing the LD signals at 280 nm between the control and the presence of 107 cells/mL of E. 
coli O157 show a significant difference as the p value (0.003) was lower than the 0.01 
significance level. Similarly the peak at 516 nm was significantly lower in comparison to the 
control as the p value (0.0036) was lower than the 0.01 significance level. These results 
clarified that the LD signals at 280 nm and 516 nm were significantly smaller in comparison to 
those in the control. This significant change in LD signal provides evidence that this assay is 
able to detect E. coli O157. 
A comparable LD signal was generated when 106 cells/mL of E. coli O157 was added to the 
double labelled M13. The peaks produced at 280 nm and 516 nm were again significantly 
smaller in comparison to the peaks seen in the control, with both p values being lower than 
the 0.01 significance level (p value of 0.0018 and 0.0025 respectively). 
The addition of 105 cells/mL of E. coli O157 into the assay resulted in an LD signal which was 
much lower than that of the control (approximately 1.3 times smaller than the LD signal at 280 
nm and 1.75 times smaller than the signal at 516 nm) but also larger than the LD signals 
produced in the presence of 107 and 106 cells/mL of E. coli O157. Both peaks at 280 nm and 516 
nm were significantly smaller than those seen in the control (p values of 0.044 and 0.015 
respectively). However these results were not as significant as when 107 and 106 cells/mL of E. 
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coli O157 cells were added into the assay as the p values are not lower than the 0.01 
significance level, but lower than the 0.05 significance level. The results however still show 
that when 105 cells/mL of E. coli O157 are present in the assay, a significantly lower LD signal is 
produced in comparison to the control. 
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Figure 5.13 - Detection of E. coli O157 using double labelled M13 and LD 
The LD spectra displayed in A demonstrates the drop in LD signal when E. coli O157 is added to double labelled M13 
(M13 conjugated with GAE and BHQ-10).  The control consisted of double labelled M13 (3.6 mg/mL) and 0.1 M 
phosphate buffer pH 7.5 and tween (0.05%).  Differing dilutions of E. coli O157 (10
5
, 10
6
 and 10
7
cells/mL) were 
added to the double labelled M13 and 0.1 M phosphate buffer pH 7.5 and tween (0.05%). An additional control of 
10
7
 cells/mL of E. coli XL10 was added to the assay to determine specificity. Graph B compares the LD signals at 280 
nm of the control and the addition of 10
5
, 10
6
 and 10
7
cells/mL of E. coli O157 to the double labelled M13, as well as 
the 10
7 
cells/mL of E. coli XL10. Graph C compares the LD signals at 516 nm of the control and the addition of 10
5
, 
10
6
 and 10
7
cells/mL E. coli O157 to the double labelled M13, as well as the 10
7 
cells/mL of E. coli XL10. Unpaired two 
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These results indicate that this assay is sensitive enough to detect 105 cells/mL of E. coli O157. 
This suggests that when 105 cells/mL of E. coli O157 are added to the double labelled M13, the 
GAE antibodies attached on to the M13 are able to detect the O and H antigens present on the 
surfaces of the heat-killed E. coli O157. As they detect these cells, they cluster around the cells 
and are no longer able to align; this causes the notable drop in LD signal. If the M13 is not able 
to align this then affects the BHQ-10 dye molecules which are covalently linked to the p8 coat 
proteins on the M13. Since they are no longer able to align with the M13 and therefore a 
decline in signal is also seen at 516 nm. When the number of cells increase from 105 cells/mL 
to 106 and 107 cells/mL, the LD signal drops further as the double labelled M13 cluster around 
more of the cells. When 106 cells/mL of E. coli O157 was added to the double labelled M13 it 
appears from figure 5.13B that on average it produced a lower signal at 280 nm than when 107 
cells/mL of E. coli O157 was added to the double labelled M13. However the standard 
deviations of both samples appear to overlap and this therefore may just be a matter of 
variation. This is supported by the results in figure 5.13C where the LD signal is examined at 
516 nm, because the standard deviation of both the 106 and 107 cells/mL of E. coli O157 
samples noticeably overlap.  
As well as being a sensitive assay, this assay has also proved to be a specific assay. The LD 
signal produced when 107 cells/mL of E. coli XL10 was added into the assay proved to be 
insignificant when compared to the control. This highlights that the GAE antibodies attached to 
M13 are only specific to the O and H antigens present on E. coli O157. The presence of E. coli 
XL10 cells in the assay therefore did not prevent the double labelled M13 from aligning and 
producing a large LD signal. 
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5.6. Conclusion  
Raul Pacheco-Gomez et al. (2012) demonstrated that it was possible to detect E. coli O157 
using LD and M13 bacteriophage. His assay however had limitations, including the lack of 
sensitivity as it was only able to detect 107 cells/mL and its inability to multiplex due to the 
non-covalent bonds between the primary and secondary antibodies. The experiments 
described in this chapter looked at how this assay could be improved to produce an assay that 
is 2 orders of magnitude more sensitive than that developed by Pacheco-Gomez et al. (2012). 
The work also takes the first step to develop an assay which is able to detect more than one 
pathogen at one time. 
The assay used by Pacheco-Gomez et al. (2012) was improved by using p8 coat protein as the 
point of contact for an antibody. This was chosen because there are 2700 copies of this protein 
along the full length of the bacteriophage, in comparison to just 5 at one end of the 
bacteriophage, which is the case for p3 coat protein. This would therefore lead to a more 
abundant conjugation of antibodies to the M13 particle. This in turn would increase the 
number of contact points between the M13 bacteriophages and the pathogens encouraging 
the de-alignment of the M13 and therefore increasing the sensitivity of the assay. The direct 
conjugation of the primary antibody to the p8 coat protein also removed the need for a 
secondary antibody reducing the cost of the assay. To enable a multiplexed system, the use of 
dyes conjugated to the M13 coat was introduced to produce an LD signal that could be used to 
distinguish between different targets. 
Before the assay was trialled, the chemistry used to conjugate the primary antibody on to the 
p8 was confirmed using eosin-5-maleimide dye and TEM of M13 conjugated with GAM. 
The improved assay consisting of double labelled M13 and LD proved to successfully detect E. 
coli O157 at a 100 fold greater sensitivity than the original assay and with the capability of 
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multiplexing the assay. The results show that this assay can detect 105 cells/mL of E. coli O157 
(in an 80 µL Couette this corresponds to a detection of 104 cells), with a reasonable degree of 
statistical certainty. Following these results further investigation would be required to 
determine if an even lower concentration of cells could be detected. Also a key experiment 
would be to investigate the detection of more than one pathogen e.g. E. coli O157 and MRSA 
to determine if the assay can be multiplexed. This would involve producing two lots of double 
labelled M13 reagents with two different dyes and two different antibodies determined by the 
target pathogens. This double labelled M13 combined with the target pathogens and LD would 
provide experimental evidence that this assay can be multiplexed. 
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6 CHAPTER 6 
- DETECTION OF SMALL 
MOLECULES USING M13 
BACTERIOPHAGE AND LINEAR 
DICHROISM 
The detection system described in the previous chapter proved to be successful in detecting E. 
coli O157. However this detection system is only able to detect large target ligands which are 
therefore able to de-align the double labelled M13. Consequently this detection system is well 
suited for pathogens, but not for small molecules like toxins, drugs and explosives, since these 
much smaller molecules are unable to de-align the M13 bacteriophages. Producing a 
multimodal detection system, capable of detecting pathogens, small molecules and also DNA 
would significantly expand the use of the M13/LD assay (figure 6.1). In order to develop a 
multimodal detection system using LD and M13 bacteriophage, the different techniques to 
detect the different targets must be examined. Research into the detection of DNA is already 
being developed in the Dafforn laboratory. The next stage is to look at the detection of small 
molecules which will focus on the detection of toxins, drugs and explosives. 
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Figure 6.1 - Diagram illustrating the idea of creating a multimodal detection system 
Diagram illustrates the idea of creating a multimodal detection system capable of detecting small molecules (e.g. 
toxins, explosives and drugs), DNA from pathogens and the surface antigens of pathogens. This multimodal system 
uses LD and M13 bacteriophage and can detect any of these target ligands in one test.  
6.1. Why small molecule detection? 
The detection of toxins is very important in the diagnosis of disease as various pathogens are 
known to produce toxins. Examples of such pathogens include Shiga-toxin-producing E. coli 
(STEC), Staphylococcus aureus (S. aureus) which produces toxic shock syndrome toxin-1 (TSST-
1), several enterotoxins  (A, B, C 1 , C 2 ,C 3 , D and E), exfoliative toxins (ETA and ETB) and 
leukocidin, Bacillus cereus which produces a highly stable toxin less than 10 kDa in size and 
Clostridium botulinum which produces a potent neurotoxin (Pimbley and Patel, 1998). These 
toxins have the potential to cause severe harm, for example 10-15% of individuals infected 
with E. coli O157 go on to develop haemolytic uraemic syndrome which is associated with 
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renal failure, anaemia and bleeding (Tarr et al., 2005). Similarly TSST-1 producing S. aureus is 
known to cause toxic shock syndrome (TSS) and caused an epidemic in the early 1980s in the 
USA, which was associated with the use of tampons during menstruation (Dinges et al., 2000).  
The detection of drugs is also important; in 2012-2013 it was reported that 1 in 12 adults had 
taken an illicit drug in England (Health and Social Care Information Centre, 2013). In addition, 
the United States recorded 27,000 deaths due to unintentional drug overdoses in 2007 
(Centers for Disease Control and Prevention, 2012). The illicit drug trade is reportedly growing 
with global opium production increasing from 4,700 tons in 2010 to 7,000 tons in 2011 and in 
the United States, annual prevalence of cannabis use increased by 0.4% between 2009 and 
2010 (United Nations Office on Drugs and Crimes, 2012). These facts demonstrate the 
importance and complexity of tackling the worldwide drug trade. 
Similarly, chemical explosives also pose a threat on a national and global scale. In recent years 
a growth in explosive based terrorism has been observed, this is predominantly due to the 
simple production and distribution methods as well as the shear harm they are capable of 
causing (Senesac and Thundat, 2008). For example in 1993 a urea nitrate based car bomb was 
detonated below the North Tower of the World Trade Centre (Aubrey, 2004). In 1994 a 
terrorist used a nitroglycerin compound concealed in a contact lens fluid bottle to bring down 
a Philippine plane on its way to Tokyo (Steven and Gunaratna, 2004). More recently in 2005 a 
group of terrorists set off several home-made peroxide-based explosives on the London 
transport system which resulted in 56 deaths and hundreds injured (Segell, 2006). 
To reduce and prevent the harmful effects of bacterial toxins, drugs and explosives they need 
to be detected rapidly on a molecular scale.  
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6.2. Detection methods for toxins, illicit drugs and explosives 
Currently small molecules such as bacterial toxins are detected primarily using immunological 
assays (Pimbley and Patel, 1998). These include ELISAs, radioimmunoassays (RIA) (figure 6.2) 
and agglutination assays (Pimbley and Patel, 1998). Immunological assays are similarly used to 
detect drugs and explosives; these assays include enzyme multiplied immunoassay technique 
(EMIT), ELISA, RIA, fluoroimmunoassay (figure 6.3) and fluorescence polarization immunoassay 
(FPIA) (Smith et al., 2008b, Moeller et al., 2008). 
Antibodies used in immunological assays are highly selective and this makes them good at 
discriminating between different closely related molecules (Smith et al., 2008b). However 
immunological assays do have many limitations (please see Chapter 1 for details). Although 
new research is being done to improve small molecule detection, for example Ruta et al. 
(2009) combined aptamers with fluorescence polarisation to produce a sensitive, easy to use 
and simple detection assay (Ruta et al., 2009).  
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Figure 6.2 - Schematic diagram of how a radioimmunoassay works 
RIAs are competition assays where radioactive labelled target molecules and unlabelled target molecules both 
compete for the anti-target antibody. The assay mixture is incubated and any unbound antigens are separated and 
the radioactivity of both or either fractions is determined and the concentration of unlabelled target molecules is 
calculated. This heterogeneous assay is less frequently used due to washing steps which prolong the assay time, 
health and safety concerns associated with radioactivity (Bonwick and Smith, 2004) and degradation issues with 
radioactive labels (Drost et al., 1977).  
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Figure 6.3 - Schematic diagram illustrating how fluoroimmunoassays work 
Fluoroimmunoassays are competition assays as fluorescently labelled analogues of the target molecule compete 
with unlabelled target molecules from a sample to bind to anti-target antibodies. The difference in fluorescence 
emission intensity is measured and the concentration of the target molecule in the sample can be determined by 
examining the decline in fluorescence. Fluoroimmunoassays are commonly used for the detection of explosives 
(Smith et al., 2008b, Goldman et al., 2003) and are well suited for field use as they provide more rapid throughput 
than ELISA and high performance liquid chromatography. However, some biological molecules are able to naturally 
emit light and they can affect fluorescence measurements (Smith et al., 2008b). 
A major limitation of using immunological assays are that they are capable of producing false 
positive results (Moeller et al., 2008). Consequently when detecting drugs, a confirmation test 
is routinely carried out if a positive result is produced. This secondary analysis is usually carried 
out using gas chromatography-mass spectrometry (GC-MS) (Moeller et al., 2008). This method 
is able to identify and quantify a complex mixture of volatile compounds with analytical 
sensitivities ranging from 1-100 pg (Hites, 1997). Conversely this method can be extremely 
time-consuming, requiring rigorous sample preparation and up to 20 hours to perform the 
assay. In addition GC-MS is not able to distinguish between isomeric molecules and is limited 
to samples with a vapour pressure greater than 10-10 torr (Hites, 1997). Furthermore this assay 
requires a high level of expertise to perform and is very costly (Moeller et al., 2008).  
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Ion mobility spectrometry (IMS) is an analytical technique used to identify ionised molecules 
and is currently used in flight security to screen for explosives (Ewing and Miller, 2001). This 
technique has a similar sensitivity to mass spectrometry, however IMS is less specific and is not 
able to screen low vapour pressures, which many explosives have, especially if deliberately 
concealed within containers (Steinfeld and Wormhoudt, 1998).  
This is not an exhaustive list of all of the current methods used to detect toxins, illicit drugs and 
explosives, but indicates a few of the key assays carried out currently. It is apparent that 
presently small molecule detection does have many limitations and to solve the problems 
surrounding bacterial toxins, illicit drugs and explosive based terrorism, it is essential that an 
assay capable of detecting these small molecules is developed. This chapter investigates how 
LD combined with M13 bacteriophage can be utilised to form an assay capable of detecting 
small molecules and in the future it is hopeful that this can form part of a multimodal assay.  
6.3. Small molecule detection  
At the inception of this part of the project two detection assays were originally envisaged to 
detect small molecules using M13 and LD, these were the:  
 microsphere aggregation assay  
 M13 aggregation assay 
The microsphere aggregation assay consists of M13 conjugated with target antigens which 
forms a complex with anti-target antibody conjugated microspheres. These complexes are 
large and therefore prevent the M13 bacteriophages from aligning when subject to shear flow 
and result in no LD signal. The addition of an unknown quantity of target molecules from a 
sample will compete with the target antigens conjugated on to the M13 for the binding sites 
on the microspheres. The target molecules will displace the conjugated M13, resulting in the 
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breakdown of the M13/microsphere complexes. The unbound M13 will align in shear flow, re-
establishing the M13 LD signal and indicating that the target molecule is present in the sample 
(figure 6.4).  
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Figure 6.4 - Schematic diagram illustrating how microspheres, M13 and LD may be used to detect 
small molecules 
Schematic diagram illustrates how in principle microspheres and M13 bacteriophage may be able to detect small 
molecules using LD. In the absence of free antigen a complex forms between microspheres conjugated with 
antibody and M13 conjugated with the target antigen. The formation of an aggregate prevents the M13 from 
aligning and hence the LD signal drops. In the presence of free antigen a competition assay forms as the free 
antigen competes with the antigen conjugated on the M13 to bind to the antibody conjugated on to the 
microspheres. The free antigen breaks down the aggregate and the M13 is able to align and this causes an increase 
in LD signal. 
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This assay was trialled in the laboratory (in collaboration with Toby Proctor and Florence 
Gower, University of Birmingham) with M13 bacteriophage which was conjugated with an 
antigen, fluorescein isothiocyanate isomer 1 (FITC-M13), in the hope of detecting fluorescein 
as the target molecule. The microspheres used consisted of microspheres conjugated with 
anti-fluorescein antibodies (-microspheres) and non bioconjugated microspheres 
(microspheres). After incubating the FITC-M13 with the -microspheres and the microspheres, 
a drop in LD signal was expected for the FITC-M13 incubated with -microspheres and no 
signal change was expected for the FITC-M13 incubated with microspheres. However this was 
not seen as an increase in LD signal was seen for both samples (figure 6.5). A possible 
explanation for this was that the microspheres increased the viscosity of the sample and 
therefore increased the M13 bacteriophage alignment and consequently increased the LD 
signal. The assay in this form was felt to be unsuccessful although it is possible that with extra 
optimisation the method could be made to work. However success in the second small 
molecule assay method meant that research into the microsphere based method was stopped 
so that we could concentrate on the second method.  
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Figure 6.5 - LD spectra produced from the microsphere aggregation assay 
M13 bacteriophage was conjugated with fluorescein isothiocyanate isomer 1 (FITC-M13) and incubated with 
microspheres conjugated with anti-FITC antibodies (FITC-M13--Microspheres) and non-bioconjugated 
microspheres (FITC-M13-Microspheres). According to the microsphere aggregation assay it had been hypothesised 
that the LD signal from FITC-M13 would decline in the presence of the -microspheres as they would aggregate. It 
was also thought that FITC-M13 in the presence of microspheres would result in no signal change as no aggregation 
would result. However the FITC-M13--Microspheres sample demonstrated an increase in LD signal at 280 nm (a) 
and 494 nm where FITC absorbs (b). This indicated that the presence of the microspheres supported the alignment 
of FITC-M13 and hence increased the LD signal. Similarly the FITC-M13-Microsphere sample also resulted in a slight 
increase at 280 nm, this indicated that both the microspheres and the -microspheres had the same effect on the 
FITC-M13. This assay proved to be unsuccessful due to this non-specific binding.  
 
The M13 bacteriophage aggregation assay behaves like a competition assay. It consists of M13 
conjugated with target antigens which form a complex with anti-target antibody conjugated 
M13. This complex reduces the LD signal. The addition of a sample containing an unknown 
amount of target molecules will compete with the target antigens conjugated on to the M13 
for the binding sites on the M13 bacteriophages. The target molecules will displace the M13 
conjugated with target antigens, resulting in the breakdown of the M13 complexes. The M13 
149 
 
will align in shear flow, re-establishing the M13 LD signal and indicating that the target 
molecule is present in the sample (figure 6.6). 
Figure 6.6 - Schematic diagram illustrating how LD and M13 bacteriophage are able to detect small 
molecules 
In the absence of free antigen a complex forms between M13 conjugated with antibody and M13 conjugated with 
the target antigen. The formation of an aggregate prevents the M13 from aligning and hence the LD signal drops. In 
the presence of free antigen a competition assay forms as the free antigen competes with the antigen conjugated to 
the M13 to bind to the antibody conjugated on to the M13. The free antigen breaks down the aggregate and the 
M13 is able to align and this causes an increase in LD signal. 
 
This chapter investigates and examines this assay as a technique for small molecule detection.  
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6.4. M13 bacteriophage aggregation assay 
The target molecule chosen for detection using the M13 bacteriophage aggregation assay was 
fluorescein. Fluorescein was an ideal molecule to show proof of concept of this assay because 
it is a small molecule with a molecular weight of 376 g/mol, which is similar in size to some of 
the eventual targets (e.g. molecular weight of cocaine is 303 g/mol). It is also an inexpensive, 
harmless molecule, and so could be used with minimal regulatory or safety considerations. 
6.4.1. Production of M13 labelled with FITC and M13 labelled with anti- FITC 
Fluorescein isothiocyanate isomer 1 (FITC) was used as the antigen to covalently label M13 
bacteriophage. FITC is a derivative of fluorescein; it differs because it is functionalised with an 
isothiocyanate reactive group, which is reactive towards nucleophiles including amine groups, 
which are present on the p8 coat proteins on M13. FITC was covalently linked to the free 
amine groups (one on the N-terminus and one on the lysine residue) on the p8 coat protein by 
forming a thiourea linkage. FITC absorbs in the visible region (494 nm) so the drop or increase 
in LD signal could be observed here.  
 
Figure 6.7 - Labelling M13 with FITC 
 
In order to conjugate M13 with anti-FITC antibodies, M13 had to be modified with SATA and 
anti-FITC antibodies had to be modified with SMCC. The SATA attached sulfhydryl groups on to 
free amine groups on the p8 coat protein. SMCC attached maleimide groups on to the 
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antibody and the maleimide groups were able to react with the thiol groups on the M13 to 
form thioether bonds (figure 5.5). To remove the unwanted SMCC and SATA from the final 
anti-FITC conjugated M13 solution, size exclusion chromatography (SEC) was utilised, this 
eliminated any contaminants, thus producing a pure sample (figure 6.8). The results show that 
M13 conjugated with anti-FITC antibodies eluted first, closely followed by anti-FITC antibodies 
alone. The contaminants, including SATA and SMCC eluted last with a volume between 100-
120 mL.  
Figure 6.8 - Absorbance spectra of M13 conjugated with anti-FITC when it is subjected to size 
exclusion chromatography 
Absorbance spectra of M13 conjugated with anti-FITC when it is subjected to size exclusion chromatography. This 
process allowed for the removal of unwanted contaminants including SATA and SMCC to provide a pure sample. 
The absorbance was measured at both 280 nm and 269 nm. M13 conjugated with anti-FITC antibodies eluted first, 
followed by anti-FITC antibodies alone. The peaks between 100 and 120 mL are caused from excess SATA and 
SMCC. 
 
Once M13 conjugated with anti-FITC and M13 conjugated with FITC were produced, the 
UV/Vis absorbance spectrum was measured to determine their concentration and an LD 
spectrum was measured to check the structural integrity of the M13 had not been disrupted. 
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Figure 6.9 - UV/Vis spectra of M13 conjugated with anti-FITC and M13 conjugated with FITC 
UV/Vis spectra of 0.07mg/mL M13 conjugated with anti-FITC (M13+anti-FITC) and 0.08 mg/mL M13 conjugated with 
FITC (M13+FITC). 
 
 
 
 
Figure 6.10 - LD spectra of M13 conjugated with anti-FITC and M13 conjugated with FITC 
LD spectra of 30µL of 0.08 mg/mL M13 conjugated with FITC and 50µL of 50 mM phosphate buffer pH 8.0 
(M13+FITC) and 30µl of 0.07mg/mL M13 conjugated with anti-FITC and 50µL of 50 mM phosphate buffer pH 8.0 
(M13+anti-FITC). 
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Table 6.1 - Table displaying the percentage labelling of M13 conjugated with FITC and the FITC to 
M13 LD ratio 
Extinction 
Coefficient 
of FITC  
(M-1 cm-1) 
Absorbance 
of FITC (nm) 
Mr 
of 
FITC 
% 
Labelling 
LDFITC/LDM13(280nm) Chemical structure of 
dye 
73000 
(Haugland, 
1996) 
494 389 76 0.963 
 
O
OH
OH
O
C
S
O
N
 
 
 
FITC dye absorbs at 494 nm, and figure 6.9 shows that M13 conjugated with FITC produces a 
fairly large peak at 494 nm, confirming the presence of the dye in solution. The LD signal 
confirmed that the FITC had covalently attached to the M13 as there was a peak at 494 nm in 
the LD spectrum (figure 6.10). The percentage of labelling of M13 conjugated with FITC was 
calculated from the UV/Vis absorbance spectrum, and was found to produce a very high 
labelling percentage of 76%. This could be due to FITC having a low molecular weight, allowing 
it to access the amine groups present on the p8 coat proteins of M13. The LD spectrum for 
M13 conjugated with FITC also displayed a very large peak at 494 nm, and the ratio value of 
the FITC peak to the M13 peak at 280 nm is much larger than those seen in chapter 4. This 
indicates that the FITC is much better at producing a large LD signal and this could be due to a 
number of factors including its large extinction coefficient, its high percentage labelling of M13 
and the alignment of its transmission polar moments being more parallel than perpendicular 
to the long axis of the M13. Also despite FITC being a small dye, it may be that when it has 
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covalently linked to M13, it becomes inflexible and rigid, and this may be supported by the 
high labelling which results in a compact and firm structure. 
Similar concentrations of M13 conjugated with FITC and anti-FITC were used in the assay. 
6.4.2. Detection of fluorescein using LD and anti-FITC and FITC labelled M13  
The initial stage of this assay involved showing that the addition of M13 conjugated with FITC 
to M13 conjugated with anti-FITC leads to an expected decrease in LD signal reflecting the 
formation of a non-alignable complex.  
M13 conjugated with anti-FITC produced an LD signal of 2.32E-04 OD at 280 nm and M13 
conjugated with FITC produced an LD signal of 2.94E-04 OD at 280 nm (figure 6.11). When 
these two solutions were added together to form a mixture, a significant drop in LD signal 
(5.15E-05 OD at 280 nm) of approximately 80% was seen. A two tailed unpaired t-test was 
used to statistically compare the LD signals at 280 nm of the M13 conjugated with anti-FITC (p 
value of 0.04) and M13 conjugated with FITC (p value of 0.00006) to the mixture and found 
that the mixture was significantly smaller in both cases. Theoretically if no complex was 
formed then the signal from the mixture should have been twice as large (approximately 
5.26E-04 OD at 280 nm) because twice the amount of M13 was present in this sample. 
However it is thought that the mixture produces a much lower LD signal because there is cross 
linking between the M13 bacteriophages, as the FITC antigens cross link with the anti-FITC 
antibodies. This will prevent the M13 bacteriophages from aligning and thus causes a drop in 
LD signal.  
  
155 
 
Figure 6.11 - LD spectra illustrating how M13 conjugated with FITC and M13 conjugated with 
anti-FITC can disrupt the LD signal 
LD spectra of 30µL of 0.08 mg/mL M13 conjugated with FITC and 50µL of 50 mM phosphate buffer pH 8.0 
(M13+FITC), 30µl of 0.07mg/mL M13 conjugated with anti-FITC and 50µL of 50 mM phosphate buffer pH 8.0 
(M13+anti-FITC) and 30µL of 0.08mg/mL M13 conjugated with FITC and 30µl of 0.07mg/mL M13 conjugated with 
anti-FITC and 20 µL of 50 mM phosphate buffer pH 8.0 (Mixture). The theoretical mixture is the theoretical LD signal 
if the LD spectra produced from M13+FITC and M13+anti-FITC was simply added together.  
 
The next step was to see whether the presence of free antigen (fluorescein) would disrupt the 
formation of the complex between the M13 conjugated with FITC and M13 conjugated with 
anti-FITC. To test this, the LD absorbance was measured of the M13 mixture with and without 
1 mM fluorescein. This data shows that in the presence of free fluorescein the LD signal 
increases, as predicted, to a value close to that expected if the two M13 bacteriophages did 
not interact (figure 6.12). 
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Figure 6.12 - LD spectra illustrating how the presence of fluorescein can re-establish the LD signal 
LD spectra of 30µL of 0.08mg/mL M13 conjugated with FITC and 30µl of 0.07mg/mL M13 conjugated with anti-FITC 
and 20 µL of 50 mM phosphate buffer pH 8.0 (Mixture), and the “1 mM Fluorescein” solid line is the result of 
incubating 1 mM fluorescein with 30µl of 0.07mg/mL M13 conjugated with anti-FITC overnight and then competing 
it off with 30µL of 0.08mg/mL M13 conjugated with FITC. The theoretical mixture is the theoretical LD signal if the 
LD spectra produced from M13 conjugated with FITC and M13 conjugated with anti-FITC was simply added 
together.  
 
Once it had been established that the complex was disrupted by free antigen an experiment 
was carried out to examine how much free antigen was required to initiate disruption and 
hence a measure of sensitivity of the assay. This was done by the addition of varying 
concentrations of fluorescein to the assay. Increasing concentrations of fluorescein (0.01 mM, 
0.02 mM, 0.04 mM, 0.1 mM, 0.2 mM, 0.5 Mm and 1 mM) was added to M13 conjugated with 
anti-FITC and left to incubate overnight. M13 conjugated with FITC was added to the solution, 
after which the LD signal was measured to indicate if increasing concentrations of fluorescein 
were able to compete with the FITC conjugated on the M13 to bind with the anti-FITC 
antibodies. These signals were compared to the mixture which consisted of M13 conjugated 
with anti-FITC and M13 conjugated with FITC and contained no fluorescein.  
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Figure 6.13 - Sensitivity of the small molecule detection assay 
Graph demonstrates the LD signal at 280 nm when 0.01 mM, 0.02 mM, 0.04 mM, 0.1 mM, 0.2 mM, 0.5 mM and 1 
mM fluorescein is added to M13 conjugated with anti-FITC and competed off with M13 conjugated with FITC. The 
mixture containing M13 conjugated with anti-FITC and M13 conjugated with FITC and containing no fluorescein is 
also plotted. Inset highlights concentrations between 0 and 0.1 mM fluorescein. The error bars show the standard 
deviation.  
 
The mixture, which contained no fluorescein, revealed a low LD signal of 1.17E-04 OD at 280 
nm. The addition of fluorescein was then used to investigate whether fluorescein could be 
detected by an increase in LD signal. When 0.01 mM of fluorescein was added to M13 
conjugated with anti-FITC and competed with M13 conjugated with FITC, the signal notably 
increased by 31%. The LD signal increased by 112% when 0.02 mM of fluorescein was added to 
the assay. After this point, increasing the fluorescein concentration appeared to saturate the 
assay as the LD signal plateaus (figure 6.13).  
The low LD signal produced by the mixture which contains no fluorescein is thought to be as a 
result of cross linking. Since M13 conjugated with FITC and M13 conjugated with anti-FITC will 
form attachments as the antibodies detect their target antigens on the M13. This is likely to 
cause the formation of mesh-like structures. This will therefore prevent the M13 from aligning 
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and result in a low LD signal, which was also seen earlier in this chapter in figure 6.11. The 
initial increase in LD signal seen when 0.01 mM fluorescein was added to the assay is due to 
the free fluorescein competing with the FITC conjugated on the M13 to attach to the anti-FITC 
antibodies conjugated on the M13. The free fluorescein acts to reduce any cross linking and 
mesh-like structures from forming and thus allows the M13 to align in shear flow. The addition 
of 0.02 mM fluorescein further increased the LD signal and this LD signal was maintained 
despite additional increases in fluorescein concentration. An explanation for this is that 0.02 
mM fluorescein saturated all of the available anti-FITC antibodies in the assay, thus allowing 
the M13 bacteriophage to align to their full capacity and thus reaching their LD signal 
potential. Essentially, these results indicate that M13 and LD are capable of detecting small 
molecules whilst maintaining a high sensitivity of 0.01 mM.   
To verify that the assay was specific to the target ligand a closely related chemical, rhodamine 
6G, was introduced to the assay.  
Table 6.2 - Comparing the structures of rhodamine 6G and FITC. 
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Rhodamine 6G was added to M13 conjugated with anti-FITC and then competed off with M13 
conjugated with FITC. It was expected that the anti-FITC antibodies would be specific and 
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would consequently not detect the presence of rhodamine 6G in the sample. The complex 
between the M13 conjugated with anti-FITC and M13 conjugated with FITC would therefore 
continue to form resulting in a low LD signal (figure 6.14).  
Figure 6.14 - Schematic diagram illustrating the principle of this small molecule detection assay 
Schematic diagram displaying the mixture of M13 conjugated with FITC and anti-FITC resulting in a low LD signal 
followed by the addition of rhodamine 6G which has no proposed effect on the aggregated M13. However the 
addition of fluorescein to the mixture results in the breakdown of the aggregate resulting in a large LD signal.  
 
The results show that the LD spectra of both the mixture and the rhodamine 6G sample are 
very similar (figure 6.15), as both produce very similar LD signals at 280 nm (1.17E-04 OD and 
1.18E-04 OD respectively). A two tailed unpaired t-test further supported this as it revealed 
no significant difference between the mixture and rhodamine 6G sample at 280 nm (p value 
was 0.7). This indicates that the rhodamine (although chemically similar to the fluorescein) 
does not interfere with the assay.  
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Figure 6.15 - LD spectra illustrating the specificity of this small molecule detection assay 
LD spectra of rhodamine 6G which consisted of 8 µL of rhodamine 6G (0.02 mM) in solution with 30 µL of M13 
conjugated with anti-FITC (0.07 mg/mL) and 30 µL of M13 conjugated with FITC (0.08 mg/mL) and 12 µL of 50 mM 
phosphate buffer pH 8.0. The mixture consisted of 30 µL of M13 conjugated with anti-FITC (0.07 mg/mL), 30 µL of 
M13 conjugated with FITC (0.08 mg/mL) and 20 µL of 50 mM phosphate buffer pH 8.0.  
These results demonstrate that M13 and LD combined are able to detect small molecules with 
a sensitivity of 0.01 mM and maintaining specificity. 
6.5. Conclusion 
The previous chapter demonstrated that LD combined with M13 bacteriophage could 
successfully form a detection assay capable of detecting pathogens with a high sensitivity and 
specificity. However that detection system was limited to large target ligands. The eventual 
goal of this research is to develop a multiplexed and multimodal system, capable of detecting 
pathogens, small molecules and DNA. The next step in this process was to look at small 
molecule detection which is vital when looking at toxins, drugs and explosives. The current 
assay used for pathogen detection had to be redesigned to detect small molecules as small 
molecules are not able to disrupt M13 alignment and therefore cause an LD signal change. 
Consequently a competition assay was developed which used two M13 bacteriophage 
reagents, one with a target ligand and one with a cognate antibody. These reagents produce 
LD signals that are lower than would be expected if the reagents did not interact indicating the 
formation of a complex with a low propensity to align. Addition of free ligand disrupted this 
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complex inducing a reappearance of the LD signal. This assay was found to detect 0.01 mM of 
the target ligand while not being disrupted by a chemically related ligand indicating good 
specificity.  
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7 CHAPTER 7 
- CONCLUSIONS AND FURTHER 
WORK 
The initial objective of this project was to produce a detection system using LD and M13 
bacteriophage to detect assay targets. The reasoning behind developing a detection technique 
was that despite almost 100 years of research, detection techniques still lack either in speed, 
sensitivity, specificity, cost or stability. Additionally, many of the current techniques involve 
large machinery which acts as a barrier to bedside diagnosis.  
This project utilised a simple hypothesis based on LD as the optical technique which is sensitive 
to the molecular alignment of M13 bacteriophage and is therefore utilised as the reagent in 
this homogeneous assay. M13 bacteriophage can be chemically modified to allow for antibody 
conjugation to its coat proteins and therefore enables it to detect target molecules. In the 
presence of its target, the alignment of the bacteriophage is disrupted and consequently 
causes a change in LD signal. This concept had been investigated by Pacheco-Gomez et al. 
(2012); their research provided the first stepping stone in developing M13 and LD as a 
detection assay. This research has moved on from their preliminary work to establish M13 and 
LD as a platform technology.  
LD is a spectroscopic technique utilising linearly polarised light and is typically used to analyse 
long biological molecules. LD only requires approximately 3 minutes to take a measurement; 
this is extremely rapid in comparison to most of the current detection techniques used. 
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Previous research has proved that M13 bacteriophage is a very stable scaffold (Holliger et al., 
1999, Olofsson et al., 2001, Petrenko and Vodyanoy, 2003) and can easily be chemically 
modified and conjugated with foreign molecules including dyes and antibodies (Lee et al., 
2012, Li et al., 2010). This made M13 bacteriophage a suitable reagent for this assay. 
The first limitation faced during the development of this assay was the production of M13 
bacteriophage. M13 bacteriophage had previously been produced in small quantities, however 
for this assay, large amounts were required. Current M13 production methods by Sambrook 
and Russell (2001) and New England Biolabs (2011) were investigated, more specifically their 
methodology, product yield and specific activity. UV absorbance and LD were utilised to 
measure their yield and specific activity. It was found that both methods had limitations 
concerning their methodologies, yields and specific activity. The two methods were combined 
to form an optimised M13 production method. It was later found that the precipitation steps 
involved in M13 production could produce further improvements (Branston et al., 2011a) and 
this led to varying the precipitation times to optimise the M13 yield and M13 specific activity. 
The steps taken to optimise and improve the M13 production process proved to be rewarding 
because enough M13 bacteriophage was produced to progress with the development of the 
assay. If time had permitted, further work could have been done to look at producing M13 on 
an industrial scale using fermenters (a larger number of E. coli cells will enable a larger number 
of bacteriophage), since if this assay is to be successful, its demand of M13 bacteriophage will 
have to be catered for. Research already suggests that M13 bacteriophage is a viable process 
material for industrial applications (Branston et al., 2011b). If M13 is produced on an industrial 
scale then long term storage will be another area of research that may be required. 
The assay developed by Pacheco-Gomez et al. (2012) is not able to multiplex and is reliant on 
detecting the wt M13 signal which is located in the near UV region of the electromagnetic 
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spectrum. Subsequently, expensive, large and complex machinery is required to probe the 
near UV wavelengths and to detect different targets several experiments would be required. 
To ensure this assay reaches an accessible and multiplexed format, chromophores were 
chemically introduced to the protein coat of M13, moving the optical signals to the visible 
region of the electromagnetic spectrum. This will facilitate the development of an affordable, 
small and portable detection system, capable of multiplexing and multimodality.  
Various chromophores were covalently attached to M13 bacteriophage and tested using 
UV/VIS absorbance and LD. The results showed that different dyes behave differently when 
conjugated to M13. The dyes produced varying LD signals and it was concluded that several 
factors determined the size of the LD signal, including the percentage labelling of the M13 
(calculated from the UV/Vis absorbance spectrum), dye mobility, dye extinction coefficient and 
lastly the alignment of transition polar moments. M13 conjugated with BHQ-10 was found to 
produce the largest ratio of dye LD signal to M13 LD signal. This was predominantly explained 
by the large molecular weight of BHQ-10 which would have caused steric hindrance and 
therefore increased the rigidity of the structure. This along with the large extinction 
coefficient, reasonable labelling and the alignment of transition polar moments all contributed 
to the large LD signal. Whereas M13 conjugated with rhodamine produced the lowest ratio of 
dye LD signal to M13 LD signal, and this was largely explained by the long chemical linker used 
to conjugate the rhodamine to the coat proteins of M13. Since the flexible chemical linker 
increased the dye mobility and reduced the rigidity of the structure, consequently producing a 
smaller LD signal. 
These results demonstrate that dyes can be used to label M13 bacteriophage and that they 
behave differently depending on several characteristics, which should be considered when 
selecting dyes for the assay. This work only looked at a limited number of dyes and further 
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work should be done to investigate a broader range of dyes and at optimising the labelling of 
M13 bacteriophage. 
After successfully labelling M13 bacteriophage with numerous dyes, the subsequent step was 
to incorporate these structures into the assay. In addition to this, the assay design had been 
refined to improve its sensitivity by covalently conjugating the primary antibodies (anti-target 
antibodies) directly to the p8 coat proteins on the M13 bacteriophage. It was thought this 
would improve the assay sensitivity because there are 2700 copies of the p8 coat protein along 
the whole length of the bacteriophage, whereas previously p3 was utilised which only has 5 
copies at one end of the bacteriophage. Utilising p8 would therefore increase labelling and 
also ensure good adherence of the M13 to the target. This new design also reduced costs and 
time because no secondary antibody was required and improved reagent stability. 
To demonstrate that this detection assay was capable of detecting a pathogen, an attenuated 
form of E. coli O157 was used as the target molecule. M13 covalently conjugated with both 
GAE and BHQ-10 was utilised as the reagent. BHQ-10 was the chromophore of choice as it had 
previously demonstrated that it was capable of producing a large LD signal in the visible 
region. Following the addition of E. coli O157 to the assay, the results confirmed that this assay 
could successfully detect E. coli O157, and at a much higher sensitivity of 105 cells/mL 
compared to 107 cells/mL achieved by the existing assay. This detection assay proved to be 
extremely quick (less than 3 minutes), specific and sensitive with the LD signal dropping 
significantly in both the near UV region and the visible region of the spectrum. This research 
has exposed LD coupled with M13 bacteriophage as being a sensitive novel system of 
detection. Given further time, additional work on optimising the labelling of M13 with both 
chromophores and antibodies could have been done. This could primarily enhance the 
sensitivity of the assay, and ensure the chromophores and antibodies are efficiently used thus 
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reducing costs. The effect of mixing positive and negative E. coli on the efficiency of the assay 
was not investigated and could form an interesting area of future study. Moreover, it would 
also be interesting to examine this assay in a multiplexed format with differing M13 
bacteriophages conjugated with differing antibodies and chromophores. If this is achieved it 
would make this detection system highly appealing, especially for the medical industry 
because this assay in a multiplexed format could be used to detect pathogens from patients 
with infections which are known to be caused by more than one pathogen. For example 
urinary tract infections can be caused by numerous pathogens including E. coli and Klebsiella 
pneumoniae (Behzadi et al., 2010). 
This assay demonstrated that it was effective in detecting pathogens; however the design of 
this assay meant it was limited to large molecules which were able to de-align M13 
bacteriophage. With global issues relating to the drugs and explosives industry and health 
concerns associated with toxin secretion from many pathogens, it was apparent that small 
molecule detection should be investigated. A new assay design was hypothesized, still 
maintaining LD and M13 bacteriophage as the key components. This was done because there 
is the future prospect of incorporating the existing detection assay with small molecule 
detection and DNA detection to form a multimodal and multiplexed detection system. With 
this being the long term goal, M13 and LD was to maintain a common feature. 
LD and M13 bacteriophage were combined to form the M13 bacteriophage aggregation assay, 
which is a competition assay capable of detecting small molecules. It was hypothesised that if 
M13 was conjugated with target molecules and mixed with M13 conjugated with anti-target 
molecule antibodies they would form a mesh-like structure and de-align and consequently 
produce a low LD signal. However adding free target molecules to the assay mixture was 
thought to compete with the target molecules conjugated on the M13 to attach to the 
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antibodies. This would lead to M13 bacteriophage aligning and therefore an increase in LD 
signal. This was trialled with fluorescein as the target molecule, and the results verified that 
this small molecule detection system could detect fluorescein. This assay was specific and 
sensitive, with it detecting as low as 0.01 mM fluorescein. 
However this work was only preliminary and only showed proof of concept, thus more work is 
required on this assay. Firstly the arrangement of this assay was set up so that it initially 
incubated M13 conjugated with anti-FITC with the fluorescein, thus allowing the fluorescein 
additional time to attach to the antibodies. The M13 conjugated with FITC was then added to 
the assay mixture to compete with the fluorescein, which had already formed attachments to 
the antibodies. The results from this arrangement proved this assay could detect the presence 
of the fluorescein. However it would now be interesting to find out if this assay would work if 
M13 conjugated with anti-FITC and M13 conjugated with FITC are left to incubate first, with 
the addition of fluorescein to the assay after. This method would be a more realistic method 
for testing samples and so should be the next area of investigation. Further work also needs to 
be carried out on multiplexing this assay so that more than one target can be detected at once. 
This again could involve the use of chromophores to act as markers in detecting particular 
molecules. 
The original aims of this project were to increase M13 bacteriophage production, covalently 
label M13 bacteriophage with chromophores, increase the sensitivity of the existing pathogen 
detection assay and finally to develop a small molecule detection assay. This thesis 
demonstrates that M13 bacteriophage can be produced on a larger scale and demonstrates 
that M13 is a very chemically flexible bio-nano structure that can be conjugated with various 
other molecules. This thesis confirms that M13 bacteriophage in conjunction with LD as the 
optical technique can be used to form a pathogen detection assay with a greater sensitivity 
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than what has previously been achieved. The incorporation of chromophores provides the 
prospect of multiplexing the assay and producing a much smaller, portable, fast and 
inexpensive instrument which can aid in bedside diagnosis. This project then established that 
the LD/M13 assay could be re-designed to form a small molecule detection assay. This 
provides the huge possibility of eventually producing a multimodal detection system. 
Preliminary studies are currently being done in the Dafforn laboratory to investigate the 
detection of DNA, employing both LD and M13 bacteriophage. This presents an exciting future 
prospect of eventually producing a multimodal, multiplexed, sensitive, specific, fast, portable 
and economical diagnostic tool, capable of detecting pathogens, small molecules and DNA. 
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